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i
Structure-function studies of human SLC36 amino acid transporters 
The Solute Linked Carrier family 36 (SLC36) of integral membrane transport 
proteins has four members which are also known as the human Proton coupled 
Amino acid Transporters (hPATs).This is due to hPATs 1 and 2 having been 
functionally characterized as proton coupled transporters that bring about a 1:1 
symport of H+ and an amino acid across the membrane (with optimum uptake at an 
extracellular pH of 5.5). Their main substrates were found to be the small neutral 
amino acids glycine, alanine and proline; however, in addition to these, PATs 1 and 2 
were also observed to transport a range of other substrates including some 
pharmacologically active compounds. hPATs 3 and 4 were considered orphan 
transporters, with no information available except their mRNA localization in various 
tissues. Additionally there is no structural information available about the PAT family 
of transport proteins. 
The thesis has two broad aims. The first aim was to study the orphan PAT 
transporters and to investigate whether these proteins are also amino acids 
transporters and, if so, what their substrates are. The second aim was to use 
transmembrane domain software to predict the secondary structure of the PAT 
transporters using hPAT1 as the model protein. Epitope tags, luminometry and 
functional assays were used to test these predictions, and homology modelling then 
employed to gain a better understanding of the structure-function relationship of this 
transporter family.  The results of both these areas of investigation are reported in this 
thesis.   
The orphan transporter hPAT4 was found to be a very high affinity electroneutral 
proline and tryptophan transporter when expressed in the Xenopus laevis oocyte 
system. Preliminary data for hPAT3 suggested uptake of proline at extracellular pH 
7.4 in Xenopus laevis oocytes and in the mouse Sertoli cell line TM4. Membrane 
topology studies on hPAT1 provided experimental support for the prediction of 11 
transmembrane domains for this transporter protein. Homology modelling indicates a 
region which might play a role in the substrate specificity of PAT proteins. 
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1.1  The Plasma membrane 
1.1.1  Features of the plasma membrane 
The presence of a plasma membrane is a feature of all living cells from bacteria to 
mammals.  The cell membrane defines shape and structure of the cell and holds the 
intracellular contents. It maintains the difference between the intracellular cytoplasm 
(and organelles) and the extracellular contents. The structure of the plasma membrane 
is explained by the fluid mosaic model (Figure 1.1). According to the model, the 
membrane consists of a lipid bilayer with phosphate groups i.e a phospholipid bilayer 
which has selective permeability. One of the most important characteristics of the 
fluid mosaic model is that the lipids are capable of movement within the membrane. 
It allows a variety of molecules such as oxygen and carbon dioxide to pass through 
readily while the movement of some other solutes like most nutrients and ions is 
regulated. In addition to this, the bilayer consists of a number of molecules, such as 
lipid rafts and protein-protein complexes. The fluidity of the bilayer is dependent on a 
number of factors including the type of cell and the contents it encloses. In the 
phospholipid bilayer, the hydrophobic (non polar) lipid tails of both layers face each 
other while the hydrophilic (polar) phosphate region faces either the cytoplasm or the 
outside of the cell. Within the lipid bilayer are a plethora of proteins that facilitate 
different reactions. Proteins are found to be embedded within the bilayer or found on 
the surface of the bilayer only partially attached at the hydrophilic regions. Proteins 
attached to the external side often tend to have conjugated carbohydrate groups 
(forming glycoprotein complexes). Also found in the plasma membrane are receptor 
molecules which participate in various signalling pathways. In case of some of these 
receptors the protein tends to form a pore within the membrane and has the binding 
site on the membrane surface. In addition to this embedded within the bilayer are 
channels, pumps, transportes and adhesion sites. Apart from enclosing the cell and 
being a component of the plasma membrane, lipid bilayers/membranes are also found 
around organelles like the nucleus, mitochondria, and chloroplast. 
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Figure 1.1: The Lipid bilayer. Figure(A) shows an micrograph of the human RBC, figures (B) and (C) show the two and three 
dimensional structures of the cell membrane (Alberts et al., 2002). 
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1.1.2  Membrane potential of the plasma membrane and its 
maintenance  
A resting membrane potential is a phenomenon of all cells across their cell 
membrane. It is the difference in electrical potential between the interior and exterior 
of the cell i.e the potential difference on either side of the membrane. This potential is 
maintained due to the uneven distribution of ions across the membrane. The 
difference in charge is maintained primarily by the sodium-potassium ATPase (Na+-
K+ ATPase) and Na+/K+ channels of the membrane. The Na+-K+ ATPase or the Na+ 
pump, which is one of the most well studied transporters, brings about transport of 
Na+ and K+ (Figure 1.2). 3 Na+ and an ATP molecule first bind to the transporter 
intracellularly. The hydrolysis of the ATP molecule causes the phosphorylation of the 
transporter (at an apartate residue) and causes the release of ADP.  A conformational 
change in the transporter takes place which drives the Na+ ions outside the cell. In 
this conformation, the pump can now bind 2 K+ ions externally. This causes 
dephosphorylation of the pump allowing it to revert back to its original conformation 
and moving the K+ ions internally in the process. This process is in fact responsible 
for consuming 1/3rd of the energy in animal cells.  The exchange of the 3 Na+ for 2 K+ 
provides energy to facilitate movement of molecules by membrane transporters both 
through the membrane potential and the ionic electrochemical gradient. The 
membrane potential is maintained on account of the fact that that the membrane has a 
much greater permeability for K+ ions and as a result of this a large number of K+ 
ions move down the concentration gradient from within a cell to the extracellular 
region. At the same time, on account of the relatively lesser permeability of Na+ a 
relatively small number of Na+ ions are moving down their gradient from the 
extracellular region across the membrane. This causes the extracellular region of the 
membrane to have a (relative) positive charge and the intracellular region to have a 
negative charge. Together the channels and the Na+/K+ ATPase helps maintain the 
resting potential. 
These mechanisms of transport will be discussed further in the next section (1.2).  
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Figure 1.2: Diagrammatic representation of the Na
+
-K
+
 pump.  The pump 
actively transports Na+ and K+ against the electrochemical gradient. One complete 
reaction involving the hydrolysis of one ATP molecule results in the movement of 3 
Na+ outside the cell and 2 K+ into the cell (Alberts et al., 2002). 
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Membrane potential is critical for a number of reasons including indirectly being 
responsible for providing energy for the efficient working of transporters and 
channels and for bringing about the transmission of signals in excitable cells such as 
neurons. 
 
 
1.2  Introduction to membrane transporters 
As discussed in section 1.1.1, the lipid bilayer of the cell membrane helps maintain 
concentration of solutes within the cell at a level different from that outside. It allows 
water and non polar molecules to pass through without hindrance. It must be 
mentioned however that despite the relative free permeability of water molecules in 
through the membrane, there are still specialised integral membrane proteins that 
exist within the membrane viz. aquaporins that allow water molecules to rapidly pass 
through but prevent other molecules from doing so (Agre, 2003). In order for certain 
components such as polar molecules, ions, amino acids etc. to move across the 
bilayer transmembrane proteins are required. These proteins allow a specific 
component or a group of similar molecules to pass through. Halvor Christensen’s 
group (Riggs et al., 1958) showed that Na+ coupled transport of Glycine takes place 
across the membrane. Around the same time Peter Mitchell (1961) had put forth the 
chemiosmotic hypothesis which suggested that the H+ electrochemical gradient was 
capable of transporting carbohydrates across the membrane. This was first shown 
using the H+ lactose co transporter in E.coli which had the LacY gene.  
The vast genomic level studies undertaken over the past decade have unravelled a 
plethora of transporters. The two main classes of membrane transport proteins are 1) 
carrier proteins which can undergo a conformational change to move bound 
molecules across the membrane and 2) channel proteins which form a narrow 
hydrophilic pore which allows solutes to pass through. For the purpose of this thesis, 
the transporters which will be dealt with are carrier proteins. Due to the selective 
nature of their binding sites, these transport molecules generally only transport a 
certain class of molecules and in most cases only a few members of a particular class. 
Transporters regulate the influx and efflux of various components important to the 
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cell, thereby maintaining cellular homeostasis. Transporters generally have a fixed 
stoichiometry which means that at the end of one cycle, a fixed number of solute/ion 
molecules would have been transported across the membrane.  
Amino acids are one such family of substrates that need transporters to aid in their 
movement across membranes. Amino acids are the building blocks of proteins and 
are very important in different metabolic processes. A number of different amino acid 
transporters exist which vary depending on the charge/size of the amino acid 
substrates. 
Physiologically speaking the concentration of the different amino acids in the cells 
varies depending on a number of factors including cell type. For instance, the 
nonessential amino acid proline is found at a concentration of 0.17 mmol/l in the 
plasma and 0.83 mmol/l in the muscle. The essential amino acid valine on the other 
hand has similar concentrationsboth in the plasma and the muscle (0.22 and 0.26 
mmol/l respectively) (Bergström et al.,1974). The concentrations of non essential 
amino acids are generally observed to be higher. The non essential amino acids are 
those which can be synthesised in the body in various metabolic processes. The non 
essential amino acids on the other hand cannot be synthesized in the body and is 
obtained through dietary sources.   
 
 
1.3  Mechanism of transport across the lipid bilayer 
The movement of solutes across the lipid bilayer can be brought about in two main 
ways viz., non-mediated and mediated (Figure 1.3). Each of the mechanisms are 
discussed in further detail in the following sections. 
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1.3.1  Non-mediated transport 
Non-mediated transport/simple diffusion involves movement of solutes from a region 
of high concentration to a region of low solute concentration. Examples of molecules 
transported by this mechanism are non polar molecules such as steroids and oxygen 
which can easily pass through the membrane. 
 
1.3.2  Mediated transport 
Mediated transport can be further divided into 2 main categories, channels and 
transporters. Transporters can be further classified based on the mechanism as non-
facilitated/powered and facilitated transport. 
 
1.3.2.1  Channels 
Channels allow movement of solutes/ions down the electrochemical gradient. They 
are different from transporters in that the amount of solute moving across the 
membrane is governed by how long the channel stays open i.e the gating of the 
channel. This is in contrast to transporters where the amount of substrate translocated 
per cycle is fixed. Molecules that are transported across channels include molecules 
such as sodium and chloride where the amount of movement across the membrane is 
dependent on how long the channel stays open, in other words the gating 
mechanisms, and the electrochemical gradient for that ion. 
 
1.3.2.2  Transporters 
A)  Non-facilitated/Powered transport 
These transporters are classified based on whether they use ATP directly or indirectly 
to bring about the movement of substrates across the membrane. 
a)  Pumps/ Primary active transport 
Transporters that use this mechanism of transport bring about movement by using 
energy. Primary active transport is where the energy spent by the hydrolysis of ATP, 
causes a conformational change and brings about transport of the solute molecule. An 
example of primary active transport is the Na+-K+ ATPase which was discussed in 
section 1.1.2. 
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b) Secondary active transport 
The other form of active transport is secondary active transport where the movement 
of ions down their electrochemical potential difference and across the membrane 
which helps bring about the conformational change of the transporter and causes 
movement of the solute across the membrane. The electrochemical gradient is 
generated by the movement of ions such as Na+ or H+ across the membrane. The 
solute molecules either move in the same direction as the ion (termed as symport) or 
in the opposite direction (called antiport). One example of secondary active transport 
is SGLT1. This transporter brings about symport of one glucose molecule and two 
sodium ions across the membrane. This movement is aided by the downhill Na+ 
gradient created by the Na+/K+ ATPase. 
 
c)  Tertiary active transport 
In tertiary active transport, the movement of solutes across the membrane is driven by 
a transporter is caused due to a gradient generated by a secondary active transporter. 
PepT1 is one such transporter that brings about movement of substrates across the 
membrane via tertiary active transport. PepT1 requires the H+ gradient to bring about 
transport of di and tri peptides across the membrane. This gradient is supplied by 
NHE3. Both these transporters are present in the brush-border membrane of intestinal 
epithelium (Bookstein et al. 1994, Adibi, 2003). NHE3 brings about the movement of 
Na+ and H+ across the membrane via secondary active transport using the 
Na+supplied by the Na+/K+ pump (primary transport). This region has an H+ gradient 
which is generated by the NHE3. When the H+ ions bind to the transporter a 
conformational change of the PepT1 transporter is brought about and this caused the 
transport of di and tri peptides across the membrane (Watanabe et al., 2005). 
 
B) Facilitated diffusion 
Molecules that use this mechanism to move across the lipid bilayer do not require 
energy expenditure but still have specific molecules dedicated to their movement 
across the membrane. There are a number of factors however that affects transport of 
molecules by this mechanism such as the concentration and the electrochemical 
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gradient. Transporters which bring about movement of solutes by facilitated diffusion 
include GLUT1 (the erythrocyte glucose transporter) that transports glucose across 
the membrane by using the glucose binding sites which are present on both sides of 
the membrane (Nelson and Cox, 2008), in other words the transport of glucose can be 
brought about in either direction. Unlike for active transport, facilitated diffusion 
processes do not affect the equilibrium, just the rate at which equilibrium is reached. 
 
1.3.2.3  Differences in the mechanism of transport by a transporter protein 
A particular transporter protein does not necessarily bring about transport by a fixed 
mechanism in all cell types. There can be a variation depending on the cell type, the 
membrane where it is expressed and the other transporters that are expressed on the 
membrane. An example of this can be illustrated using the PAT1 (SLC36A1). This 
transporter has been localised to the brush border membrane of intestinal epithelium 
and the lysosomal membrane. In both these regions the transporter brings about a 
symport of a proton and an amino acid. 
In the brush border membrane the primary active transport is brought about by the 
Na+-K+ pump which pumps out Na+ and thereby increases the relative amounts of 
Na+ in the extracellular region. The increase in Na+ is used as a driving force by the 
secondary active transporter NHE3 which exchanges the Na+ for an H+ (thereby 
acting as a secondary active transporter). The H+ rich microclimate is then utilised by 
PAT1 which uses this as a driving force to bring about a symport of an H+ and an 
amino acid across the brush border membrane (figure 1.4). 
Contrary to this, in the lysosomal membrane PAT1 brings about the movement of 
solutes by secondary active transport. In this case the driving force is provided by the 
H+-ATPase (primary active transport) which causes an influx of H+ into the 
lysosomes (figure 1.5).  
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Figure 1.4: PAT1 as a tertiary active transporter.  
Interactions between the Na+-K+ pump, NHE3 and PAT1 which bring about primary 
secondary and tertiary active transport respectively in the intestinal epithelium. BBM 
is the brush border membrane and BLM is the basolateral membrane. 
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Figure 1.5: PAT1 as an ssecondary active transporter. 
H+-ATPase brings about primary active transport which supplies the energy for 
secondary active transport by PAT1. 
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1.4  The MFS and ABC superfamily 
The wealth of genomic data and bioinformatics tools has resulted in the discovery of 
the MFS (major facilitator superfamily) and ABC (ATP-binding cassette 
superfamily) group of proteins, both of which are expressed in all organisms. The 
ABC permeases are observed to bring about primary active transport. The MFS on 
the other hand, forms one of the largest family of membrane transporters which 
generally bring about secondary active transport (Sigal, Molshanski-Mor and Bibi, 
2006). 
 
 
1.5  The SLC family of transporters 
The solute linked carriers (SLCs) consist of 48 families containing over 300 genes 
which encode transporters (Hediger et al., 2004). They are characterized to bring 
about transport by a variety of mechanisms including exchange, passive transport and 
coupled transport (Figure 1.6). Apart from the cell membrane they are found in the 
membrane of a variety of organelles such as vesicles and mitochondria (Hediger et 
al., 2004). 
Members present within the same SLC family have at least 20% identity to other 
members within the family. The nomenclature for members of the SLC family 
involves the abbreviation SLC (Slc in case of non human) followed by a number 
which is common to all the members of the SLC family under consideration, then the 
letter A which divides the family number from the number of the gene. A capital ‘A’ 
indicates a human gene whereas a small ‘a’ indicates a non-human gene. For instance, 
the proton coupled amino acid transporters PATs which are studied in this thesis 
belong to the SLC36 family. SLC36A1 indicates the solute carrier family 36 and the 
gene 1 (Thwaites and Anderson, 2007).  
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Figure 1.6: Diagrammatic representation showing the SLC transporters on the 
plasma membrane or membranes of different organelles in a cell and the other 
transport proteins that are expressed alongside 
(http://www.bioparadigms.org/slc/intro.htm).  
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1.6  The SLC36 (PAT) family 
The SLC36 family is commonly grouped under the β-group of SLC transporters 
which bring about the transport of neutral amino acids (Sundberg et al., 2008). The 
SLC36 family belongs to the amino acid auxin permease (AAAP) family. The SLC36 
family of transporters was characterized based on homology based cloning to the H+ 
coupled amino acid transporter families in yeast and plants (Boll, et al., 2003). H+-
coupled transport plays a very important role in bacteria, plants, fungi and in recent 
years there has been considerable evidence to indicate its significance in mammals 
too (Metzner,  et al., 2006). Although most transporters in animals tend to use Na+ as 
a driving force for the movement of solutes across membranes, there are cells in 
animals which still use H+ as the ion which drives transport (Boll et al., 2003). 
There are three sub-families of the AAAP present in mammals: 1) the vesicular 
GABA transporter expressed in the brain and which brings about the transport of 
GABA and glycine, 2) a few representatives of the system A and N transporters 
which play a role in maintaining the balance of neutral amino acids in different 
tissues and 3) the Proton coupled Amino acid Transporters (PAT) transporters 
(Rubio-Aliaga et al., 2004). 
The members of this family are dependent on the H+ electrochemical gradient to 
facilitate transport across the membrane (Thwaites and Anderson, 2007). In humans, 
the SLC36 (hPAT) family consists of four members SLC36A1 (hPAT1), SLC36A2 
(hPAT2), SLC36A3 (hPAT3) and SLC36A4 (hPAT4).  
SLC36A1 to A3 are located on the chromosome 5q33.1 whereas SLC36A4 is present 
on 11q14.3. These genes encode proteins containing about 500 amino acids. Different 
membrane prediction software predicts that the PATs contain 9-11 transmembrane 
domains.  
As one of the major nutrition groups, proteins constitute an important part of our 
daily food intake. About 30% of our daily nutrition comes from proteins. These in 
turn are hydrolysed into peptides and amino acids in the stomach and the intestine 
and absorbed. In nature, amino acids play an essential role in the synthesis of 
proteins. Apart from this, amino acids also play a vital role in various biological 
functions such as cell growth, acting as carbon and nitrogen donors and as 
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components in various buffering systems. In the Central Nervous System they play an 
important role in neuro transmission. In order to be able to function efficiently these 
amino acids need to be transported across various biological membranes. This is an 
indispensible step in their metabolism. The SLC36 family of transporters are one 
such group which help in the movement of amino acids across the membrane. 
(Agulhon et al., 2003). 
The epithelial layer of the small intestine plays an important role in absorbing 
peptides and amino acids. The importance of intestinal transporters is further 
emphasized by the fact that they also play an important role in mediating the 
absorption of certain drugs and it is believed that the hPATs can play a significant 
role in this case  (Brandsch, 2006). 
 
 
1.7  PAT1 
Initial evidence for the existence of  PAT1 was in the 1960s when Newey and Smyth 
(Newey and Smyth 1964) reported a glycine-proline carrier which was later modified 
to an imino acid transport system by Lerner and Karcher in the 1970s (Lerner and 
Karcher 1978). By the 1980s two groups had shown the presence of an H+-L-proline 
co-transporter (Roigaard-Petersen, et al., 1987) and an H+-glycine co-transporter 
(Rajendran et al., 1987). Sagné et al. (2001) established the existence of a PAT 
transporter in the rat brain (LYAAT1, the lysosomal amino acid transporter 1), it was 
then cloned from mouse intestine (and named PAT1) and eventually the human form 
was isolated from Caco2 cells (Boll et al., 2002). hPAT1 shows 85% similarity to the 
rat PAT1 ie LYAAT1 (Chen et al., 2003). 
 
1.7.1  Function 
PAT1 acts as a proton coupled symporter of small neutral amino acids. The transport 
activity is pH dependent and Cl- independent. Its activity was initially thought to be 
partially Na+dependent but it has since been shown that this is only an artefact of its 
initial studies in vivo (Boll et al., 2004). In this case it was observed that PAT1 shows 
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a dependence on the Na+/H+ exchanger 3 (NHE3) and was considered as partially 
Na+dependent. The NHE3 exchanger helps maintain an acidic microclimate thereby 
facilitating transport via the PATs. NHE3 is involved in the inward movement of Na+ 
using the downward electrochemical gradient in exchange for an outward movement 
of H+ thereby creating a proton motive force available for transporters such as PATs 
to utilise (Thwaites and Anderson, 2007). However it was noted that in the 
lysosomes, H+-ATPase helps drive the H+/amino acid symport (Sagné et al., 2001) 
and this showed that there is no Na+ dependence in this case and that the NHE 
exchanger was only aiding in driving the protons thereby creating a gradient which 
could then be utilised by hPAT1 for the movement of amino acids across the 
membrane. Furthermore, when these studies are performed in Xenopus laevis oocytes 
and cell lines in controlled Na+ free conditions at pH5.5, they are still observed to 
bring about transport similar to that in vivo (Frølund et al. 2010).  
 
1.7.2  Substrate Affinity 
The Km of an enzyme denotes the concentration at which the rate of the reaction is 
half the maximum. Similarly for a transporter the Km value is a measure of the 
affinity that a particular substrate has for that transporter, and is defined in the same 
way i.e. the concentration of substrate that causes half of the maximum transport rate.   
The Michaelis-Menten equation is the basis for calculating the Km of an 
enzyme/transporter. The equation is simplified to  
 
Where v is the initial rate of the reaction, Vmax is the maximum rate of the reaction, 
Km is the Michaelis constant which is the substrate concentration when the reaction 
rate is half of Vmax and S is the substrate concentration. 
Lineweaver and Burk eventually used a double-reciprocal plot to better estimate the 
Km of the enzyme for graphical representations.  
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In recent years various software have been observed to modified this equation taking 
into account various parameters to be able to fit differnet parameters required to 
correctly assess the Km value.  
 
If a substrate is also capable of causing inhibition then the Ki value and Km value 
will be the same. For experiments performed to determine the Km of a transporter for 
a substrate, it usually is not the true Km but the apparent Km. This is explained by the 
fact that there is always an amount (usually small amounts in the micromolar range) 
of substrate present in the radiolabelled tracer used for these measurements. hPAT1 
has Km values in the mM range (1-10mM) (Boll et al., 2004). As discussed in the 
previous section, the physiological concentration of proline is less than 1 mM. Thus 
there is no possibility of the transporter being saturated and being unable to bring 
about transport of substrates across the membrane. SLC36A1 acts as a transporter for 
a number of amino (beta and gamma) and imino (both D- and L-) acids in addition to 
certain drugs (Thwaites et al., 1994, Thwaites and Anderson, 2011). The main 
substrates for PAT1 are D and L proline, glycine and L alanine (Metzner et al., 2006). 
Proline has a higher affinity than glycine or alanine for PAT1 (Bröer et al., 2006). 
PAT1 is able to distinguish between D and L amino acids. In fact for some amino 
acids the affinity for some D amino acids is greater than that for L form (Bröer et al., 
2006) (Boll et al., 2002). For instance it cannot transport the L form of serine and 
cysteine but can transport the D form. PAT1 loses the ability to transport the L form 
of the amino acid if there is more than one -CH2 group in the side chain (Foltz et al., 
2004) (Boll et al., 2003). 
PAT1 is also capable of transporting small unbranched, apolar, zwitterionic (alpha, 
beta and gamma) amino and imino acids, D and L amino acids, heterocyclic 
amino/imino acids with 4-6 membered rings and N-methylated amino and imino 
acids (Hediger  et al., 2004). The drugs that PAT1 can transport include L-azetidine-
2-carboxylic acid (which is an anti-angiogenic) and δ-aminolevulinic acid (which is 
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used in photodynamic therapy) (Frølund et al., 2010). The aliphatic amino acids have 
a higher affinity than aromatic ones (Metzner et al., 2006). Methylation of the amino 
group in case of the aliphatic amino acids enhances the affinity further (Boll  et al., 
2003). PAT1 is also observed to be one of the transporters responsible for the uptake 
across the membrane Anderson et al., 2009). Analysis of PAT1 kinetics indicates that 
the proton binds to the transporter first followed by the substrate. The H+ and 
substrate then move across the membrane simultaneously (Foltz et al., 2005). 
 
1.7.3  Localisation 
The PAT1 protein is found in a variety of tissues ranging from the intestinal 
epithelium to neurons. Even the sub-cellular localisation in these tissues is found to 
vary. In the intestinal epithelia PAT1 is isolated to the brush border whereas in the 
neurons it is localised mainly in the lysosomal membrane and to a smaller extent in 
the plasma membrane (Hediger et al., 2004).  
PAT1 transport in both the neurons and the intestinal epithelium is driven by the H+ 
(Boll et al., 2004). Lysosomes are an important organelle in eukaryotic cells which 
help bring about the degradation of macromolecules. The products of this degradation 
are then transported out via specific membrane transporters and are reused. Defects in 
the working of these transporters can result in lysosomal storage diseases; such as 
sialic acid storage disease and nephropathic cystinosis (Sagné et al., 2001). PAT1 in 
the lysosomal membrane helps transport amino acids which are a formed as a result 
of proteolysis into the cytoplasm. The H+ rich conditions are provided by the V-type 
ATPases that cause the movement of H+ into the lysosome by using the energy 
derived by the hydrolysis of an ATP molecule. In the brush border membrane of the 
intestinal epithelium which is another region from where PAT1 was isolated, the 
acidic micro environment is provided by NHE3 (Boll et al., 2004). LYAAT1 was 
found to localise to lysosomes in some neurons. This seemed to be independent of the 
type of neuron it was (Agulhon et al., 2003). 
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1.8  PAT2 
1.8.1  Function  
PAT2 has been shown to bring about 1:1 amino acid: H+ symport. While PAT2 
transports amino acids, it is also suggested that it might play a role in myelination of 
neurons (Boll et al., 2004). PAT2 is also believed to be a regulating factor in myelin 
differentiation (Chen et al., 2003). Experiments involving the giant patch clamp 
technique using glycine as a substrate on oocytes showed that it is capable of 
transporting in both directions. 
 
1.8.2  Substrate affinity 
PAT2 shows higher substrate selectivity and affinity than PAT1 with Km values in 
the micromolar range (100-600 µM) (Boll et al., 2004). It is also observed to be pH- 
dependent like PAT1 and is also dependent on the membrane potential.  
The small neutral amino acids glycine, alanine and proline are the main substrates for 
PAT2 (Boll et al., 2002). Sarcosine is found to inhibit the transport activity. PAT2 
has narrower substrate specificity than PAT1 (Rubio-Aliaga et al., 2004). PAT2 is 
Na+ independent similar to PAT1 (Chen et al., 2003). While both β and γ-ABAs 
(amino butyric acids) can inhibit PAT1 the ABAs seem to have no effect on PAT2 
(Kennedy et al., 2005). PAT2 has a lower substrate affinity for GABA and β alanine. 
1.8.3  Localisation 
hPAT2 mRNA shows a high abundance in organs such as the kidneys, lungs and the 
brain (Foltz et al., 2004). In recent years immuno histochemistry studies have 
indicated the presence of the PAT2 protein in very specific regions of the spinal cord 
and the brain. The sub-cellular localisation of PAT2 is still to be determined, but in 
HeLa cells it does not localize to lysosomes but seems to be expressed in the plasma 
membrane (Boll  et al., 2004). PAT2 (endogenous) is shown to localise at least in part 
to the plasma membrane of neurons (Rubio-Aliaga et al., 2004). However studies 
have also shown that PAT2 localised to the endoplasmic reticulum and also on the 
surface of the recycling endosomes present in the neurons (Rubio-Aliaga et al.,  
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2004).  In the kidneys hPAT2 is expressed in the apical surface. Its presence appears 
to be restricted to the proximal tubule in the kidneys (Vanslambrouck et al., 2010) 
The PATs could play an important role in causing iminoglycinuria and hPAT2 has 
always appeared to be the strongest contender for this on account of its substrate 
specificity and lower affinity (Broer et al., 2008). This will be further discussed in 
section 1.11. 
 
 
1.9  PAT3 and PAT4 
PAT3 and 4 are considered as orphan transporters. PAT3 was first cloned from mice 
(Boll et al,. 2003). The PAT3 mRNA expression was found to be very high in the 
testis and negligible elsewhere (Bermingham and Pennington, 2004). There are two 
variants of PAT3 in humans variant 1 which is 123 bp longer than variant 2. 
Throughout the thesis variant 1 will be referred to as hPAT3.1 and variant 2 will be 
referred to as hPAT3.2. PAT4 was first identified based on sequence similarity to the 
remaining members of the SLC36 family. It seems to have a more ubiquitous 
expression (Foltz et al., 2004). 
 
 
1.10  Transporters and diseases 
The importance of these transporters is further highlighted by the fact that mutations 
in these transporters can often lead to diseases.  
For instance cystinuria which is the inability to transport cystine and can result in the 
accumulation of this product in the urine and lead to kidney stones is caused by a 
mutation in either the cationic amino acid transporter (SLC7A9) or in the cystine, 
dibasic and neutral amino acid transporter (SLC3A1) genes (Harnevik, Hoppe and 
Söderkvis, 2006). The fatal disease cystic fibrosis is caused by a mutation in the 
Cystic fibrosis transmembrane conductance regulator (CFTR) gene. Another disease 
which is caused by a defect in membrane transporter is Wilson’s disease which is the 
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result of a mutation in the ATP7B gene which results in a defect in the transportation 
of copper across the membrane (Orquin, 2011).  
 
 
1.11  PATs – Diseases and mutations 
Iminoglycinuria involves the excretion of proline and glycine in the urine. It is an 
autosomal recessive disorder and is of particular interest due to the complex 
phenotypes that are observed and the pedigree studies involved. There are three 
phenotypes observed. Two of these forms show normal heterozygotes who have renal 
iminoglycinuria but either with or without a defect in renal absorption. In the third 
type, heterozygotes show renal iminoglycinuria but with a normal intestinal 
phenotype (Chesney, 2001, Scriver, 1968).  Mutations in the SLC36A2 gene have 
been shown to be the major gene responsible for iminoglycinuria. Two mutations 
have been found in the gene, the first one is found to introduce a stop codon which 
causes translation of a non functional protein. The other mutation is a G87V point 
mutation which is a missense mutation which only partially affects transport function 
(Bröer et al., 2008).  
Another PAT related mutation which has been observed is the champagne mutation 
in horses. This point mutation causes a C to G mutation in exon 2 of PAT1 which 
changes the amino acid bein encoded from threonine to arginine. This point mutation 
is observed to be responsible for the champagne coat colour which is observed in 
horses (Cook et al., 2008). 
 
 
1.12  Research in the transport field 
Studies on characterizing transporter systems were undertaken initially in the 1960s. 
Most research was focussed on studying the substrates for the different transport 
systems and how they interact in intact tissues. Transport proteins (rather than 
systems) as we know them today were started in the 1980s with the cloning of 
SGLT1 (Ikeda et al. 1989).  
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Studies in the transport systems field prior to molecular and genomic techniques were 
made particularly difficult by the fact that different transporters were capable of 
transporting the same substrates. This overlapping substrate specificity is also why 
defects in transporters are generally not lethal. For example one of the first families of 
amino acid transport systems existence was established was the IMINO system. 
Although the IMINO system is considered as a classical transport system for amino 
acids in mammals it has yet to be well characterized at the molecular level. The vast 
genomic level studies undertaken over the past decade have unravelled a plethora of 
transporters, many of which have not been well characterized. Many of these were 
until now undiscovered mainly due to their low levels or tissue/cell/ sub-cellular 
specificity. In many cases these transporters are considered important for drug 
delivery. Transporters showing cellular specificity and high affinity for a drug that 
needs to target the region where it expresses it will be indispensible to the medical 
world. For this purpose, extensive studies are now being undertaken on these 
transporters to understand their substrate affinities so that they can then influence 
drug design (Kennedy et al., 2005). 
Intestinal transporters have always been considered important for nutrient absorption. 
However, in recent years they have gained a lot of importance as mediators of drug 
uptake. A variety of drugs have been designed and used which rely on the proton 
coupled transporters to aid in drug transport. The H+ proton gradient especially in the 
small intestine has been found to be responsible in aiding absorption of a variety of 
substrates including amino acids, peptides, vitamins and short chain fatty acids. 
 
 
1.13  Membrane topology studies of transport 
proteins 
1.13.1  Commonly used techniques 
The tertiary structure of transport proteins are generally very difficult to study due to 
the difficulties associated in extraction of the transport protein from the bilayer using 
detergent in addition to the conformational changes they undergo. Therefore when a 
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large amount of protein is isolated, which is one of the requirements of 
crystallography, the odds that most or all of them are in the same conformation are 
slim. Since there are very few crystal structure available for membrane transporters, 
different sratergies are used instead. Indirect methods are used to determine the 
membrane topology secondary structure) and then to predict the tertiary structure. 
Epitope tags have previously been used to characterize transporters for instance the 
EYMPE epitope tag has been used to characterize the H+ dipeptide transporter PepT1 
(Covitz et al., 1998). 
Determining how many transmembrane domains (TMDs) exist and what their relative 
orientation is the first step in trying to decipher the structure of these molecules. 
Various techniques have been developed by groups the world over for this purpose. 
In some cases, people generated fusion proteins using sections of phoA (Ehrmann et 
al., 1990) or lacZ (Wu et al., 1992). However, this is often found to result in a protein 
with an incorrect conformation due to its bulkiness. In the past few years, with 
increased development of software to predict the protein structure, the study of 
protein conformation has undergone a drastic change. The first step used in trying to 
understand the structure of a membrane transporter is to use prediction software to try 
and determine the various regions of the protein. The software analyses the primary 
structure of the protein and predicts the TMDs and N-C termini orientation (intra- or 
extra-cellular).  
Some of the commonly used membrane protein prediction software includes 
MEMSAT3, TMHMM, TopPred, SVMtm and TMpred. These were used for 
determining the various possible TMD regions of the hPATs. The results obtained 
based on these are discussed in the results chapter 4. Hydropathy plots of AAAP 
family members (to which PATs also belong) indicate that its members tend to have 
11 TMDs unlike the more common 12 TMD structure (Young et al., 1998). While 
similar considerations are taken into account by each of these softwares the level of 
stringency applied varies. This means that for the same transporter, depending on the 
software used the number of transmembrane domains predicted can vary making it 
necessary for experimental data to back up the membrane predictions. 
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Apart from crystallography, epitope insertion can also be used to study the 
conformation of the protein and the location of the TMDs. One of the methods 
commonly used to check the structure predicted using different programs is to use a 
combination of site directed mutagenesis and luminometry. Both these techniques are 
described in greater detail in the following section. In the initial stages, an epitope tag 
to which a commercial antibody is available is inserted into different regions of the 
gene via site directed mutagenesis.  
 
1.13.2  Site directed mutagenesis 
Site directed mutagenesis is a commonly used technique in molecular biology to help 
better understand the structure or function of genes. These mutations may be 
insertions or deletions; of single nucleotide mutations or larger regions such as 
epitope tags and multiple amino acids. The primary technique involved in site 
directed mutagenesis (SDM) is the Polymerase Chain Reaction (PCR) developed by 
Kary Mullis (Saiki et al., 1985). Primers designed for the PCR reaction are designed 
to contain the mutations that are to be introduced.  
The gene is then converted into a form suitable for introduction into the orgamism, 
(such as cDNA or cRNA injections). It is then to be expressed in the organism of 
choice. It is expected that unless the insertion has caused a loss of function, the 
functional transporter will be expressed on the membrane of the cells. The presence 
of the epitope, i.e whether external or internal, can be determined by luminometry. In 
intact cells, if the region where the epitope is inserted is present in TMD or within the 
intracellular region, then the region will not be available for the antibody to bind to 
and consequently it will remain undetected. However if the cells are permeabilised, 
then these sites will become accessible and can be detected. On the other hand, if the 
epitope is present on the extracellular region, then the antibody can interact and its 
presence can be detected even when the cell is unpermeabilised. FLAG is one such 
commonly used epitope, consisting of 8 amino acids (DYKDDDDK) (Hopp et al., 
1988). Antibodies are commercially available to this epitope already conjugated to 
the enzyme horseradish peroxidise (HRP). When the HRP conjugate is subjected to a 
high efficiency ELISA substrate it emits photons which can be detected by a 
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luminometer. In order to determine that the epitope tagged protein is functional, 
transport assays are performed. This involves comparing the transport activity of the 
protein containing the FLAG and one without it to check that the epitope tagging has 
not affected the function. However in case of proteins whose function is unknown 
(such as the orphan transporters), this technique of using a transport assay might not 
prove conclusive to ascertain whether the protein is functional. In these cases, the 
epitope tagging technique will have to be well established using members of the same 
family whose function is known before moving on to one which may not necessarily 
have known transport activity.  
 
 
1.14  Studies of SLC36 homologs in Drosophila 
Apart from mice, homologs of the PATs have also been studied in Drosophila. There 
are eleven PAT-related transporters in Drosophila (Boll et al., 2004). These studies 
have proved especially useful in case of the orphan PATs whose functions have not 
been established. Due to the ease with which the organism can be maintained and the 
short time required to observe the changes when a gene is over/under expressed, 
Drosophila allow the researcher to study if there are other functions which the protein 
could be participating in.  
It is known that signals from the insulin receptors (InR) and local nutrients help 
regulate cellular growth. These signals in turn help modulate the TOR (Target of 
Rapamycin) kinase activity. Nutrient signals are in part modulated by amino acid 
levels which in turn are modulated by amino acid transporters. In Drosophila InR 
pathway plays an important role in regulating local nutrient levels especially amino 
acid levels. These levels in turn are dependent on amino acid transporters. Goberdhan 
et al., 2005 showed that the PAT family can regulate growth in tissues in vivo. The 
components of InR/TOR also interact at a molecular level with genes such as PATH 
(pathetic) which is a member of the Drosophila PAT family. 
This is an experimental tool, over-expressing genes in these particulat ‘reporter 
tissues’. Path is expressed during various developmental stages and is important for 
both local and overall growth. CG1139 which is functionally similar to PAT1 has 
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been characterized in Drosophila melanogaster and is found to be associated with 
growth. Defects in eye and wing, size and development were found to be associated 
with mutations in this gene. CG1139 can regulate growth similar to PATH which has 
different transporter properties indicating that members of this family which have 
sequence similarity but different substrates can have a conserved function of 
regulating growth (Goberdhan et al., 2005).  
 
 
1.15  Choice of model system 
1.15.1  Xenopus oocytes 
Oocytes from Xenopus laevis, the South African clawed frog are commonly used as a 
popular system to study the expression of proteins (Gurdon and Melton, 1981). They 
were first developed as a model system in the University of Oxford by Gurdon as a 
graduate student. He had observed that Xenopus laevis oocytes which had their own 
nuclei removed/destroyed and replaced by one from another cell could express the 
non-nature proteins from the cell type of the donor nucleus. 
The oocytes have the ability to translate RNA that they are injected with into proteins 
(Laskey et al., 1972) using their own translation machinery. The oocyte system is 
commonly used to study ion channels and transporters since the translated protein is 
then directed to the membrane and its functions can be observed (Brown, 2004). The 
Xenopus oocytes have a fairly large diameter (1.1-1.3 mm) and are well equipped to 
bring about translation of a heterologous protein. In addition to this, they express a 
rather small range of endogenous membrane proteins, which in turn implies that the 
heterologous proteins which are expressed will have a fairly low background. This 
makes the Xenopus laevis oocyte a favoured model system in which to study 
transporters (Wagner et al., 2000). They are also extremely useful in 
electrophysiological studies. In addition to this the membrane proteins that the oocyte 
expresses such as receptors and channels have been well characterized and 
documented over time. For instance, the Xenopus ooccyte expresses endogenous 
muscarinic acetylcholine receptors but not nicotinic ones (Herrera et al., 1993). 
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Perhaps the most popular application of the Xenopus laevis oocyte was in the 
discovery of aquaporins by Peter Agre for which he won the Nobel Prize in 2003.  
 
 
1.15.2  TM4 cell line 
Currently, there is no evidence to indicate the presence of PAT3 in any tissues except 
in the early developmental stages of the mouse testis. TM4 is a mouse Sertoli cell line 
and it appears to be a good candidate to investigate for the endogenous expression of 
PAT3. In case there was no endogenous expression of PAT3, it could then be a good 
system to study PAT3 using transfections to express the PAT3 gene. On the other 
hand, if there was expression this cell line could then be used to test transport 
function directly and interactions that it may have with the other PATs could then be 
studied using RNAi. As a Sertoli cell line, it is hoped that TM4 cells will provide an 
environment similar to that in the testis thereby facilitating expression of PAT3. 
 
1.15.3  HEK 293 cell line 
The Human Embryonic Kidney 293 cell line as the name suggests was derived from 
primary embryonic kidney cells and is one of the most commonly used cell lines. 
They are used extensively on account of the ease of culturing them and performing 
transfections. They tend tend to give very good transfection efficiencies in the range 
of >80 % with most reagents. HEK293 cells are therefore used extensively to study 
recombinant proteins. 
There is a lot of debate about whether the origin of these cells is epithelial or 
endothelial with new research even suggesting that these cells could have properties 
of neuronal cells (Shaw et al., 2002). Due to these reasons, the HEK 293 cell line is 
not used to study a particular cell type but to get a better idea about what the roles of 
recombinant proteins in a cell culture. 
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Aims of the Thesis 
 
The general aim of the project was to better understand the hPAT transporter family. 
hPAT1 and hPAT2 had been functionally characterized as proton coupled amino acid 
transporters. hPAT3 and hPAT4 on the other hand were categorised as orphan 
transporters and their functions unknown. The main aims of the project were as 
follows 
 
• To elucidate the function of hPAT4 (using the oocyte expression system) 
 
• To characterize substrate affinities, specificity and other features of the 
transporter 
 
• To predict the Trans Membrane Domain structure using different membrane 
prediction software 
 
• To confirm the predicted structure using the techniques of site directed 
mutagenesis, epitope tagging and luminometry 
 
• To study the champagne mutation using expression in Xenopus laevis oocytes 
and to study how the mutation might produce effects. 
 
• To use Xenopus laevis oocytes and cell culture techniques to study the 
functions of hPAT3 
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Chapter 2:  
Materials and methods 
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A  General materials and methods 
2.1  General materials 
The table summarises where the products used for the different experiments were 
purchased from. Antibodies etc are mentioned in the relevant sections 
 Product/ Material Supplier 
 General chemicals Sigma Aldrich 
Molecular 
biology- 
Subcloning/ 
Mutations 
Easy A polymerase Stratagene 
GoTaq Flexi polymerase/ GoTaq polymerase  Promega 
Plasmid extraction 
Miniprep, midiprep, maxiprep 
Promega 
PCR purification  
Gel extraction 
Qiagen 
RNA extraction Qiagen 
Subcloning grade competent cells Stratagene 
Quickchange Pfu polymerase Stratagene  
Antibiotics- Kanamycin, Ampicillin Sigma Aldrich 
LB agar, LB broth Sigma Aldrich 
Primers for cloning / mutating genes into the 
pXT7 vector 
Sigma Aldrich 
Primers for cloning genes into the mammalian 
vector pcDNA3.1(-) 
Fisher Scientific 
Oocyte work [3H] L- amino acids Perkin Elmer 
Scintillation cocktail Perkin Elmer 
   
Cell culture  Confocal compatable dishes (zero thickness) IBIDI 
6 well plates BD Biosciences 
 75 ml flasks Nunc 
 Bradfords reagent Bio-rad 
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2.2 General methods 
2.2.1 Plasmid DNA extraction 
a) For minipreps 5 ml culture was grown overnight in a 50 ml tube at 37 ºC in LB 
broth containing antibiotic 
b) For midipreps 50 ml culture was grown overnight in a 50 ml tube at 37 ºC in LB 
broth containing antibiotic 
c) For maxipreps 250 ml culture was grown overnight in a 500 ml tube at 37 ºC LB 
broth containing antibiotic 
In all three cases even though the initial volumes were different from the 
manufacturer’s recommendations, the protocol followed was still the same (Promega 
UK, PureYield Plasmid Mini-Prep system, PureYield Plasmid Midiprep System and 
Pureyield Plasmid Maxiprep System). Mini preps were eluted in 50 µl, midipreps in 
600 µl and maxi preps were generally eluted in 1.5 ml nuclease free water. 
 
2.2.2 Transformation of ligation/PCR products/plasmids into 
competent cells 
a) using heat shock 
1. 100 µl (in case of ligation and 50 µl for general plasmid transformations) 
subcloning grade competent cells were transferred into 15 ml tubes placed on ice. 
2. 4 µl of the ligation product or 1 µl of the plasmid was added to the cells and mixed. 
3. The tubes were then placed on ice for 30 mins 
4. They were then subjected to heat shock for 45 seconds at 42 ºC and then placed on 
ice for 2 minutes. 
5. 450 µl SOC medium was then added to the tube and placed in the incubator for 2 
hours. 
6. 200 µl of the medium was then placed on LB agar plates with antibiotic overnight 
at 37 ºC. 
 
b) using electroporation (XL1 blue electroporation competent cells) 
1. 30 µl of cells are placed in a 0.5 ml tube placed on ice. 
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2. 0.5 µl plasmid DNA or 2 µl ligation product was then added to the cells and mixed. 
3. This mixture was then transferred to the cuvettes specially designed for 
electroporation (Equibio-ECU102, 0.2-cm gap).  
4. A pulse was then given and the cuvettes were placed on ice for 2 minutes (200W 
resistance, 2500Volts using a Gene pulser from Bio-Rad, UK). 
5. After this time, the cells were transferred into 15 ml tubes with 950 µl SOC 
medium and placed in the shaker at 37 ºC for 2 hours. 
6. 50 µl – 100 µl was then plated on LB agar plates (with antibiotic) and placed in the 
37 ºC incubator overnight. 
 
2.2.3  PCR purification and gel extraction 
PCR purifications and gel extractions were performed as per manufacturer’s 
instructions (Qiagen, UK) but were then eluted in 25 µl nuclease free water. 
 
 
B  Molecular biology of transporter encoding genes 
2.3  Obtaining the clones 
Clones of hPATs 2, 3 and 4 were purchased from Source BioScience, UK. hPAT1 
(clone no. 9020426) was obtained from Deborah Goberdan (personal communication) 
in the insect vector pUAST.  hPAT2 (clone number 40010274) was in the pCR 
BluntII TOPO vector, while PAT4 (clone number 5313230) was in the pBluescriptR 
vector. Two clones of hPAT3 i.e the two different splice variants (clone numbers 
40009826 and 400009832) were also in the pCR BluntII TOPO vector.  
 
 
2.4  Preparation of miniprep stocks and glycerol 
stocks 
The most common technique for making stocks of DNA plasmids is to use minipreps 
or midepreps. Minipreps generally tend to usually give smaller amounts (approx. 75 
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µl of 0.3-0.5 µg/ µl) of DNA whereas midipreps tend to give about 1 ml of 1 µg/µl 
DNA. Overnight cultures were set up and the plasmid DNA was extracted using 
either a miniprep or a midiprep. The quality of the plasmid obtained was observed to 
be better using minipreps as compared to midipreps. Multiple sequential minipreps 
were observed to give better quality DNA which was more useful for cRNA synthesis 
as opposed to midipreps. For both the midi prep and mini prep the manufacturer’s 
instructions were followed (Promega). 
The colonies which were confirmed by sequencing were transformed as described 
earlier and plated on LB agar plates containing ampicillin. Colonies were selected the 
following morning and incubated in 5 ml LB broth with ampicillin. 100 µl of the 
sample was then added to six 50 ml Corning tubes containing 10 ml of LB medium 
each (with 50 mM Amp) in the evening and incubated overnight at 37°C. The 
following day, 1000 µl of the sample was taken from one of the tubes to prepare 
glycerol stocks. Glycerol stocks were prepared by adding 800 µl of cell culture and 
200 µl glycerol , mixed and stored at -80°C The tubes were spun at 13000 rpm and 
the pellet was resuspended in 500 µl resuspension solution (promega) and divided 
into two tubes and the mini prep (Promega) was performed as per the manufacturers 
instructions. The DNA was then eluted in 50 µl each and pooled together at the end 
giving a final volume of approximately 600 µl. The concentration of the DNA was 
measured and a sample sent for sequencing to confirm the sequence 
 
 
2.5  Subcloning of hPATs into the oocyte vector 
2.5.1  Introduction  
Preliminary experiments were set up to express the hPATs in Xenopus using the 
vectors that the clones were purchased in. The results obtained however showed very 
low transport activity even for the controls. It was therefore decided to subclone the 
hPATs into an oocyte expression vector. Figure 2.1 shows a schematic representation 
of the stratergy followed for subcloning the hPATs into the Xenopus vector.  
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Figure 2.1: Schematic representation showing the subcloning stratergy adopted 
to clone the hPATs into the oocyte expression vector. The hPAT gene was first 
subcloned onto the pGEM-T Easy. The gene was then digested out of pGEM-T Easy 
and introduced into pXT7 which had also been digested using the same restriction 
endonucleases.  
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Subcloning is a technique that involves removing a gene out of the vector, which 
might not be suitable for expressing the gene in the model system and cloning it into 
a vector which expresses well in the system of choice (in this case Xenopus laevis). 
The preliminary step in subcloning is choosing restriction sites which are unique to 
the final vector that the gene is to be introduced into. 
 
2.5.2  Subcloning of hPATs into pGEM-T Easy 
Prior to cloning the genes into the final vector (pXT7 which will be explained further 
in the next section), the genes were first cloned into the pGEM-T Easy (Promega) 
system. This was primarily so that we can grow the gene in pGEM-T Easy as much 
as required and could have a large stock of it. This would be useful if the direct 
ligation were to fail we would have to start with the initial PCR step again. In 
addition to this the pGEM-T Easy step also ascertained that a single clone was used 
to grow up the final template. 
 
2.5.2.1  PCR 
As described in section 2.5.1 primers unique to the final vector are required to insert 
the gene of choice into it. Since none of the hPATs have KpnI or EagI sites present in 
the genes or the vectors, these sites were introduced via PCR into them.  The primers 
used for subcloning hPATs 1-4 are enlisted in table 2.1 
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Primer Sequence 
PAT1 
Forward 
GCTGGTACCCCATGTCCACGCAGAGACTTCG 
PAT1 
Reverse 
AGCCGGCCGTCCCTATATGAAGGCACAGGTGGAATTG 
PAT2 
Forward 
GCTGGTACCGCTCCTTGTTTCTTAAGCAGTCATGTCTGTG 
PAT2 
Reverse 
AGCCGGCCGTCGGGTGCTGGTAGGCAAGGA 
PAT3 
Forward 
GCTGGTACCGTTGAAGATGTCATTGCTTGGAAGGGACTAC 
PAT3 
Reverse 
AGCCGGCCGGAATAAAAACAGATAATTATGCATGGACACCTG
TGG 
PAT4 
Forward 
GCTGGTACCGGCGGCGTCCTGGAGACC 
PAT4 
Reverse 
AGCCGGCCGGAAGACTCATGATTCTGCTTTTACTATTTCAAAC
CAG 
 
Table 2.1: Primers used in the subcloning of the hPATs into pGEM-T Easy and 
eventually the pXT7 vector 
KEY  
Alaline linker     
Res site  
Forward: KpnI  
Reverse: EagI     
Untranslated region  
 
The PCR was set up using Easy A polymerase which adds aditional A nucleotides 
which will facilitate ligation with the vector pGEM-T Easy which is an open vector 
that has T nucleotides flanking the ends (table 2.2) 
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Reagent Amount 
10x easyA buffer 1x 
Forward primer (10 µM) 1.25 µl 
Reverse primer (10 µM) 1.25 µl 
dNTPs (25 mM) 1 µl 
Template (50ng) 1 µl 
H2O To bring up the volume to 50 µl 
Enzyme 1 µl 
Table 2.2: PCR set up using Easy A 
 
The PCR conditions were set up with an initial denaturation step 95 °C for 3 minutes, 
followed by 35 cycles of denaturation at 95 °C for 30 seconds, annealing at 65 °C for 
1 minute and extension at 72 °C for 2 minutes. This was followed by a final extension 
step for 10 minutes. The reaction was then allowed to soak at 4  
An annealing temperature of 65°C was selected since each of the primers had a Tm of 
about 70 °C. 
 
2.5.2.2  DpnI treatment and ligation of the PCR product with pGEM-T Easy 
The PCR product was DpnI (New England Biolabs) treated for thirty minutes at 37 
ºC and then PCR purified. DpnI digests only the methylated bacterial DNA template 
leaving behind only the PCR product. 5 µl of the sample was run on the gel to check 
that the product was the correct size. The concentration of the product was 
determined and an overnight ligation was set up using the pGEM-T Easy vector. 
Ligations were set up using 1:3, 1:1 and 3:1 molar ratios of insert:vevctor. The 
reaction was set up to contain reagents as enlisted in table 2.3. Control reactions were 
also set up alongside. 
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 1:1 3:1 Negative 
control 
(without 
vector) 
Negative 
control 
(without 
insert) 
Positive 
control 
Insert 1 µl  
at 25 
ng/µl 
1 µl  
at 75 
ng/µl 
1 µl 
at 75 ng/µl 
- 1 µl 
(supplied 
with the kit) 
Vector 
(50ng/µl) 
1 µl 1 µl - 1 µl 1 µl 
Buffer 2 µl 2 µl 2 µl 2 µl 2 µl 
ddH2O 2 µl 2 µl 3 µl 3 µl 2 µl 
T4 ligase 1 µl 1 µl 1 µl 1 µl 1 µl 
Total volume 10 µl 10 µl 10 µl 10 µl 10 µl 
Table 2.3: Table showing pGEM-T Easy ligation set up 
 
The tubes were then placed in the 17 ºC incubator overnight. On the following day, 2 
µl of the ligation product was transformed into electrocompetent cells and placed in 
the 37°C for an hour. LB agar plates containing ampicillin were prepared. When the 
transformants were being incubated for an hour, 100 µl X-Gal IPTG was spread on 
the ampicillin plates. The plates were allowed to dry for 2 mins and placed in the 
37°C incubator till the cells were ready to be plated. After the 1 hour incubation in 
SOC, 100 µl of cells was then plated onto LB agar plates with Ampicillin and X-Gal-
IPTG to help select positive colonies. Colonies which are white are possible positive 
clones. The principle of Blue-white screening involves genetic engineering of the lac 
operon. Disruption of the subunit of the lacZα gene by the insert prevents the lacZα 
gene from being encoded . If the vector had religated in the absence of the insert then 
the lacZα subunit from the vector and the Ω subunit encoded by the bacterial gene 
can complement to form the functional β-galactosidase enzyme. β-galactosidase 
enzyme is capable of breaking down X-Gal to form an insoluble blue product,  5-
bromo-4 chloroindole. IPTG is used to induce the synthesis of Lac operon. The plates 
were then incubated overnight at 37 °C. On the next day 5-10 positive colonies (white 
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colonies) were selected and incubated overnight in LB medium containing 
Ampicillin. The cultures were then purified (promega miniprep). 
 
2.5.2.3  Analysing positive clones 
The possible clones were then checked for the presence of the insert by using 
restriction digests (sites which were present within the gene but not in the vector), 
and those that appeared to be positive were send for sequencing to confirm 
(GeneService). Primer T7F was used for sequencing unless specified otherwise. 
 
2.5.3  Ligation of hPATs with pXT7 
2.5.3.1  Introduction 
hPATs which were cloned into pGEM-T Easy were then used as a template to 
perform the ligation of the genes into pXT7.  
The pXT7 vector is a modified pGEM-4Z vector. PepT1 was cloned into the pXT7 
vector by Dr. David Meredith (personal communication). This vector had previously 
been used by the lab to study transporters such as PepT1 and PepT2 and is found to 
be a good expression vector for the oocyte system. pXT7 contains an Ampicillin 
resistance gene in addition to two strong promoters T7F and SF6. pXT7 has 
untranslated regions (UTR) of the rabbit beta globin gene flanking the multiple 
cloning site; 50 bp at the 5' end and 290 bp at the 3' end. These UTR regions increase 
the efficiency of translation. Figure 2.2 gives a diagrammatic representation of the 
pXT7 oocyte expression vector. 
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Figure 2.2 : Diagrammatic representation of the pXT7 vector with the hPAT 
gene. Flanking the hPAT gene are the Xenopus Beta globin untranslated regions. The 
vector has both T7 and SP6 promoters; however for the purpose of cRNA synthesis 
the T7 promoter was used. The gene was subcloned into the vector using 5’ KpnI and 
3’ EagI sites. 
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Prior to subcloning the hPAT genes into the pXT7 vector, it was necessary to remove 
the PepT1 gene from it. For this purpose it was necessary to chose two restriction 
enzymes which were absent in the genes (hPATs) and the pGEM-T Easy vector 
system (which will be explained further in the next section). The two restriction 
enzymes selected were KpnI and EagI. KpnI was found upstream of the PepT1 gene 
within the pXT7 vector. EagI  on the other hand is found close to the stop codon 
within the PepT1 gene. PepT1 in pXT7 was digested with KpnI (New England 
Biolabs) and purified (table 2.4). PCR purification was done after all the restriction 
digestion steps using the manufacturer’s instructions (Quiagen).  
Reagent Final concentration 
pXT7-PepT1 15 µg 
10x Buffer (NEB3) 1x 
EagI (NEB) 15 units 
Nuclease free water To bring up the final volume to 50 µl 
Table 2.4: Linearization of pXT7-PepT1. Sequential digest Part 1 
 
Following this the EagI digest was performed (table 2.5), PCR purified and then run 
on the gel. The vector was then cut out of the gel, purified and its concentration 
measured.  
Reagent Final concentration 
pXT7-PepT1 linearised with EagI 10 µg 
10x Buffer (NEB3) 1x 
BSA 100 µg/ml 
KpnI (NEB) 10 units 
Nuclease free water To bring up the final volume to 50 µl 
Table 2.5: Digesting the linearised pXT7-PepT1 to obtain an open pXT7 vector. 
Sequential digest Part 2 
 
2.5.3.2  Restriction digests 
The genes were sequentially restriction digested using EagI (table 2.6) for three hours 
and KpnI (table 2.7) for an hour. The restriction digest was purified both in between 
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the two digests and after the second digest. The products were then run on the gel to 
check for the fragment of the correct size. The fragments of the expected size 
(approximately 1.5 kb) were then cut out and purified; the concentration of the 
products was measured. 
Reagent Final concentration 
Template (hPAT in pGEM-T Easy) 5 µg 
10x Buffer (NEB3) 1x 
EagI (NEB) 10 units 
Nuclease free water To bring up the final volume to 50 µl 
Table 2.6: Linearisation of hPAT in pGEM-T Easy with EagI (PartI of the 2 step 
sequential digest) 
Reagent Final concentration 
Template (hPAT in pGEM-T Easy) 
linearised with EagI 
5 µg 
10x Buffer (NEB1) 1x 
BSA 100 µg/ml 
KpnI (NEB) 10 units 
Nuclease free water To bring up the final volume to 50 µl 
Table 2.7: Restriction digest of hPAT (linearised with EagI and purified ) using 
KpnI (Part 2 of the sequential digest) 
 
2.5.3.3  Ligation of hPAT genes with pXT7 
 3:1 Negative control 
(without vector) 
Negative control 
(without insert) 
Positive 
control 
Insert x 75 ng 75 ng - PepT1 75ng 
Vector y (50ng/µl) 50 ng - 50 ng 50 ng 
Buffer 2 µl 2 µl 2 µl 2 µl 
ddH2O 10-(x+y+2) µl 
T4 ligase 1 µl 1 µl 1 µl 1 µl 
Total volume 10 µl 10 µl 10 µl 10 µl 
Table 2.8: Ligation of hPAT with pXT7 
Chapter 3                                                                                           Molecular Biology 
 
 
45
Overnight ligations were set up using molar ratios of insert:vector of 3:1, 1:1 and 1:3 
as shown in table 2.8. 
The next day transformations were set up using electrocompetent cells as described in 
section on general methods. Positive clones were detected as described earlier in 
section 2.3.4.  
 
2.5.3.4  Confirming positive ligations 
Colonies were selected the following day and incubated in LB Broth with ampicillin 
overnight. The following day plasmid DNA was extracted from the cultures and 
concentration measured. Potential positive clones were checked by restriction digest 
using NdeI which is present in pXT7 but not in hPATs 2, 3 (both isoforms) and 4. For 
hPAT1 restriction digest was done using SalI which is present in the pXT7 vector but 
absent from hPAT1. Clones that were digested and appeared to be positive were then 
sent for sequencing to confirm. 
 
 
2.6  Site directed mutaganesis for introduction of the 
FLAG epitope tags into hPAT1 
2.6.1  Primer design for the introduction of epitope tags in the 
hPAT1 gene 
Based on the MEMSAT3 (Jones, Taylor and Thronton, 1994) prediction results 
which will be discussed in the results chapter, twelve separate FLAG tags were 
introduced into the PAT1 gene (in the pXT7 vector). FLAG epitope contains the 
amino acid sequence DYKDDDDK which as a nucleotide sequence can be written as  
5’ gac tac aaa gac gac gac gac aaa 3’. The primer sequences used to insert the FLAG 
are in the table below (2.9 and 2.10). Two sets of FLAGs were inserted, one set of 
potential external FLAGs and one set of potential internal FLAGs. 
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Primer name Sequence  
1F CTC CCT CTG GCG GTG GAC TAC AAA GAC GAC GAC 
GAC AAA AAT GCA GGC ATC 
1R GAT GCC TGC ATT TTT GTC GTC GTC GTC TTT GTA 
GTC CAC CGC CAG AGG GAG 
2F GCT GAC AAC TTT GAC TAC AAA GAC GAC GAC GAC 
AAA CAG GTG ATA GAA GCG 
2R CGC TTC TAT CAC CTG TTT GTC GTC GTC GTC TTT GTA 
GTC AAA GTT GTC AGC 
3F AGG ATC CCA GAC TAC AAA GAC GAC GAC GAC AAA 
CCC AGC CAC CTC CCC 
3R GGG GAG GTG GCT GGG TTT GTC GTC GTC GTC TTT 
GTA GTC TGG GAT CCT  
4F GCT AAT ATC CAA GGC AGC GAC TAC AAA GAC GAC 
GAC GAC AAA ATA ACC CTC AAC 
4R GTT GAG GGT TAT TTT GTC GTC GTC GTC TTT GTA 
GTC GCT GCC TTG GAT ATT AGC 
5F CCC CGC CTG GAC CTG GAC TAC AAA GAC GAC GAC 
GAC AAA GTC ATC TCC CTG  
5R CAG GGA GAT GAC TTT GTC GTC GTC GTC TTT GTA 
GTC CAG GTC CAG GCG GGG 
6F CCC ATC TTC ATC AAT TCC GAC TAC AAA GAC GAC 
GAC GAC AAA ACC TGT GCC TTC 
6R GAA GGC ACA GGT TTT GTC GTC GTC GTC TTT GTA 
GTC GGA ATT GAT GAA GAT GGG 
Table 2.9: Primers for introducing the putative external FLAGs in hPAT1 
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Primer name Sequence 
i1F GAC TAC CAC GAC TAC AAA GAC GAC GAC GAC 
AAA GAC TAC AGC TCC 
i1R GGA GCT GTA GTC TTT GTC GTC GTC GTC TTT GTA 
GTC GTG GTA GTC 
i2F AGG CTG AAT AAA GAC TAC AAA GAC GAC GAC 
GAC AAA TCC TTT GTG 
i2R TCC GAC TTA TTT CTG ATG TTT CTG CTG CTG CTG 
TTT AGG AAA CAC 
i3F CCT CCG AGC CCT GAC TAC AAA GAC GAC GAC GAC 
AAA GTC CAT CTT CTC 
i3R GAG AAG ATG GAC TTT GTC GTC GTC GTC TTT GTA 
GTC AGG GCT CGG AGG 
i4F GAT CCT CGG AAG GAC TAC AAA GAC GAC GAC 
GAC AAA TTC CCA CTC ATC 
i4R GAT GAG TGG GAA TTT GTC GTC GTC GTC TTT GTA 
GTC CTT CCG AGG ATC 
i5F GAG CAC TGT GAG GAC TAC AAA GAC GAC GAC 
GAC AAA TTA GTG GTG GAC 
i5R GTC CAC CAC TAA TTT GTC GTC GTC GTC TTT GTA 
GTC CTC ACA GTG CTC 
i6F GGC ATG AGC CCC GAC TAC AAA GAC GAC GAC 
GAC AAA CTC ACC ATC TTT AAG 
i6R CTT AAA GAT GGT GAG TTT GTC GTC GTC GTC TTT 
GTA GTC GGG GCT CAT GCC 
Table 2.10: Primers for introducing the putative internal FLAGs in hPAT1 
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2.6.2  Introduction of the epitope tag using PCR 
For the intrroduction of the FLAG epitope either the quick change lightning site 
directed mutagenesis kit (Agilent/Stratagene) was used. The PCR reaction was set up 
to contain reagents as shown in table 2.11 
Component  Volume 
Template (50ng) 1 µl 
Forward primer (10 µM) 1.25 µl 
Reverse primer (10 µM) 1.25 µl 
Quickchange solution 1.5 µl 
dNTP mix 1 µl 
H2O To a final volume of 50 µl 
Enzyme 1 µl 
Table 2.11: PCR set up for site directed mutagenesis to introduce the FLAG 
epitope into the hPAT gene 
The PCR reaction was set up using initial denaturing at 95°C for 2 minutes, followed 
by 18 cycles of denaturation at 95°C for 20 seconds, 60°C for 10 seconds and 68°C 
for 2.5 minutes. A final extension step at 68°C was performed for 5 minutes before 
storing at 4°C.  
 
2.6.3  DpnI treatment and transformation of the PCR products into 
bacterial cells 
The PCR product was then treated with DpnI for 30 minutes and purified before 
transforming it into XL-10 Gold competent cells. To 40 µl of cells on ice, 2 µl of beta 
mercaptoethanol was added and mixed. After 2 minutes, 2 µl of the PCR product was 
added and mixed and placed on ice for 30 mins. The mixture was then heat-shocked 
for 40 seconds and placed on ice for 2 minutes before adding 200 µl of SOC medium 
to it and incubating it for 1 hour. 200 µl of the mixture was then plated on LB agar 
plates containing Ampicillin.  
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2.6.4  Analysis of positive clones 
The following day positive clones were selected and confirmed by sequencing. T7F 
was used for sequencing FLAGS 1-4 and internal FLAGSi1-i4, the sequencing 
primer seq1.4 (TCTGGGGTACCTGCAATTTG) was used to confirm the sequences 
FLAGS 5, 6, i5 and i6. 
 
 
2.7  Introduction of champagne mutation (using 
SDM) 
2.7.1 Primer Design 
The champagne mutation was introduced using the primers enlisted in table 2.12. The 
champagne mutation is a C  G point mutation which causes a change in the amino 
acid from a threonine  arginine. 
Primer name Sequence 
champF GGC AAC ATT GGC AGA GGA CTC CTG 
champR CAG GAG TCC TCT GCC AAT GTT GCC 
Table 2.12: Primers to introduce the champagne mutation in the hPAT1 gene 
 
2.7.2 PCR reaction to introduce the mutation 
The mutation was introduced using both the PAT1 and the FLAG1 PAT1 templates. 
The PCR set up using the same conditions as for the FLAG insertions. The PCR 
reaction was set up using initial denaturing at 95°C for 2 minutes, followed by 18 
cycles of denaturation at 95°C for 20 seconds, 60°C for 10 seconds and 68°C for 2.5 
minutes. A final extension step at 68°C was performed for 5 minutes before storing at 
4°C.  
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Component  Volume 
Template (50ng) 1 µl 
Forward primer (10 µM) 1.25 µl 
Reverse primer (10 µM) 1.25 µl 
Quickchange solution 1.5 µl 
dNTP mix 1 µl 
H2O To a final volume of 50 µl 
Enzyme 1 µl 
Table 2.13: PCR mix for the SDM of hPAT to introduce the champagne 
mutation 
 
2.7.3  DpnI treatment, transformation and analysis 
The product was DpnI treated for 30 minutes, PCR purified and transformed into XL-
10 Gold cells (as described in section 2.1.4.3) and plated on LB agar plates as 
described. Clones were selected at random and grown in LB medium with Ampicillin 
and analysed by sequencing. 
 
 
2.8  Subcloning of hPATs into the mammalian vector 
pCDNA3.1(-) (Invitrogen) was the mammalian vector which was used to subclone 
the hPAT3. Since there weren’t any restriction sites that were unique and common to 
both pCDNA3.1(-) and hPATs in pXT7 and in the same orientation as required it was 
necessary once again to introduce restriction sites via PCR as used in the subcloning 
into the pXT7 vector. This time both the 5’ and 3’ ends were designed to have KpnI 
sites.  
Figure 2.3 gives a diagrammatic representation of the subcloning strategy followed. 
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Figure 2.3: Cloning strategy to subclone hPATs 2, 3.1 and 3.2 into the 
mammalian expression vector pcDNA3.1(-). The pcDNA3.1(-) was lineared using 
KpnI and ligated with the hPAT genes (which which were restriction digested out of 
pGEM-T Easy vector using the same restriction site. 
pcDNA3.1
(-) 
pcDNA3.1(-) 
digested 
with KpnI 
pcDNA3.1(-) 
with hPAT 
pGEM-T 
Easy 
pGEM-T 
Easy with 
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hPAT PCR 
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The same forward primer was used as the one for subcloning hPAT2 and 3 into pXT7 
but the reverse primer was designed to contain a KpnI site instead of an EagI site as 
used in case of the pXT7 subcloning. 
Primer Sequence 
PAT2 
Reverse 
AGCGGTACCTCGGGTGCTGGTAGGCAAGGA 
PAT3 
Reverse 
AGCGGTACCGAATAAAAACAGATAATTATGCATGGACACCTG
TGG 
 
 
KEY Alanine linker     Res site Reverse: KpnI Untranslated region 
Table 2.14: Primers used to subclone hPATs 2, 3.1 and 3.2 into the mammalian 
vector 
The hPAT genes was first subcloned into the pGEM-T Easy vector and then digested 
out using the KpnI site and inserted into the pcDNA3.1(-) vector (which was also 
digested with KpnI). 
 
The vector was digested using KpnI (high Fidelity)  table 2.15 
Reagent Final concentration 
pcDNA3.1(-)  10 µg 
Buffer J (Promega) 1x 
BSA 100 µg/ml 
Alkaline phosphatase 5 µl 
KpnI (Promega) 10 units 
Nuclease free water To bring up the final volume to 50 µl 
Table 2.15: Linearistion of pcDNA3.1(-) using KpnI 
The template was PCR purified and its concentration measured and the digested 
vector stored at -20 °C  
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The PCR was set up under the following conditions  
Reagent Amount 
10x easyA buffer 1x 
Forward primer (10 µM) 1.25 µl 
Reverse primer (10 µM) 1.25 µl 
dNTPs (25 mM) 1 µl 
Template (50ng) 1 µl 
H2O To bring up the volume to 50 µl 
Enzyme 1 µl 
Table 2.16: PCR set up for the amplification of hPAT2, 3.1 and 3.2 genes to 
introduce KpnI sites at the 5’ and 3’ ends  
 
The product was PCR purified and run on a gel to confirm the size. The PCR product 
was then ligated with the digested vector using a molar ratio of 3:1 (insert:vector) and 
50 ng of Vector DNA and adjusting the volume of the insert to adjust for the molar 
ratio. 10 µl of the solution was set up to contain a final concentration of 1x buffer and 
2 µl T4 DNA ligase (Promega) and kept in the 17 degree incubator overnight. 4 µl of 
the ligation product was transformed using subcloning grade heat shock cells as 
described in section (2.4.1) and plating it on Ampicillin plates followed by overnight 
incubation at 37 degrees. 
The presence of hPAT genes with KpnI sites in pGEM was confirmed by sequencing 
and this was used as the template to set up restriction reactions with KpnI. 
Reagent Final concentration 
hPATs 5 µg 
Buffer J (Promega) 1x 
BSA 100 µg/ml 
KpnI (Promega) 10 units 
Nuclease free water To bring up the final volume to 50 µl 
Table 2.17: Restriction digest of hPATS with KpnI 
The digestion products corresponding to the correct size (approx 1.5 kb) was gel 
extracted, purified and used to set up ligation reactions with 100 ng vector. The 
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strategy followed was the same as the subcloning of the genes into pXT7. The 
positive clones were confirmed for the presence of the gene using restriction digest 
and sequencing. 
 
 
2.9   cRNA synthesis 
In vitro cRNA synthesis was performed using either the Ribomax T7 RNA synthesis 
kit (Promega) or T7 RNA synthesis kit (Ambion).  
 
2.9.1  Linearisation of the plasmid DNA 
For either kit, the first step was linearising the DNA template (table 2.18). For hPATs 
2, 3 and 4 the restriction enzyme NdeI (NEB) was used. 
Reagent Final concentration 
Template (hPAT in pGEM-T Easy) 10 µg 
10x Buffer (NEB3) 1x 
NdeI (NEB) 10 units 
Nuclease free water To bring up the final volume to 50 µl 
Table 2.18: Linearisation of hPATs 2, 3 and 4 using NdeI 
For linearising hPAT1 and its mutants/FLAG (table 2.19) variants the restriction 
enzyme SalI was used 
Reagent Final concentration 
Template (hPAT in pGEM-T Easy) 5 µg 
10x Buffer (NEB3) 1x 
SalI (NEB) 10 units 
BSA 100 µg/ml 
Nuclease free water To bring up the final volume to 50 µl 
Table 2.19: Linearisation of hPAT1 using SalI 
The digested template was then purified and eluted in 30 µl. 5 µl was run on the gel 
to confirm the linearisation.  
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2.9.2  Invitro transcription of cRNA 
The synthesis of RNA was performed depending on the kit used 
For the Ribomax kit, a 20 µl reaction was set up to contain components as described 
in the table 2.20 
 
Component Final amount Volume 
Template (+ nuclease free water) 1-5 µg 6.5 µl  
Buffer 1 x 4 µl  
RNTP mix (25mM CTP, UTP, ATP and 2 mM GTP)  6 µl  
Cap Analog  1.5 µl  
Enzyme  2 µl  
 Total volume 20 µl  
Table 2.20: Invitro synthesis of cRNA (Promega Ribomax T7 kit) 
 
For the Ambion kit, a 20 µl reaction was set up as shown in table 2.21 
Component Final amount Volume 
Template 1 µg 6 µl  
Buffer 1x 2 µl  
NTP mix  10 µl  
Enzyme  2 µl  
 Total volume 20 µl  
Table 2.21: Invitro synthesis of cRNA (Ambion T7 RNA synthesis kit) 
In both cases the tubes were mixed and incubated for 4 hours at 37°C.  
 
2.9.3  Dnase treatment and purification 
After 4 hours, Dnase (5 for the Promega kit and 2 µl for the Ambion kit) was added 
to the mixture and incubated at 37°C for 15 minutes. After the incubation, the RNA 
was purified using the RNA clean up kit (Quiagen). The RNA was then eluted in 25 
µl.  
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2.9.4  Confirmation of the size and quality of the RNA obtained 
The concentration and quality of the RNA was determined using a spectrophotometer 
(NanoDrop 1000 Spectrophotometer) and was generally found to be around 1 µg/µl. 
A 260/280 ratio of 2.0 (+/-0.2) and a 260/230 ratio of 1.8-2.2 was considered 
acceptable.  The integrity of the RNA was checked by running it on a 1% agarose gel 
for 20 mins at 80 volts and checking for distict bands which corresponded to the 
expected size. If a smear was observed then the RNA was discarded and fresh RNA 
synthesized.  
 
 
C)  Exogenous expression of transporters 
2.10  The Xenopus laevis expression system 
As discusses in the introduction, the Xenopus laevis oocyte system provides a very 
good model system to study transporters. Before preparing the oocytes for cRNA 
injection, Barth’s and Calcium free solution were prepared prior to harvesting the 
eggs. 
 
2.10.1  Solutions for preparation and maintenance of oocytes 
2.10.1.1 Barth’s Solution 
This solution has a composition similar to that found in the extracellular fluid of 
Xenopus laevis and was used to store to oocyte at all stages except during collagenase 
treatment and during uptake experiments. The composition of this solution is shown 
in the table below (Table 2.22) 
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Compound Concentration (mM) g/litre 
Sodium chloride (NaCl) 88 5.14 
Potassium chloride (KCl) 1 0.07 
Magnesium sulphate (MgSO4) 0.82 0.2 
Calcium nitrate (CaNO3) 0.33 0.08 
Sodium carbonate (NaHCO3) 2.4 0.2 
Calcium chloride (CaCl2) 0.41 0.06 
HEPES 15 3.57 
 
After adjusting the pH of the solution to 7.6 using sterile 1 M NaOH, the following 
compounds are then added to the solution 
Compound Concentration (mM) g/litre 
Sodium pyruvate 5 0.55 
Gentamycin 50 µg/ml 0.05 
Table 2.22: Composition of Barth’s solution. This solution is the medium used to 
store oocytes in 
The solution was stored at 4 degrees. Before using the solution it was always filtered 
using a 10uM filter 
 
2.10.1.2  Calcium free solution 
This solution is used during the collagenase treatment of oocytes and while cleaning 
the ovaries after harvesting them (table 2.23). This solution contains 
Compound Concentration (mM) g/litre 
Sodium chloride (NaCl) 80 4.68 
Potassium chloride (KCl) 2 0.15 
Magnesium chloride (MgCl2) 1 0..095 
HEPES 5 1.19 
Table 2.23:  Composition of the Calcium free solution 
The pH of the solution was adjusted to 7.6 using sterile 1 M NaOH 
The Ca2+ free solution was stored at 4 degrees. Before using the solution it was 
always filtered using a 10uM filter. 
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2.10.2  Preparation of the oocytes 
Oocytes were harvested from the female Xenopus laevis. The frogs were 
anaesthetized in regulation with home office regulations. They were placed on ice for 
30 mins following which an incision was made and the spinal cord broken. Following 
this an incision is made on the ventral region below the abdomen and the ovaries 
removed using a pair of foreceps. The follicles (containing the oocytes) were then 
placed in 50 ml petri dish containing Barth’s solution. They were then washed to 
remove any debris or blood with Barth’s solution. The oocytes were then ready to be 
collagenased. 
 
2.10.3  Collagenase treatment of oocytes 
The final stage in the treatment of oocytes prior to cRNA injection is to remove the 
follicular layer that envelops the oocytes. The removal of the follicular layer is 
essential to aide the cRNA injection and protein expression in oocytes. The oocytes 
were initially manually separated into groups of 30-50 oocyte using 2 pairs of 
foreceps under the light microscope (Leica). The oocytes were then transferred into a 
50 ml Corning tube containing Ca2+ free solution and washed. The oocytes were then 
incubated in a 50 ml tube with Ca2+ free solution containing 1 mg/ml Collagenase 
(Sigma Aldrich) on a roller mixture. After 45 minutes, the Ca2+ free solution 
containing collagenase was discarded and replaced with fresh Ca2+ free solution 
containing 1 mg/ml Collagenase and incubaetd for a futher 45 minutes (total 
collagenase treatment 1.5 hours). Following this incubation, the oocytes were 
repeatedly washed with Ca2+ free solution till the solution until the supernatant 
poured off was clear. The oocytes were then repeatedly washed with Barth’s solution 
and transferred to a 90 mm petri dish with Barth’s for future use. 
 
2.10.4  Selection of oocytes for microinjection 
Defolliculated oocytes which appeared healthy and were blemish free were selected. 
Oocytes which were in the Vth-VIth stage of development and were about 1 mm in 
diameter were chosen and placed in a 20 mm petri dishes containing Barth’s solution 
and stored in the incubator at 17°C overnight. 
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2.10.5  Injection of oocytes 
2.10.5.1  Preparation of needles 
Fine glass needles were prepared using glass capillaries (Drummand Sciences, Biohit) 
that were pulled. The glass needles were observed under the light microscope (Leica) 
and the tip was manually cut using a pair of forceps. The needle was then back filled 
with mineral oil prior to attaching it to the semi automatic Drummond Nanoject 
injector and filling with cRNA. 
 
2.10.5.2  Injecting cRNA into the oocytes 
Any unhealthy oocytes were removed from the petri dish prior to injection.  The 
oocytes ready to be injected were transferred into fresh 25 mm petri dishes.  25 
oocytes were selected at a time and transferred onto Perspex slides with a groove.  
This helps facilitate injection rather than using a pair of forceps to hold the oocytes 
while injecting. 
 
 
Figure 2.4: Diagrammatic representation showing the injection of cRNA into 
Xenopus laevis oocytes 
 
cRNA was filled into the glass micro pipette needle attached to the Nanoject system. 
It is possible to arrange the range of the volume injected from 2-69 nl. The Nanoject 
needle was adjusted manually so that the glass capillary tip was very close to the slide 
and then adjusted with the controls so that the tip of the needle entered the vegetal 
Transcription 
of  
RNA in vitro 
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pole of the oocyte. A conscious effort was made not to enter the animal pole which 
contains the nucleus, which might be damaged with the needle. 27 ng of the cRNA 
was injected into the oocyte while adjusting the volume accordingly.  Since water 
injected oocyes were observed to be similar to non injected ones, non injected 
oocytes were generally used as control throughout the thesis unless stated otherwise.   
 
2.10.6  Incubation of oocytes 
Post injection the oocytes were transferred into petri dishes containing Barth’s 
solution. 2-3 hours post injection, the oocytes which were undamaged and had no 
blemishes were transferred into fresh petri plates (25 mm) containing fresh Barth’s 
solution. The oocytes were stored in an incubator at 17 degree for at least 72 hours 
which is the time that it takes to bring about efficient translation of proteins and cell 
surface expression of transporters. The oocytes were transferred into fresh Barth’s 
solution every day.  In this period the oocyte translation machinery, translates the 
cRNA into proteins and trafficks it to the oocyte membrane. 
 
 
D)  Functional assay of transporters in Xenopus 
oocytes 
2.11  Assays to characterize function of hPAT4 
2.11.1  Basic transport assay 
2.11.1.1  Preparation of uptake solution 
Uptake assays were performed at three different pHs, 5.5, 7.4 and 8.4 were prepared 
as shown in table 2.22 
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Compound Concentration 
Choline chloride 100 mM 
Potassium chloride 2 mM 
Magnesium chloride 1 mM 
Calcium chloride 1 mM 
HEPES-Tris/ MES-Tris* 10 mM 
Table 2.24: Uptake medium for transport assay 
MES-Tris solution was adjusted to 5.5 and the HEPES-Tris solution was adjusted to 
pH 7.4 or 8.4. The pH of the solution was adjusted by adding 200 ul of this solution 
to a total 10 ml  
 
2.11.1.2  Influx Assay 
72 hours after injection the oocytes were tested for transport function.  The oocytes 
each were incubated in uptake medium without substrate for 2 minutes prior to 
performing uptake experiments. After the preliminary 2 minute incubation 10 oocytes 
for each data point, 5 oocytes each were transferred into 100 µl/well of uptake 
medium each containing radiolabelled substrate [3H] L-Proline unless specified 
otherwise. experimental details). The radio-labelledamino acids used were as follows 
(final concentration, µM): [3H] L-Pro (0.10), [3H] L-Trp (0.25), [3H] L-Ala (0.11) and 
[14C] L-Cys(50.0), [14C] L-Ser (6.21) and [14C] Gly (10.1). The specific activities of 
the amino acids were [3H] L-Pro 25 Ci/mmol, [3H] L-Trp 20 Ci/mmol, [3H] L-Ala, 
[3H] 47 Ci/mmol, L-Leu 69 Ci/mmol, [14C] L-Cys 20 Ci/mmol, [14C] L-Ser 164 
Ci/mmol and [14C] Gly 102 Ci/mmol. The [3H] amino acids (L-Pro, L-Trp, L-Leu and 
L-Ala) were supplied at a concentration of 1µCi/µl. The [14C] amino acids L-Cys, L-
Ser and L-Gly were supplied at 50 µCi/µl, 51 µCi/µl and 52 µCi/µl respectively. The 
radioactivity was always supplied with >97% purity and in a 2:98 solution of 
ethanol:water. The uptake medium was at a pH of 5.5, 7.4 or 8.4 as per the 
requirements of the experiment. The oocytes were incubated in the uptake medium 
for 1 hour (with the exception of time course experiments). 
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For Na+ dependence experiments, the same uptake medium was used as described in 
table 2.22, except that the choline chloride was replaced with sodium chloride and the 
transport assay performed as usual. 
 
2.11.1.3  Wash and measurement of uptake 
Oocytes for each point were washed 5 times sequentially with cold NaCl (0.12 M) 
before transferring one oocyte into one of the wells of the 96 well scintillation plate. 
Any excess NaCl was removed before adding 50 µl 2 % SDS into each of the wells 
and placing it on a shaker for 1 hour or till no visible particles of the oocyte could be 
seen. After one hour incubation, 250 ul scintillant was added to each well. In addition 
to this 10 ul of each of the standards was added to the scintillation plates and 250 ul 
scintillant (Optiphase Scintillation cocktail, Perkin Elmer) was added to it. The plate 
was then shaken for at least an hour before counting the plate. Cpm readings were 
recorded. 
   
2.11.2  Time course 
For the time course experiments, the preliminary wash in the uptake medium without 
radiolabelled substrate was performed. This was followed by incubation of oocytes (5 
oocytes in 100 ul) as described in the section on influx assays in the uptake medium 
at pH7.4. After the required time period the oocytes were washed, lysed with SDS 
and counted as described in section 2.3.1.3 
 
2.11.3  Ki determination 
2.11.3.1  Experimental setup 
Ki determination experiments were set up using varing amounts of non radiolabelled 
substrate in the uptake medium with the same amount of [3H] L-Proline to adjust the 
final concentration of the test substrate as required. Oocytes were incubated (10 
oocytes per concentration) 5 in each well containing 100 ul uptake medium with the 
substrate at the required concentration and the radiolabelled tracer. Depending on the 
transporter and the substrate varying concentrations were used.  
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 2.11.3.1  Calculation of Ki 
Affinity calculation was calculated with Sigma Plot using the method of Deves and 
Boyd (1989). In all cases [3H] L-Proline was used as a tracer. This means that even 
when L-Proline (unlabelled is used as a substrate) there is already some L-Proline 
(contributed by the tracer), present in the medium making it an apparent Km as 
opposed to a true Km. In case of other substrates, we are measuring the inhibition of 
L-Proline transport due to competitive inhibition. Once again in this case there is a 
component of the recorded transport which is contributed by L-Proline while the 
majority is the effect of the unlabelled excess. 
 
2.11.4  Electrophysiology 
Oocytes were collagenased and injected in the same way as for the transport assays. 
72 hours post injection the oocytes were then used for two electrode voltage clamp 
experiments. Barth’s solution without any substrate was used as a perfusion solution 
and Barth’s solution with substrates was used to test the oocytes. Different 
concentrations of substrates were used to test whether 1) the transporter was 
electrogenic, as in the case of hPAT4 and 2) to test whether a compound is a substrate 
for the electrogenic transporter hPAT1. 
The needles for electrophysiology were prepared by a two stage electrode puller. To 
perform the two voltage electrode clamp, electrodes were prepared by back-filling 
(approximately 5 mm from the top) with a 1 mg/ml solution of agarose in 3 M KCl 
solution. Prior to use the needles were then filled with 3 M KCl and electrodes with a 
resistance between 0.5 to 1 MΩ were used. The oocytes were placed in a 0.1 ml 
chamber and were then impaled by the two electrodes. Oocytes were clamped at -60 
mV (Geneclamp 500B amplifier was used to measure the recordings). Continuous 
perfusion was performed at a rate of 10 ml/min. The different solutions were selected 
manually. Data were recorded on a paper chart and the numbers were noted manually. 
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E)  Surface expression in Xenopus oocytes 
2.12  Luminometry to determine the topology of the 
membrane protein 
As discussed in the introduction, epitope tagging is a technique by which FLAG tags 
can be inserted into different regions of the gene. The process relies on 
chemiluminescence to help determine the topology of the membrane protein.  
 
2.12.1  Solutions required for the luminometry analysis 
2.12.1.1  Barth’s-BSA 
Barth’s-BSA solution was prepared to contain 1% w/v of BSA in a Barth’s solution 
and placed on the roller to dissolve. The solution was then filtered through a 0.1µM 
filter and stored at 4 degrees till required.  
 
2.12.1.2  Primary Antibody 
The primary antibody (Anti-FLAG M2 monoclonal Antibody-HorseRadish 
Peroxidase conjugate, C-terminus HRP Sigma Aldrich) was prepared by making a 
1:500 solution of using Barth’s-BSA. 
 
2.12.1.3  Secondary Antibody 
High sensitivity ELISA femto substrate conjugated to the HRP (SuperSignal ELISA 
Femto substrate) was used for detection of the primary antibody. 
 
2.12.2  Methodology 
All the steps leading upto the final measurement were performed on 24 well plates 
which were placed on ice using chilled solutions of Barth’s-BSA, Barth’s and 
primary antibody. 
 
2.12.2.1  Blocking of the oocytes 
At least 12 oocytes per data point were incubated in 400 ul Barth’s-BSA for 30  
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minutes. 
 
2.12.2.2  Incubation of the oocytes in primary antibody 
The oocytes were incubated in 300 ul of the primary antibody (1:500 v/v with 
Barth’s-BSA as described earlier) for 1 hour. 
 
2.12.2.3  Washes with Barth’s-BSA and Barth’s 
The oocytes were washes sequentially with 400 ul Barth’s-BSA  six times for 1 and a 
half hours (once every 15 minutes). The oocytes were then transferred to Barth’s 
solution (400 ul) and sequentially washed 5 times for 30 minutes (once every 3 
minutes). 
 
2.12.2.4  Preparation of luminometry plates 
100 ul of filtered Barth’s is added to each well of the Luminometry plate (black and 
white isoplate-96, Perkin Elmer). The oocytes which were washed were ready for use. 
One oocyte was placed into each well of the plate. Equal volumes of the two 
solutions (ELISA high sensitivity HRP-conjugated substrate) were added to a 15 ml 
Corning tube wrapped in aluminium foil (since the substrate is light sensitive). The 
plate was then placed into a rigid plate holder which fits into the plate counter. Just 
prior to use 20 ul of the substrate was added into each well rapidly while covering the 
wells into which substrate had been added by constantly covering it with a opaque 
cover to prevent light from initiating the reaction. The plates were then manually 
shaken and placed in the counter ready for counting. 
In order to eliminate variation in techniques as much as possible, the luminometry 
readings were started within 10 minutes after the ELISA substrate was added to the 
first well. If more time was taken, the counts were not performed. Luminometry 
readings for the internal and external FLAGs were done at the same time as much as 
possible. The controls used were non injected oocytes and hPAT1 (without a FLAG 
epitope) injected oocytes to confirm that the FLAG antibody was binding only to the 
epitope and not to an endogenous protein of the oocyte or the nonFLAGed hPAT1 
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protein. There were no tagged hPAT available so a tagged PepT1 was used as a 
positive control in the initial experiment to ensure that the technique worked. 
 
 
F)  Cell culture 
2.13  TM4 cell culture 
2.13.1  Growth and maintenance of TM4 cells 
TM4 cells were grown in 1:1 mixture of Ham’s F12 medium and Dulbecco’s 
modified Eagle’s medium with 1.2g/litre sodium bicarbonate, 15 mM HEPES, 5 % 
horse serum (HS), fetal bovine serum (FBS) and 2 mM glutamine. Penicillin-
streptomcin was used as an antibiotic. 
The flasks were kept at 37 ºC in an incubator with 95 % air and 5 % CO2. 
When the cells had reached confluence they were subultured. The medium was 
removed and the cells were washed using 3 ml PBS and the PBS removed. 3 ml 1x 
trypsin was then added to the flask and placed in the incubator for 5 minutes. Fresh 
medium was then added and the cells resuspended to avoid any clumping. 
Subculturing was carried out in a ratio of 1:25.  
 
2.13.2  Endogenous expression of mPATs 
2.13.2.1  Primers  
For endogenous expression of mPATs the primers used are shown in table 2.25. With 
the exception of GAPDH, the mPATs were exon-exon spanning 
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Primer name Sequence 
mPAT1 Forward GTCCCGAGTGCCTGAGC 
mPAT1 Reverse CTCTACATGCATAACAAGTGGTTTG 
mPAT2 Forward CAACTGCTGGCTGTACCAATC 
mPAT2 Reverse CACTGAATAAACATGGTGGAGTTG 
mPAT3  Forward GCCTGACCTGTTTCTCAGCC 
mPAT3 Reverse CCATGTAAAAGTGGGTCTGC 
mPAT4 Forward GGACATGTGGTTGTATCAGTCAGTG 
mPAT4 Reverse CAAACCATTGTTATGCATGTAGAG 
mGAPDH Forward AGGCCGGTGCTGAGTATGTC 
mGAPDH Reverse TGCCAGTGAGCTTCCCGTTCA 
Table 2.25: Primers used to check for the expression of mPATs 
 
2.13.2.2  Cell culture preparation 
To check for the endogenous expression of mPATs in the mouse Sertoli cell line 
TM4 the principle of reverse transcriptase PCR was used. Two days after the passage 
when the TM4 cells showed about 90% confluence, the cells were washed with PBS 
and harvested using 2ml trypsin. 10 ml DMEM:F12 medium was then added to the 
flask, the cells mixed by pipetting and transferred to a 15 ml tube. 0.1 ml of the cell 
suspension was taken and kept aside to count the number of cells. The cells were then 
spun at 1000 rpm for 10 mins at 4 ºC. The supernatant was discarded and the cells 
resuspended in 2 ml PBS and transferred to a 1.5 ml tube. The cells were spun again 
and the supernatant discarded. Total RNA was then extracted from the pellet 
(Quiagen RNA clean up kit).  
 
2.13.2.3  cDNA synthesis 
cDNA was synthesized using the RNA which was collected from the cells. The RNA 
was treated with Dnase for 30 mins at 37 ºC. Reverse transcriptase reaction for cDNA 
synthesis was set up using the GoScript Reverse Transcription system (Promega) as 
shown in table 2.26. 
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Component Volume (sample) 
RNA from cells 8 µl 
Primer oligo (dT)15 2 µl 
Final volume 10 µl 
Table 2.26: Components for cDNA synthesis in TM4 cells 
The tubes were then placed in a pre heated heat block at 70 ºC for 5 minutes. The 
tubes were then immediately placed on ice until ready to be used for the reverse 
transcriptase reaction.  
A mastermix was prepared to allow 14 µl of the reaction mix for each the control and 
the sample. The reverse transcription reaction mixture was prepared to contain  
Component Volume  
5X GoScript reaction buffer 4 µl 
MgCl2 (25 mM) 2 µl 
PCR nucleotide mix 1 µl 
H2O 7 µl To bring the final volume to 14 µl 
Table 2.27: Reverse transcription reaction set up (TM4 cells) 
The reaction buffer contained RNAse inhibitors thereby eliminating the need to add 
them separately. The cRNA was aliquoted into two tubes containing 5 µl each, 
labelled sample and the other control. 14 µl of the reaction mixture was added to both 
the control and sample reaction tubes which were placed on ice and mixed gently. 1 
µl of reverse transcriptase was then added to the sample and 1 µl of nuclease free 
water was added to the control reaction and the contents of the tube were mixed by 
pipetting. The tubes were then incubated on a heating block for 25 minutes for 5 
minutes. The reaction tubes were then incubated at 42 ºC for 60 minutes. The reverse 
transcriptase was inactivated by heating at 70 ºC for 15 minutes. The concentration of 
the DNA (single stranded) was measured and stored at -20 ºC or used directly for the 
PCR. 
 
2.13.2.4  PCR amplification of mPATs and controls 
PCR amplification reactions were set up using two sets of primers, one set designed 
specifically for mPATs and another set designed of GAPDH as shown in table 2.28.  
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Reagent Amount 
Go Taq Flexi buffer 5 µl 
Forward primer (10 µM) 1.25 µl 
Reverse primer (10 µM) 1.25 µl 
dNTPs (25 mM) 1 µl 
Template (100ng) 1 µl 
H2O To bring up the volume to 50 µl 
Enzyme 0.5 µl 
Table 2.28: PCR set up to check for endogenous expression of mPATs in TM4 
cells 
 
Thermal cycling was set up using initial denaturing at 95°C for 2 minutes, followed 
by 35 cycles of denaturation at 95°C for 30 seconds, 60°C for 30 seconds and 72°C 
for 1.5 minutes. A final extension step at 72°C was performed for 5 minutes before 
storing at 4°C.  
 
 
2.14  HEK cell culture – growth and maintenance 
HEK cells were grown in Dulbecco’s modified Eagle’s medium with 1g/litre glucose 
and sodium bicarbonate, pyridoxine, 5 % fetal bovine serum (FBS) and 2 mM 
glutamine. Penicillin-streptomycin was used as an antibiotic. 
The flasks were kept at 37 ºC in an incubator with 95 % air and 5 % CO2. 
When the cells had reached confluence they were subcultured. The media was 
removed and the cells were washed using 3 ml PBS and the PBS removed. 1 ml 1x 
trypsin was then added to the flask and placed in the incubator for 5 minutes. Fresh 
medium was then added and the cells resuspended to avoid any clumping. 
Subculturing was carried out in a ratio of 1:10.  
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G)  Transfections and transport studies in cell culture 
2.15  Transfections using TM4/HEK293 Cells  
TM4/HEK293 cells which had reached confluence were trypsinised, resuspended and 
then resuspended in medium. The cells were then spun for 5 mins at 1200 rpm and 
the supernatant removed. Fresh antibiotic free medium was then added to the pellet 
and resuspended. 50 µl of the cell suspension was mixed with 50 µl trypan blue and 
loaded onto a haemocytometer.  
The cells were counted and the cells plated at the appropriate density. For 6 well 
plates, 5 x 105 cells were plated per well in 2 ml medium. The cells were placed in the 
incubator overnight. By the next day the cells had reached about 70 – 80 % 
confluence.  
The medium was removed and 1.5 ml OPTIMEM (Invitrogen) was added to each 
well. 2.25 µg plasmid DNA (1.125 µg E-GFP C and 1.125 µg pcDNA3.1(-)/ hPAT2/ 
hPAT3.1/ hPAT3.2) was added 250 µl OPTIMEM per reaction. 6 µl Lipofectamine 
LTX was added to 250 µl OPTIMEM per reaction. Both these (OPTIMEM-Ltx and 
OPTIMEM-DNA) were incubated for 5 min and then mixed and left at room 
temperature for 30 min.  
500 µl of the mixture was then added to each well. The plates were rocked from side 
to side a few times to mix the medium and placed in the incubatr. 
The following day, the OPTIMEM was removed and fresh DMEM:F12 was added to 
the wells. Confocal analysis were done 48 hours after transfection and transport 
assays were performed 
 
 
2.15  Transport assays in cell culture 
Krebs Ringer solutions at different pH were prepared to study the hPATs in cell lines. 
Three different pH were used 5.5, 7.4 and 8.4. The medium used for studying 
transport assays is described in table 2.27 
 
Chapter 3                                                                                           Molecular Biology 
 
 
71
Component Final concentration 
(mM) 
g/litre 
NaCl 137 8.01 
KCl 5.4 0.40 
CaCl2 2.8 0.41 
MgSO4 1.0 0.25 
NaH2PO4 0.3 0.04 
KH2PO4 0.3 0.04 
Glucose 10 1.8 
HEPES-Tris (each 0.5 M adjusted to a final pH 
of 7.4 or 8.4) 
10 20 ml 
MES-Tris (each 0.5 M adjusted to a final pH of 
5.5) 
10 20 ml 
Table 2.39: Composition of the Krebs Ringers solution 
The cell culture medium was aspirated from the wells. The cells were then washed 
with warm Kreb’s solution at the appropriate pH using 2 ml solution per well. The 
solution was then aspitated and this process repeated again. After the wash solution 
had been removed completely, the incubation mixture (containing [3H] L-Proline) 
was added to each well. The proline tracer was diluted 5 µl/ml of medium 
 
 
H)  Data analysis 
2.16  Software used 
The programs which were used to help with the statistical analysis were Excel, 
GraphPad and SigmaPlot. Excel was used to tabulate the data from different 
experiments. GraphPad Prism 5 was used to analyse the data and determine if it was 
significant (student t-test, paired/unpaired p < 0.05). SigmaPlot was use to analyse 
substrate affinity experiments and to plot graphs. 
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2.17  Statistical analysis 
2.17.1  Transport and luminometry assays 
The data was tested for outliers and removed by using the Grubbs’ test for detection 
of outliers (GraphPad Software, Quick calcs online). For each experiment the values 
were calculated as mean +/- SEM.  
 
2.17.2  fmol/oocyte/hour calculations 
Students unpaired t-test with p < 0.05 was used to determine significance except in 
the case of cell culture experiments where a one sample t-test was used (with p < 
0.05).  
In each case, the uptake for the non injected oocytes were subtracted from the mean 
values, to give the hPAT mediated amino acid transport. The values are then 
expressed in terms of fmol/oocyte/ hour or as normalized data.  
Normalised data was presented after subtracting the non injected from the injected 
oocytes and presented as a fraction of a control transporter (for instance SLC36A2 
which has been characterised as a transporter). The sample to which it was 
normalized is specified in the figure legend/text. The rates of uptake for these oocytes 
are also mentioned.  
 
2.17.3  Ki measurements 
Ki measurements were done using SigmaPlot. The equations used were as described 
by Deves and Boyd (1989). 
This equation is a derivative from the Michaelis-Menten equation which was 
discussed earlier , 
 
 
The Deves and Boyd method was initially used to help determine the kinetic 
parameters for carrier protein mediated transport in placental membrane vesicles. 
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This was done by using an excess of unlabelled substrate (or a substrate analog) 
which would competitively bind to the transporter thereby decreasing the amount of 
labelled transporter that can bind to it.  
The schematic representation of the interaction between the different factors can be 
summaried as shown below 
 
Figure 2.5: Transport scheme for a substrate and an analog with a competitive 
inhibitor. S represents the substrate, A the analog, I the competitive inhibitor, CI and 
CO are the inward and outward facing conformations which  can bind to ligands in the 
medium depending on the dissociation constants K and rate constant f. (Deves and 
Boyd, 1989). 
The final calculations for substrate affinity calculations were made using SigmaPlot, 
by plotting normalised uptake and the corresponding errors against the substrate 
concentrations and using a curve to fit in the data. Following this the Ki or apparent 
Km could then be obtained. 
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3.1  Subcloning of hPATs into the pXT7 vector 
For checking heterologous protein expression in Xenopus oocytes the genes of 
interest first needed to be introduced into the oocyte expression vector, pXT7. 
Similarly for transfecting the genes of interest into cell lines, they were first 
subcloned into the mammalian expression vector pcDNA3.1(-). In this section the 
different results obtained during each stage will be discussed. As discussed 
 
3.1.1  PCR amplification of the hPATs to introduce KpnI and EagI 
sites  
The hPAT genes were amplified using specific primers (materials and methods) to 
introduce KpnI and EagI at the 5’ and 3’ ends respectively. The choice of restriction 
sites was based on the presence of both these sites in the pXT7 vector and its absence 
in the cloning vector pGEM-T Easy. In addition to these both these sites were absent 
from hPATs 2, 3 and 4 which was ideal. There was however a KpnI site within the 
gene however this problem was solved using partial digests. Figure 3.1 shows the 
PCR products obtained by amplification of the hPAT genes. PCRs were set up in the 
presence of Easy-A polymerase which has proof-reading activity in addition to 
adding A overhangs at the end of the PCR product. 
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Figure 3.1: PCR amplification of hPATs1,2,3.1,3.2 and 4. Panels A, B, C and D 
show the products obtained by PCR amplification of hPATs 1, 2, 3 and 4 respectively 
using primers with 5’ KpnI and 3’ EagI sites. In each image 1.5 kb is marked on the 
DNA ladder (marker). 
1.5 kb 
1.5 kb 
1.5 kb 
1.5 kb 
 
hPAT1 hPAT2 
hPAT4   hPAT3.1   hPAT3.2 
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3.1.2  Ligation of the hPATs with pGEM-T Easy 
Ligation of the PCR product with A-overhangs was performed with pGEM-T easy 
which has complementary T overhangs thereby facilitating ligation. Positive clones 
which were selected by blue white screening, restriction digests and sequencing were 
then grown up as stock for the next stage of introducing the genes into the pXT7 
vector. 
 
3.1.3  Restriction digests of hPATs 
The hPATs were sequentially digested with PCR purification after each digestion 
step (materials and methods) and run on the gel to confirm complete digest (partial 
digest in case of hPAT1) had taken place. Figure 3.2 shows the restriction digests and 
an indication of the fragments which were cut out, purified and used to set up ligation 
reactions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 A 
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Figure 3.2: Restriction digestion of hPATs with KpnI and EagI. Panels 1, 2, 3 and 
4 show the products obtained by performing restriction digestion of hPATs 1, 2, 3 
and 4 respectively with KpnI and EagI. For panels 1, 2 and 4 both the digested (D) 
and undigested template (UD) are shown. In panel 3 only the digestion products are 
shown. In each image 1.5 kb is marked on the DNA ladder (marker). 
hPAT1 hPAT2 
hPAT4   hPAT3.1 hPAT3.2 
 UD       D  UD  D   D    D  
UD  D   D    D      D         D  
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3.1.4  Ligation of hPATs with pXT7 and confirmation of insert 
Ligation reactions were set up using vector (pXT7) and insert (hPATs) as described 
in the materials and methods. The ligation products were transformed, plated on LB 
agar and eventually grown on LB broth and plasmid DNA extracted. To confirm the 
presence of the insert hPATs 2,3 and 4 were digested with NdeI and hPAT1 was 
digested with SalI. Colonies which appeared positive were then sent for sequencing. 
The results were analyzed to check for the genes and to confirm that the orientation 
was correct i.e. T7 53’. This was to facilitate T7 RNA synthesis since that was the 
only usable one in pXT7. 
 
 
 3.2  Introduction of FLAG epitope tags into the 
hPAT1 gene 
The FLAG tag was introduced into different regions of the hPAT1 gene and will be 
discussed in detail in chapter 5. Eleven epitope tags were designed and inserted using 
site directed mutagenesis. F1, F2, F3, F4, F5 and F6 were the presumptive external 
FLAGs inserted while iF1, iF2, iF3, iF5 and iF6 were the presumptive internal 
FLAGs. The colonies obtained by transforming DpnI treated ligation products were 
incubated in LB (+Amp) overnight and plasmid DNA extracted from them. The 
inserts were confirmed by restriction digest and sequencing. 
 
 
3.3  Introduction of the champagne mutation in the 
hPAT1 gene and the FLAG labeled hPAT1 gene 
The G to C champagne mutation which is present in the SLC36A1 gene causes a 
change in the amino acid being coded from Threonine to Arginine. This mutation has 
been shown to be responsible for champagne coat colour in horses. This mutation was 
introduced into two variants of the hPAT1 gene; the wildtype hPAT1 gene and the 
hPAT1 gene with an external FLAG epitope tag. The reason for doing this was to 
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check that if the champagne mutation caused a loss of function mutation then the 
expression of the gene could be confirmed using luminometry techniques.  
 
 
3.4  Invitro cRNA synthesis and confirmation 
cRNA was synthesized invitro as described in the introduction. Following the 3-4 
hour incubation and the RNA clean up, the concentration of RNA was measured. To 
confirm that the RNA was intact the RNA was then run on a gel at low voltage. 
Figure 3.3 shows an example of a typical gel which is run following RNA synthesis. 
Uncut plasmid DNA, linearised DNA and cRNA are run on the gel for 30 mins on a 
1% agarose gel (TBE). The bands observed for the RNA are single standed RNA 
(which appears to be half the size of the ladder) and complex bound RNA. Since the 
marker used is for double stranded DNA therefore cRNA which is about 1.5 kb will 
typically be present close to 750 kb; the bound double stranded one would be 1.5 kb. 
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Figure 3.3: An example of a RNA gel. The undigested (circular plasmid), linearised 
plasmid and cRNA which has been synthesized in vitro are shown. The cRNA 
synthesized is smaller than the size of the gene (~1.5 kb) on account of it being single 
stranded. 
 
 
 
 
 
Undigested DNA     Linearised DNA       RNA 
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3.5  Subcloning of hPATs into the pcDNA3.1(-) vector 
For cell culture purposes, it was essential to subclone the hPATs into a mammalian 
expression vector. The vector used for this purpose was pcDNA3.1(-) which has a 
CMV promoter. 
 
3.5.1  PCR amplification of the hPATs to introduce KpnI sites at 
both the 5’ and 3’ ends 
hPATs 2, 3.1 and 3.2 were subcloned into the mammalian expression vector for cell 
culture experiments. hPATs were PCR amplified using specific primers with both 5’ 
and 3’ KpnI sites. The choice of the KpnI site was based on the fact that there was 
very little choice of restriction sites which were present in the vector multiple cloning 
site but absent from the gene. Figure3.4 shows the products obtained by PCR 
amplification of the hPATs when run on a 1% agarose gel. 
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Figure 3.4: Products of PCR amplification of hPAT2, hPAT3.1 and hPAT3.2 
using primers containing KpnI sites. 
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3.5.2  Ligation of the hPATs with pGEM-T Easy 
The PCR products were purified and ligated into the pGEM-T Easy vector. The 
colonies which were selected using blue white screening were then digested using 
KpnI to check for the presence of the insert. Sequencing was then carried out to 
confirm the sequence and to ensure that no mutations were introduced. 
 
3.5.3  Restriction digests of hPATs and pcDNA3.1(-) 
Plasmids which confirmed to contain the hPAT genes in pGEM-T Easy vector were 
used as stock to set up restriction digests with KpnI. Figure 3.5 shows the products 
obtained by digestion of hPATs and pcDNA3.1(-). These products were then gel 
extracted to use for ligation reactions. 
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Figure 3.5: Restriction digestion of hPAT2, hPAT3.1 and hPAT3.2 with KpnI 
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3.5.4  Ligation of hPATs with pcDNA3.1(-) and confirmation of 
insert 
Ligation reactions were set up with alkaline phosphatase treated vector and hPATs. 
The ligation products were transformed, plated on LB agar and eventually grown on 
LB broth and plasmid DNA extracted. To confirm the presence of the hPATs 
restriction digests were set up using KpnI. Plasmids which appeared to have the insert 
were then confirmed using sequencing. The orientation of the insert was also required 
to be 5’3’ in the direction of the T7 promoter (which is also the same orientation as 
the CMV promoter).  
 
 
3.6  Chapter summary 
• 5’  3’ KpnI and EagI sites were introduced into hPATs 1, 2, 3.1, 3.2 and 4 
which were then subcloned into the cloning vector pGEM-T. 
• Sequential restriction digestion was then carried out and the products purified 
before introducing it into the restriction digested pXT7 oocyte expression 
vector. 
• The sequence was then confirmed by restriction digestion and sequencing. 
• 5’  3’ KpnI sites were introduced into hPATs 2, 3.1 and 3.2 which were 
then subcloned into the cloning vector pGEM-T 
• KpnI digestion was then performed on the genes in pGEM-T and the 
mammalian expression vector pcDNA3.1(-) and purified. 
• The genes were then ligated to pcDNA3.1(-). 
• To confirm that the orientation of the genes was in the direction of the CMV 
promoter, sequencing reaction were performed for confirmation. 
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This chapter deals with the characterization of the orphan transporter hPAT4. The 
data are generally expressed in two ways either in fmol/oocyte/hour or as normalized 
values i.e. a fraction of the control (in this case the value for 1, is mentioned in 
fmol/oocyte/hour).  In each case they have been corrected for the endogenous uptake 
(non injected) values. The fmol/oocte/hour data for different experiments are 
observed to show variability on account of variations in the oocytes observed 
seasonally. The results were calculated for each experiment by comparing it to the 
non injected oocytes from the same set. This practice also extends to normalised data 
where each experiment was normalised v/s the non injected and the means were then 
calculated for n number of experiments to overcome any variations due to seasonal 
changes. 
 
4.1  hPAT2 as a positive control 
As discussed in the introduction, hPAT4 is a member of the Proton coupled Amino 
acid Transporter family which had not been previously characterized but was placed 
into the PAT family based on sequence homology to the other members of the family. 
Before establishing an assay to test for the functionality of hPAT4 it was necessary to 
have suitable controls. Since both hPAT1 and hPAT2 had been well established to be 
amino acid transporters at an acidic pH, either of these could then be used as a control 
for hPAT4 experiments 
When hPAT2 and hPAT4 was expressed in the oocyte system without subcloning it 
into the pXT7 vector no significant uptake was observed compared to non injected 
oocytes (fig4.1).  
After subcloning into oocyte expression vectors,  hPAT2 showed a significantly 
higher uptake of [3H] L-Proline compared to the non injected oocytes (described in 
detail in section 4.2).  
Similar results were also obtained when uptake assays were performed using hPAT1, 
therefore either of these could be used as a control to assist in the characterization of 
hPAT4. 
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Figure 4.1: pH dependence of hPAT2 and hPAT4 when expressed in the 
bacterial expression vector. The graph shows that there was no significant uptake 
for the hPAT2 positive control at pH5.5 or the hPAT4 test sample at pH 7.4 (p>0.05). 
This was perhaps due to the fact that the vector was not an oocyte expression system. 
Proline present in the radiolabelled tracer which is 0.25 µM. 
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4.2  pH dependence 
It had been shown by previous groups that both hPAT1 and hPAT2 are pH dependent 
transporters that showed an increase in transport activity when the pH is decreased to 
5.5. Similar results were obtained when the experiments were repeated during this 
project. 
Since the SLC36 family of transporters was presumed to be proton dependent with a 
maximal transport activity at pH 5.5, the first step was to check for transport function 
of hPAT4 at this pH. hPAT2 was used as a control for these experiments. 
[3H]  L-Proline was used as the tracer and uptake assay was performed as described in 
the material and methods. hPAT4 showed no significant uptake at pH5.5 whereas the 
hPAT2 control showed significant uptake as expected (fig4.2). 
Since hPAT4 did not show any [3H]  L-Proline uptake at pH 5.5 it was decided to try 
and check for the uptake at a higher pH. When the pH of the uptake medium was 
increased to 7.4 hPAT4 showed a significant uptake compared to the non injected.  
However, the transport activity was found to decrease when the pH was increased 
further to pH 8.4 (figure 4.2).  
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Figure 4.2: Dependence of hPAT4-mediated [
3
H] L-proline uptake on 
extracellular pH in Xenopus oocytes expressing either hPAT2 or hPAT4. Data 
are standardised to uptake at extracellular pH of 7.4, which for hPAT2 was 10.96 +/- 
2.04 and for hPAT4 was 14.91 +/- 2.14 fmoles/oocyte/hour, n≥3 oocyte preparations. 
The significance shown is that when compared to the non injected oocytes of the 
same data set (** p < 0.01, *** p < 0.001).  Concentration of L-Proline in the tracer 
0.25 µM. 
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4.3  Time course 
Rates of transport vary from one transporter to another. While uptake experiments for 
hPAT1 and 2 in Xenopus oocytes was traditionally done for an hour, it was possible 
that hPAT4 reaches saturation by this time (especially if it were electrogenic). Time 
course experiments were set up in uptake medium at pH7.4. The results obtained are 
shown in figure 4.3. 
All transporters go through an incease in uptake followed by a plateau. The fraction 
of the substrate is taken up i.e. concentration of substrate in the extracellular medium 
v/s intracellular can vary depending on the type of transporter. For a transporter that 
relies only on facilitated diffusion, the plateau that is reached is at equilibrium where 
the external and internal concentrations of the substrate are the same. On the other 
hand, for a powered transporter, the stage at which saturation is reached is when there 
is a much higher amount of substrate which has been moved across the membrane so 
that intracellular substrate>>extracellular substrate. 
For instance : If the standard values are 50000 cpm/10 µl (which is the same amount 
used in the uptake medium), then approximately 6 hours after incubation the 
corrected uptake values (after the non injected values were subtracted from the 
injected ones) for the transporter which has facililated diffusion would be about 5000 
cpm. This is based on the assumption that the oocyte has a diameter of 1.2 mm. If the 
transport was driven then the count would increase above 5000 cpm and eventually 
plateau. 
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Figure 4.3 : Time dependence of hPAT4-mediated [
3
H] L-proline uptake into 
Xenopus oocytes. Data are standardised to uptake at 1 hour, which was 2.96 ± 0.98 
fmoles/oocyte/hour, n=4 oocyte preparations. Concentration of L-Proline in the tracer 
0.25 µM. 
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As shown in the figure, the uptake shows a linear path indicating that one hour is a 
sensible time point to perform infllux experiments. 
 
 
4.4  Na+ dependence 
hPAT4 does not appear to be H+ dependent since its activity is higher at external pH 
7.4 than at a pH 5.5 environment.  
Majority of the trasporters in higher organisms are Na+ driven; exceptions include 
PAT1 and 2. It thus seemed possible that hPAT4 was Na+ driven. Since the four 
members of the hPAT family were placed in the same family based on sequence 
homology and not functional studies it was possible that they were not all H+ coupled. 
One of the first tests to check for was whether hPAT4 was Na+ dependent. While both 
hPAT1 and hPAT2 were shown to be Na+ independent by previous groups (Boll et 
al., 2004), it is likely, by extension to presume that the other members of the family 
must also be Na+ independent. However since hPAT4 was shown to be different from 
the other known members in terms of pH dependence, it was entirely possible that 
hPAT4 was Na+ dependent. When choline chloride (Na+ free environment) was 
replaced by sodium chloride, then the uptake of tracer [3H] L-Proline was found not 
to be significantly different (Figure 4.4). 
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Figure 4.4: Uptake of hPAT4-mediated [
3
H]  L-Proline in the absence or 
presence of sodium, normalised to that seen in the absence of sodium (replaced by 
choline, actual uptake 27.8 ± 1.52 fmoles/oocyte/hour). p>0.05 Student’s paired t-test 
n=4 oocyte preparations. Concentration of L-Proline in the tracer 0.25 µM. 
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4.5  Ki of L-Proline 
Since hPAT4 was observed to be a transporter for L-Proline, it was important to 
determine what the affinity of the transporter for this substrate was. It was observed 
that the transport of [3H]  L-Proline was completely inhibited in the presence of 5 
mM unlabelled L-Proline. This clearly showed that the affinity (the amount of 
substrate required to completely inhibit the transport of a substrate) of the transporter 
must be lower than 5 mM. Inhibition of transport was checked at lower 
concentrations 1 mM and 0.5 mM, and these concentrations were also found to 
completely inhibit uptake of [3H] L-Proline uptake indicating that hPAT4 was a high 
affinity transporter. Substrate affinity experiments were thus set up using a range of 
concentrations from 0 (which is the [3H] L-Proline alone) to 1000 µM (which is the 
[3H] L-Proline and 1 mM cold unlabelled L-Proline). The transport activity measured 
and oocytes were lysed. The values were corrected for non injected and normalized to 
tracer only hPAT uptake. The values were then plotted using Sigma Plot (figure 
4.5).The Ki of hPAT for L-Proline was observed to be 3.13 µM +/- 1.13 µM. 
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Figure 4.5: Concentration dependence of hPAT4-mediated proline uptake, as 
determined by inhibition of [
3
H] L-Proline by increasing concentrations of 
unlabelled proline. Inset shows 0-100µM proline at higher magnification for clarity. 
Apparent Km was 3.1 ± 1.1 µM, n = 3 oocyte preparations. V/V0 at 1 is 40.3 +/- 5.03 
fmol/oocyte/hour. The non-inhibitable component is in part contributed by the L-
Proline present in the radiolabelled tracer which is 0.25 µM. 
 
 
 
   Apparent Km = 3.13 +/-                        
1.13 µM 
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4.6  Inhibition of hPAT4 L-Proline uptake 
In the presence of an excess of unlabelled amino acids, competitive inhibition takes 
place. This means that a lower quantity of tracer [3H] L-Proline will enter oocytes 
incubated in medium containing other substrates.  
Figure 4.6 provides a summary of the results obtained when [3H] L-Proline uptake 
was inhibited by each of the 20 naturally occurring amino acids. For the inhibition 
experiment the non injected values were subtracted from injected values. The value 
for each of the amino acids was then normalized to the [3H] L-Proline (tracer only) 
uptake. 
With the exception (for reasons of solubility) of L-Tryptophan (1 mM), L-Tyrosine (2 
mM) and L-Phenylalanine (1 mM) all other amino acids were tested at 5 mM. The 
first two amino acids tested Glycine and L-Alanine were known to be substrates of 
hPAT1 and hPAT2. However for hPAT4 while L-Alanine shows significant 
inhibition, Glycine did not cause significant inhibition at 5 mM. Amino acids which 
inhibited tracer Proline uptake were L-Alanine, L-Isoleucine, L-Methionine, L-
Tryptophan, L-Threonine, L-Glutamine and L-Cysteine. 
Thus amino acids which were not “typical” substrates for hPATs 1 and 2 were found 
to inhibit hPAT4, these amino acids are L-Methionine, L-Isoleucine, L-Threonine and 
L-Glutamine. Neither D nor L- Serine was found to inibit hPAT4 significantly. 
However inhibition by D-Serine though non-significant at 5 mM does seem to be 
more than that of L-Serine. 
Inhibition assays generally give a good indication of the affinity of the transporter for 
different groups of molecules. For instance PAT1 and PAT2 have always been 
grouped together as relatively low affinity transporters of small neutral amino acids,  
hPAT4 appears to have a more diverse range of amino acids that can inhibit  uptake 
of [3H] L-Proline. 
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Figure 4.6: Inhibition of hPAT4-mediated [
3
H] L-Proline uptake into Xenopus 
oocytes by the proteogenic amino acids. Uptake has been normalised to that seen in 
the absence of inhibitor i.e. [3H] L-Proline alone which was 35.65 +/- 3.44 
fmol/oocyte/ hour. *p < 0.05, **p < 0.01, ***p < 0.001, one sample t-test, n ≥ 3 
oocyte preparations. Concentration of L-Proline in the tracer 0.25 µM. 
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4.7  Substrate affinity of amino acids which inhibited 
tracer uptake 
Substrate affinities were calculated for some of the amino acids which successfully 
inhibited L-proline uptake of hPAT4. The Ki values were calculated for these using 
Sigma plot and are summarized in figure 4.9. It is interesting to note that hPAT4 
appears to have a higher affinity for L-Glutamine, L-Isoleucine and L-Methionine 
compared to L-Alanine which until now has been characterized as one of the main 
substrates for hPATs. 
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Figure 4.7: Concentration dependence of  hPAT4-mediated isoleucine, 
methionine, glutamine and alanine inhibition of [
3
H] L-Proline uptake: the Ki 
values were L-Isoleucine 0.23 ± 0.03 mM, L-Methionine 0.44 ± 0.19 mM, L-
Glutamine  0.43 ± 0.10 mM and L-Alanine 1.48 ± 0.76 mM, n=2-4 oocyte 
preparations. V/V0 at 1 is 45.34 +/- 2.65 fmol/oocyte/hour. The non inhibitable 
component is contributed by the tracer present within the system. Concentration of L-
Proline in the tracer 0.25 µM. 
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4.8  The exceptional affinity of L-Tryptophan for 
hPAT4 
L-Tryptophan and some of its derivates have been shown to bind PAT1 (Metzner et 
al., 2005) and PAT2 (Edwards et al., 2011); however no transport activity for L-
Tryptophan has been shown in either of them. Inhibition assays with unlabelled L-
Tryptophan (containing only [3H] L-Proline) showed that 1 mM L-Tryptophan could 
inhibit tracer uptake. 
Affinity inhibition experiments were set up in varying concentrations (0 mM to 1 mM 
L-Tryptophan) with constant amount of [3H] L-Proline tracer. The results obtained 
are shown in figure 4.8. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4                                              Results: Functional Characterization of hPAT4 
 
 
 
103
 
 
 
 
Figure 4.8: Concentration dependence of hPAT4-mediated tryptophan  
inhibition of [
3
H] L-Proline uptake. Km was 1.7 ± 1.1 µM, n=2 oocyte 
preparations. V/V0 at 1 is 43.56 +/- 3.43 fmol/oocyte/hour. Concentration of L-
Proline in the tracer 0.25 µM. 
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4.9  Transport of other radiolabelled amino acids 
Radiolabelled amino acids were tested for transport activity in Xenopus oocytes. The 
radiolabelled amino acids tested were either 3H or 14C labeled. The 14C amino acids 
tested were L-Serine, L-Cysteine and Glycine. The 3H ones tested were L-Tyrosine, 
L-Tryptophan, L-Lysine, L-Leucine and L-Alanine. Even though some of these were 
not found to inhibit [3H] L-Proline uptake in hPAT4, they were tested nevertheless 
since they were available and there was always the possibility that hPAT4 might be a 
very low affinity transporter for the amino acid. 
Of the amino acids tested (figure 4.9), the amino acids other than L-Proline which 
showed significant uptake compared to the non injected in influx assays were L-
Alanine and L-Tryptophan. Glycine was neither transported nor inhibited. L-
Tyrosine, L-Cysteine, L-Serine and L-Tyrosine were also not found to be transported 
(data not shown). 
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Figure 4.9: hPAT4-mediated uptake of amino acids into Xenopus oocytes 
(fmol/oocte/hour). *p < 0.05, Student’s t-test, compared to non injected oocytes, n ≥ 
3 oocyte preparations. Concentration of amino acid in the tracer 0.25 µM – 1 µM. 
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4.10  Electrogenecity 
Two approaches were taken to answer the question of electrogenecity of hPAT4. The 
first was to perform electrophysiology experiments by inserting electrodes into the 
oocyte, and performing voltage clamp experiments to measure any current flow 
associated with substrate flux thrugh transport. The second was to change the 
membrane potential by biochemical methods and observe if any changes took place 
in the transport properties. 
 
4.10.1 Electrophysiology 
Changes in currents are measured when the wash medium was replaced by medium 
containing high concentrations (at least 5 times the Ki) of the substrate. The results 
obtained indicated a very small current for the hPAT4 injected oocytes which was not 
however specific to hPAT4 since it was also observed in the non injected oocytes. 
hPAT1 which was run as a control was found to show a current which was specific to 
it (i.e after correcting for non injected). The results obtained are summarized in table 
4.1 
 
Table 4.1: Characterization of hPAT4-mediated transport.  
Experiments were conducted by two electrode voltage clamp electrophysiology, as 
compared to hPAT1-expressing and control (non injected) oocytes (n≥3 oocytes per 
condition). 
 * p < 0.05 vs pH5.5 non injected, # p < 0.05 vs pH7.4 non injected,  
NMS – no measurable signal 
 hPAT1 (nA) hPAT4 (nA) Non injected (nA) 
pH5.5 20µM Pro NMS NMS NMS 
pH5.5 10mM Pro 16.8 ± 2.09* (n=17) 4.70 ± 0.60 (n=10) 7.60 ± 0.87 (n=5) 
pH7.4 20µM Pro NMS NMS NMS 
pH7.4 10mM Pro 13.5 ± 1.18# (n=6) 9.00 ± 0.93 (n=12) 8.67 ± 1.17 (n=6) 
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4.10.2  Biochemical methods 
The second approach used was a biochemical one, manipulating membrane potential 
by altering external potassium. Influx assays were set up to contain varying 
concentrations of external potassium or choline chloride. 
hPAT1 was run as a control alongside for each point and each experiment along with 
hPAT4. Since hPAT1 is an electrogenic transporter driven by H+ co-transport 
comparison with hPAT4 will indicate whether hPAT4 is electroneutral.  
For the coupled transporter hPAT1, the uptake decreases when the external potassium 
concentration is decreased. In contrast for hPAT4, there appears to be very little 
change in uptake following a change in K+ levels. 
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Figure 4.10: Uptake of hPAT4-mediated [
3
H] L-proline in normal (2mM) and 
raised (50mM) extracellular potassium, normalised to that seen in the normal 
potassium (mean uptake of 25.3 ± 12.2 and 31.8 ± 24.9 fmoles/oocyte/hour, 
respectively, n=3 oocyte preparations with p < 0.05 for 2 mM versus 50 mM for 
hPAT1 and p > 0.05 for hPAT4 in each). For hPAT1 the normalised uptake at 1 
corresponds to 63.63 +/- 2.22  and 6.36 +/- 1.56 fmol/oocyte/hour for 2 mM and 50 
mM potassium respectively). Concentration of L-Proline in the tracer 0.25 µM. 
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4.11  The inhibition of hPAT4 L-Proline uptake by 
non-proteogenic amino acids 
A few non proteogenic amino acids were tested to check if they caused inhibition of 
radiolabelled proline uptake. In recent years there has been much attention focussed 
on PAT1 and PAT2 on account of the observation that these transporters are capable 
of bringing about the movement of various therapeutic drugs and non-amino acid 
substrates across the membrane (Thwaites and Anderson, 2011).  
A variety of non-proteogenic amino acids and drugs were tested including L-Dopa, β-
alanine, γ-aminobutyric acid (GABA), δ-aminolevulinic acid and sarcosine. None of 
these substrates caused inhibition except sarcosine. Sarcosine was observed to cause 
significant inhibition (p < 0.05, one-sample t-test) with an affinity of 1.09 ± 0.35 mM. 
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Figure 4.11: Concentration dependence of hPAT4-mediated sarcosine inhibition 
of [
3
H] L-Proline uptake. Ki was 1.09 ± 0.35 mM, n=2 oocyte preparations. V/V0 at 
1 is 20.35 +/- 3.41 fmol/oocyte/hour. Concentration of L-Proline in the tracer 0.25 
µM. 
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4.12 The mysterious case of L-Leucine and hPAT4  
Neither hPAT1 nor hPAT2 have shown any evidence of inhibition of L-Proline 
transport L-Leucine or of transport of this amino acid.   
As discussed in section 4.6, hPAT4 uptake of radiolabelled L-Proline is not inhibited 
in the presence of excess L-Leucine. However, when influx assays were set up and 
[3H] L-Leucine was used as a tracer, there was significant uptake by hPAT4 injected 
oocytes as compared to non injected oocytes. This is of particular interest considering 
the importance of the amino acid in signaling. 
Leucine is found to be important in nutrient sensing and mTOR regulation. Inhibition 
assays are performed with the notion that with one binding site for two amino acids 
that are transported by a particular transporter, each can cause inhibition of the other. 
For instance [3H] L-Tryptophan uptake is inhibited by L-Proline and vice versa.  
However [3H] L-Leucine uptake was not inhibited by L- Proline but leucine was 
transported across the membrane. It is possible that there is a separate binding site for 
L-Leucine from the one where L-Proline binds. If correct, this could also explain the 
role of PAT4 in sensing mechanisms (mTOR regulation). 
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Figure 4.12: hPAT4 is shown to bring about a significant uptake of [
3
H] L-
Leucine.  The data are corrected for non injected oocytes (* p < 0.05) . n ≥ 3 oocyte 
preparation. Concentration of L-Proline and L-Leucine in the tracer 0.25 µM. 
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4.13  Chapter summary 
• The human Proton coupled Aminoacid Transporter hPAT4 had always been 
categorised as an orphan transporter. 
• For the first time this transporter was shown to bring about a pH dependent 
transport of amino acid across the membrane. 
• The maximal transport activity was observed at a pH of 7.4 
• Time course assays showed that the transporter still continued to show a liner 
uptake activity at 1 hour and was observed not to reach saturation. 
• The transporter does not show a Na+ dependence. 
• The transporter is observed to have a very high affinity for L-Proline (Ki of 3 
µM). 
• Besides L-Proline, a variety of other substrates were also observed to inhibit 
[3H] L-Proline uptake. These include, L-Alanine, L-Tryptophan, L-Glutamine. 
• hPAT4 shows a high affinity for L-Tryptophan (range of 2 µM) 
• hPAT4 shows a lower affinity for the  other amino acids similar to that shown 
by the characterized hPATs 1 and 2, around 200 – 1000 µM. 
• Of the radiolabelled amino acids that were tested, L-Tryptophan, L-Alanine 
were observed to be transported across the membrane, whereas amino acids 
like L-Serine, L-Cysterine and L-Tyrosine.  
• Electrophysiological approaches indicated that the transporter is 
electroneutral. This was done by using voltage clamp experiments and by 
altering the membrane potential by changing the potassium concentration in 
the uptake medium. 
• Among the non-proteogenic amino acids that were tested, sarcosine was 
found to inhibit [3H] L-Proline uptake. 
• L-Leucine could inhibit labeled L-Proline uptake and vice versa. However 
when labeled L-Leucine was used as a tracer, hPAT4 was shown to bring 
about transport across the membrane. 
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5.1  Transmembrane domain prediction for hPAT1 
As discussed in section 1.3, membrane transporters are difficult to study using 
techniques such as X-ray crystallography which are commonly employed in 
definitive structural studies.  
In an effort to get around this, various programs have been designed which utilize 
algorithms that have taken into consideration factors such as hydrophobicity, the 
amino acids present and can attempt to predict the topology of the membrane 
transporter. Different transmembrane prediction software use different algorithms to 
do the same and as a result, as shown in table 5.1, hPAT1 is predicted to have 
anywhere from 9 to 11 transmembrane domains.  
These predictions can be used to design and insert epitope tags using site directed 
mutagenesis, and the predictions then confirmed or refuted experimentally.  
The epitope tag used is the eight amino acid sequence FLAG (DYKDDDDK). This 
epitope tag has previously been used to characterize PepT1 (Panitsas, Boyd and 
Meredith, 2006). As shown in figure 5.1 different numbers and regions were 
predicted for the TMDs of hPAT1. It was decided to use the MEMSAT3 (Jones, 
Taylor and Thornton, 1994) predictions to design the epitope tags. This was due to 
the positive results the predictions had given with PepT1 (Meredith and Price, 2006), 
predictions later confirmed when PepT1 was modelled on the peptide transporter 
PepT(So) for which a crystal structure is now available (Newstead et al., 2011).  
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Program 
Transmembrane domains 
1 2 3 4 5 6 7 8 9 10 11 
MEMSAT3 50-73 76-100 139-163 192-211 218-241 259-278 291-315 330-352 377-400 403-422 434-458 
TMHMM 53-72 77-99 141-163 194-211 218-240 255-277 290-312 341-363 376-393 403-425 438-460 
TopPred 52-72 75-95 143-163 216-236 258-278 289-309 335-355 398-418 437-457   
SVMtm 78-98 145-162 198-214 216-237 259-273 291-311 337-359 376-400 402-418 438-453  
TMpred 75-99 145-163 196-212 216-236 259-278 291-309 337-355 376-394 398-415 434-453  
 
 
Table 5.1: Transmembrane domain prediction of hPAT1. Depending on the software used hPAT1 is predicted to have 9-11 TMDs, 
each TMD being atleast 18 amino acids in length (as indicated by the first and last amino acid residue number for each predicted 
TMD). 
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Figure 5.1: Diagram generated using MEMSAT3 transmembrane domain prediction software. The model consists of 11 
transmembrane domains with an internal N-terminal and an external C-terminal. 
MEMSAT3 was used in designing the epitope tags 
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5.2  Epitope tagging of hPAT1 – External FLAGs 
 
5.2.1  Confirmation of epitope insertion 
FLAG epitopes were inserted by site directed mutagenesis as described (materials and 
methods). The sequences were confirmed and the regions containing the inserts are 
shown in figure 5.2. The sequencing confirmed that there were no other mutations 
except the FLAG insert.  
 
hPAT1           KGNIGTGLLGLPLAV-------KNAGIVMGPISLLIIGIVAVHCMGILVKCAHHFCRRLN 110 
FLAG1           KGNIGTGLLGLPLAVDYKDDDDKNAGIVMGPISLLIIGIVAVHCMGILVKCAHHFCRRLN 117 
                ***************       ************************************** 
 
 
hPAT1           VMYGLESSPCSWLRNHAHWGRRVVDFFLIVTQLGFCCVYFVFLADNF-------KQVIEA 172 
FLAG2           VMYGLESSPCSWLRNHAHWGRRVVDFFLIVTQLGFCCVYFVFLADNFDYKDDDDKQVIEA 180 
                ***********************************************       ****** 
 
                       
hPAT1           LVSLVMIYQFIVQRIPD-------PSHLPLVAPWKTYPLFFGTAIFSFEGIGMVLPLENK 281 
FLAG3           LVSLVMIYQFIVQRIPDYKDDDDKPSHLPLVAPWKTYPLFFGTAIFSFEGIGMVLPLENK 288 
                *****************       ************************************ 
 
hPAT1           ILYISLGCLGYLQFGANIQGS--------ITLNLPNCWLYQSVKLLYSIGIFFTYALQFY 352 
Flag4           ILYISLGCLGYLQFGANIQGSDYKDDDDKITLNLPNCWLYQSVKLLYSIGIFFTYALQFY 360 
                *********************        ******************************* 
 
 
hPAT1           VCLTCILAILIPRLDL--------VISLVGSVSSSALALIIPPLLEVTTFYSEGMSPLTI 412 
FLAG5           VCLTCILAILIPRLDLDYKDDDDKVISLVGSVSSSALALIIPPLLEVTTFYSEGMSPLTI 420 
                ****************        ************************************ 
 
 
hPAT1           LIQPSNAPIFINS--------TCAFI                                   476 
FLAG6           LIQPSNAPIFINSDYKDDDDKTCAFI                                   484 
                *************        ***** 
 
Figure 5.2: Sequence confirmation of external FLAGs F1, F2, F3, F4, F5 and F6. 
 
5.2.2  Confirmation of functionality of the epitope tagged 
transporters (external FLAGs) 
Mutations of genes with hPAT1 FLAG inserts F1, F2, F3, F4, F5 and F6 were 
checked for transport function. The uptake influx assays for transport were performed 
using oocytes injected with either hPAT1 (control) or the six external FLAG inserts 
or in non injected oocytes. Figure 5.3 shows the normalized uptake assays for these 
groups of oocytes. 
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Figure 5.3: Transport of [
3
H] L-Proline by external FLAGs. The figure shows the 
uptake of hPAT1, the putative external FLAGs F1, F2, F3, F4, F5 and F6 after 
correcting for non injected oocytes i.e the hPAT mediated uptake. The 
fmol/oocyte/hour reading for the non injected oocytes was 7.43. The significance 
levels are those when compared to non injected oocytes. (** p < 0.01, *** p < 0.001) 
n=7 oocyte preparations. Concentration of L-Proline in the tracer 0.25 µM. 
 
***        **         ***      ***         **        ***       ** 
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5.2.3  Luminometry studies on the putative external FLAGs 
Luminometry assays were performed on the same batch of oocytes as those studied in 
figure 5.3. The luminometry set up was performed as discussed (materials and 
methods). hPAT1 was used as a control along with non injected oocytes. This was 
done to ensure that hPAT1 did not show any reactivity with the anti-FLAG antibody.  
The results showed that the luminometry data for the putative external FLAGs was 
significantly higher than those injected with wild type hPAT1. The luminometry 
readings obtained for the FLAG inserts were significantly higher than either PAT1 or 
non injected oocytes (Figure 5.4).If the region where the epitope tags were inserted 
lies outside the membrane, the HRP tagged antibody can readily access it and its 
presence can then be detected by luminescence.  
The results obtained thus indicate that the regions which were tagged lay external 
region of the oocyte plasma membrane.  
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Figure 5.4: Normalised luminometry results of the putative external FLAGs. 
Luminometry experiments were set up on hPAT1, the external FLAGs F1, F2, F3, 
F4, F5, F6 and non injected oocytes. The oocytes injected with cRNA for the external 
FLAGs were compared to the hPAT1 injected oocytes to determine significance. (* p 
< 0.05, **p < 0.01, *** p <0 .01) n=7 oocyte preparations. 
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5.3  Epitope tagging of hPAT1 – Internal FLAGs 
 
5.3.1  Confirmation of epitope insertion 
Sequencing reactions were performed to confirm that FLAGs were inserted in the 
appropriate locations. No other mutations were observed in the sequence. Figure 5.5 
shows the epitope insertions. As discussed in the materials and methods internal 
FLAGs 1, 2, 3, 5 and 6 were designed, but it was not possible to get a successful 
insertion of the internal epitope FLAG 4 on account of the region being extremely 
G+C rich. 
 
 
hPAT1           MSTQRLRNEDYHDY--------SSTDVSPEESPSEGLNNLSSPGSYQRFGQSNSTTWFQT 52 
iFlag1          MSTQRLRNEDYHDYKDDDDKDYSSTDVSPEESPSEGLNNLSSPGSYQRFGQSNSTTWFQT 60 
                **************        ************************************** 
 
hPAT1           IGTGLLGLPLAVKNAGIVMGPISLLIIGIVAVHCMGILVKCAHHFCRRLN--------KS 112 
iFlag2          IGTGLLGLPLAVKNAGIVMGPISLLIIGIVAVHCMGILVKCAHHFCRRLNKDYKDDDDKS 120 
                **************************************************        ** 
 
hPAT1           HNNETVILTPTMDSRLYMLSFLPFLVLLVFIRN--------LRALSIFSLLANITMLVSL 232 
iFlag3          HNNETVILTPTMDSRLYMLSFLPFLVLLVFIRNDYKDDDDKLRALSIFSLLANITMLVSL 240 
                *********************************        ******************* 
 
hPAT1           FFVSRAPEHCE--------LVVDLFVRTVLVCLTCILAILIPRLDLVISLVGSVSSSALA 412 
iFlag5          FFVSRAPEHCEDYKDDDDKLVVDLFVRTVLVCLTCILAILIPRLDLVISLVGSVSSSALA 420 
                ***********        ***************************************** 
 
hPAT1           VTTFYSEGMSP--------LTIFKDALISILGFVGFVVGTYEALYELIQPSNAPIFINST 472 
iFlag6          VTTFYSEGMSPDYKDDDDKLTIFKDALISILGFVGFVVGTYEALYELIQPSNAPIFINST 480 
                ***********        ***************************************** 
 
Figure 5.5: Shows the sequence confirmation of internal FLAGs iF1, iF2, iF3, 
iF5 and iF6. 
 
5.3.2  Confirmation of functionality of the internal epitope tagged 
transporters 
The putative internal FLAGs iF1, iF2, iF3, iF5 and iF6 were used for cRNA 
synthesis. The cRNA for the internal FLAGs along with hPAT1 was injected into 
oocytes. Influx assays were performed using these injected oocytes and non injected 
ones. The internal FLAGs (figure 5.6) did not cause a change in transport activity 
compared to [3H] L-Proline uptake by wild type hPAT1. This indicates that the 
insertion of the epitopes did not cause a loss of function. 
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Figure 5.6: Transport of [
3
H] L-Proline by the internal FLAGs. The figure shows 
the normalized uptake of the internal FLAGs when normalized to hPAT1. The uptake 
of the injected oocytes was corrected for the non injected oocytes (i.e. the mediated 
transport). The fmol/oocyte/hour reading for the non injected oocytes was 5.30. The 
significance levels are those observed on comparison with the non injected oocytes. 
(* p < 0.05, ** p < 0.01, ***p < 0.001) n=5 oocyte preparations. Concentration of L-
Proline in the tracer 0.25 µM. 
 
  ***         **           ***         **          ***         ***       
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5.3.3  Luminometry studies on the internal FLAGs 
Oocytes injected with cRNA for the internal FLAGs iF1, iF2, iF3, iF5, iF6, hPAT1 
and non injected oocytes were used to set up luminometry experiments. As for the 
external FLAG experiments, hPAT1 expressing oocytes were used as a control to 
compare the internal FLAG injected oocytes against.  
The results indicated that the predicted internal regions showed no significant 
increase when compared to wild type hPAT1 injected oocytes.  
This indicates that the regions where these epitopes were inserted was not accessible 
from the extracellular medium, that is that  the tags were present in the intracellular 
region or in the trans membrane domain (generally an insertion in the trans membrane 
region might be expected to cause a change in confirmation and a loss of function. 
Figure 5.7 shows the luminometry readings of the internal FLAGs, hPAT1 and non 
injected oocytes). 
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Figure 5.7: Normalised luminometry analysis of the predicted internal FLAGs. 
The internal FLAGs were compared to the hPAT1 injected oocytes. The readings of 
antibody binding for any of the individual FLAGs were nomalised to that of hPAT1. 
Compared to hPAT no significant difference was observed. n=5 oocyte preparations.  
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5.3.4  Permeabilisation of oocytes 
The experiments on the internal FLAGs indicate that these regions are in the 
intracellular region (or possibly the trans membrane region) when performed in intact 
oocytes. To confirm this, oocytes which were injected with the cRNA for the internal 
FLAGs iF1, iF2, iF3, iF5, iF6 (with hPAT1 injected oocytes and non injected oocytes 
as control) were permeabilised. Permeabilisation was performed using TritonX 
(0.01%) through all the stages of luminometry from the initial blocking stages to the 
final wash just prior to addition of the ELISA substrate. Prior to couting the plates the 
oocytes were checked to make sure that they weren’t damaged. In addition to the 
permeabilisation of the oocytes with the internal FLAG, the oocytes injected with the 
external FLAG were also performed as a control to check that the increase observed 
in both of them was similar. To ensure that none of the oocytes had been damages, 
they were inspected by eye and against the non injected and hPAT1 injected controls. 
The results showed that permeabilised cells show an increase in all the luminometry 
readings compared to that in intact cells. However when compared to hPAT1 injected 
oocytes, the internal FLAGs showed a significant increase compared to hPAT1 and 
non injected. This is consistent with the hypothesis that in permeabilised cells the 
antibody is able to interact with the epitope tag indicating that the FLAGs are in the 
internal region (Figure 5.8a). 
In case of the external FLAGs an increase is still observed since there will also be an 
increase since there will be transport proteins that have not reached the surface of the 
membrane yet and are being detected (Figure 5.8b). However perbeabilisation studies 
with both the external and the internal flags show very similar results indicating that 
the net amount of tagged transporter present within the oocyte is similar. 
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Figure 5.8a: Normalised luminometry readings performed on permeabilised 
oocytes. TritonX was used as the permeabilising reagent. The significance levels are 
those observed on comparison with the hPAT1 injected oocytes. (** p < 0.01, ***p < 
0.001). n=4 oocyte preparations. 
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Figure 5.8b: Normalised luminometry readings performed on permeabilised 
oocytes (external FLAGs). TritonX was used as the permeabilising reagent. The 
significance levels are those observed on comparison with the hPAT1 injected 
oocytes. (** p < 0.01, ***p < 0.001). n=4 oocyte preparations. 
Luminometry analysis of putative external 
FLAGs on permeabilised oocytes 
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5.4  Modelling studies on hPAT1 
Due to the difficulties associated with crystallizing transporters and obtaining a 
tertiary structure, there is an increasing amount of focus on modelling studies. In 
recent years, a number of different software have been developed to study 
transporters using homology modeling. Different algorithms are used to analyse 
amino acid sequence of the protein and predict the where the helices lie (similar to 
TMD prediction software). This data is then used to model the transporter against a 
transporter for which the crystal structure is available. 
One such modelling software is provided on the LOMETS server (Zhang lab, 
University of Michigan, Wu, S. and Zhang, Y., 2007). Based on homology 
modelling, the software modelled hPAT1 onto the E.coli transporter AdiC. According 
to this model hPAT1 has 11 TMDs. The model is produced based on the hydropathy 
plots obtained from PSI-PRED. The results obtained from this prediction are shown 
in figure 5.9 across the following two pages 
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Figure 5.9: Results used for prediction of structure by LOMETS. LOMETS 
generates hydropathy plots and then uses the information to generate the model. 
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Before generating a model, the LOMETS server analyses the scores for target to 
template alignment using 8 programs, FUGENE, HHsearch, MUSTER, PPA, 
PROSPECT2, SAMT02, SPARKS and SP3. Based on the data generated from these, 
the LOMETS server then provides a summary of the various transporter molecules 
that the test transporter molecule has been aligned to and the scores obtained. 
 
The hPAT model obtained by this prediction is shown in figure 5.10. Highlighted in 
red are the first and last amino acid residues as predicted by MEMSAT3. The 
predictions according to the model and MEMSAT3 (epitope tagging experiments) are 
in agreement. Also indicated in the model (in dark blue) is the amino acid 63 which 
will be discussed more in detail in the next section.  
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Figure.5.10: hPAT1 model as predicted by homolog modeling hPAT1 against 
Adic using LOMETS. There are 11 TMDs. The figure shows an inernal N-terminal 
and an external C-terminal. The first and last amino acids of each TMD as predicted 
by MEMSAT3 are shown in red. Amino acid 63 (which is discussed further in the 
next section is shown in dark blue and indicated with the white arrow). 
outside 
inside 
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There have also been predictions made using the crystal structures from LeuTAa. 
According to predictions made from these transporter families SLC6, SLC7, SLC36 
and SLC38 show an inverted 5+5 repeat. SLC6 and dSLC7 show 12 TMDs i.e. 2 
more TMDs after the 5+5 inverted repeat. SLC36 and SLC38 do not show the 12th 
TMD and have an 11 TMD structure (Broer and Palacin 2011). 
 
 
Figure 5.11: The 5+5 inverted repeat structure which  is shown by a few families 
of transporters including  SLC6, SLC7, SLC36, and SLC38. SLC36 and 38 do not 
have the last TMD (Broer and Palacin 2011). Figure from Yamashita et al., 2005. 
 
 
5.5  The champagne mutation 
The champagne mutation was first discovered in horses. The champagne coat colour 
is much sort after by horse breeders. Large scale genetic screens had been performed 
to check what the source of this coat colour was. A single point mutation was 
observed in exon 2 of the PAT1 gene (Cook et al., 2008). The mutation is at 
nucleotide position 76 of exon 2 and causes a C to a G base. This in turn causes a 
change in the amino acid being formed at position 63 from a threonine to an arginine. 
The threonine residue is observed to be conserved across species as shown in Figure 
5.12. 
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Figure 5.12: Sequence alignment of the PAT1 across species showing a 
conserved Threonine residue at amino acid position 63. From Cook et al., 2008 
 
            
Using the model obtained from LOMETS, amino acid 63 was marked onto it (figure. 
5.9). According to the LOMETS prediction this site is also predicted to be one of the 
potential substrate binding sites. The location of this site (based on the model), in the 
middle of a TMD which is fairly close to the middle of the transporter protein.  
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Figure 5.13: Modelling of hPAT1 on AdiC with the champagne mutation. The 
orientation is such that the transporter is viewed from the extracellular region into the 
intracellular region. The champagne mutation is marked in dark blue and is noticed to 
be in the first TMD both according to the model and MEMSAT3 prediction. 
 
Champagne mutation 
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5.6  Chapter summary 
• Various trans membrane domain (TMD) prediction software predict between 
9 – 11 TMDs. 
• MEMSAT3 prediction suggested 11 TMDs with an internal N-terminal and an 
external C-terminal. 
• Six putative external FLAGs were designed. These were confirmed for 
transport function prior to performing luminometry assays. Each of these 
FLAGs was observed to show a significantly higher luminometry reading 
compared to the hPAT1 and non injected oocytes. 
• Five putative interrnal FLAGs were designed. These were confirmed for 
transport function prior to performing luminometry assays. Each of the 
FLAGs was observed to show no difference in luminometry compared to 
hPAT1 and non injected oocytes. To confirm that the absence of signal was 
due to the region being internal rather than due to the fact that the antibody 
cannot access the epitope, the oocytes were permeabilised. On 
permeabilisation, the oocytes were observed to show a significantly higher 
uptake compared to the non injected oocytes. Similar data was also observed 
on permeabilisation of oocytes injected with the external epitope tags. 
• Modeling studies using LOMETs also indicates an 11 TMD structure. 
• The LOMETs prediction also shows that the champagne residue at amino acid 
63 is found to lie within the first TMD and is one of the regions thought to 
play a role in substrate binding/recognition. 
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hPAT3, like hPAT4 has always been characterized as an orphan transportrer as 
discussed in the introduction. Unlike hPAT1 and 2, which are expressed in a range of 
organs and hPAT4 which is expressed ubiquitously, hPAT3 expression has only been 
noted in mouse testis. 3.1 refers to the hPAT3 variant 1 which is 123 bp longer than 
3.2 (variant 2). 
 
 
6.1  Testing hPAT3 function in oocytes 
Both the clones of hPAT3 (variant 1 and variant 2) were subcloned into the pXT7 
Xenopus oocyte vector (as described in section materials and methods). Transport 
assays using [3H] L-Proline were set up under different conditions. Proline was 
selected as a substrate since it was observed to be a good substrate for both the 
transporters hPAT1 and 2 and the orphan transporter hPAT4 which we characterized. 
Basic influx assays were set up across a range of pH. The pHs at which hPAT3 
transport activity was tested were pH 5.5 (which is the optimal pH for hPAT1 and 
hPAT2), pH 7.4 (which is the pH at which hPAT4 showed optimal transport activity), 
pH 8.4 and pH9.4. The reason for selecting an alkaline pH higher than 7.4 was the 
localization of hPAT3 in the testis and that due to transporters including those such as 
HCO3
- transporters it is possible that hPAT3 works best in an alkaline environment.  
The experiments were performed along with hPAT4 as control. 
Preliminary experiments indicated some pH dependence for hPAT3 transport with 
transport being more rapid at higher pH. However repeated experiments indicated 
that hPAT3 did not always transport proline across the membrane and the uptake 
wasn’t always significant. It was therefore considered that hPAT3 perhaps has an 
ionic dependence (eg. Na+ dependence). 
Experiments were set up for influx assays at different pHs but with Na+ containing 
medium. The pH dependence then appeared to shift towards 7.4 with maximum 
uptake at this pH. Despite this however the uptakes were not consistently 
significantly greater than non injected oocytes. It was therefore decided to use cell 
lines to study PAT3 function. 
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Figure 6.1: Mediated uptake of [
3
H] L-Proline by hPAT3.2. Uptake was corrected 
for non injected oocytes. hPAT4 in Na+ free medium at pH5.5 was used as a positive 
control. (** p < 0.01) n>5 oocyte preparations. Concentration of L-Proline in the 
tracer 0.25 µM. 
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6.2   Testing PAT endogenous expression in the TM4 
cell line 
 
6.2.1  Introduction 
TM4 is a mouse cell line. Its origin is testicular cells (Sertoli cells) from a 11-13 day 
old mouse pup. This cell line is commonly used to study features which are common 
to the testicular cells. As discussed in the introduction PAT3 was found to be specific 
only to the testis.  
Using the mouse testicular cell line presented two options regarding how to proceed 
with the experimental analysis 
i) To check if mPAT3 (murine PAT3) was endogenously expressed in TM4 
cells. If this was the case we could directly use this cell line to perform 
transport assays and characterize its function 
ii) If the cell line did not express mPAT3, we could transfect this with hPAT3. 
Since the cell line is of testicular origin it would give us a suitable 
environment to study the transport function. 
 
6.2.2  Checking for endogenous expression of mPAT3 in TM4 cells 
To check for the presence of mPAT3 in TM4 cells, the principle of reverse 
transcription polymerase chain reaction (RT-PCR) was used. In this process RNA 
from cells was used to synthesize cDNA which was then used as a template for PCR 
reaction 
RT-PCR reactions were set up using + RT and –RT template with primers specific to 
exon-exon boundaries. GAPDH was used as a positive control. The sample from the 
PCR was run on a gel and the results analyzed.  
There were no fragments observed for the mPAT3 +RT samples as shown in figure 
6.2. There was however a fragment for the positive control GAPDH. Since mPAT3 
was absent in the TM4 cells, it was decided to transfect these cells with hPAT3.  
Prior to transfection however two things needed to be done  
1) To check if TM3 expressed any other PATs (i.e. mPATs) 
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2) To subclone the hPATs into a mammalian vector 
Primers spanning exon-exon boundaries were designed for mPATs 1, 2 and 4. 
Repeated experiments were performed using different batches of cells and RNA but 
no fragments were observed. Different annealing temperatures and MgCl2 
concentrations were also used to ensure that the absence of fragments were to ensure 
that the absence of fragments was not due to the use of non optimal PCR conditions.  
cDNA was synthesised as explained in the materials and methods and used as a 
template for PCR reactions. GAPDH was used as a positive control. The PCR 
products were then analysed on a 1% gel. The results obtained are shown in figure 
6.3.  
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Figure 6.2: PCR products from reverse transcription PCR of mPAT3 and 
GAPDH. +RT and –RT indicate the presence and absence of reverse transcriptase in 
the cDNA synthesis process respectively. 
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Figure 6.3: PCR products from reverse transcription PCR of mPAT1, PAT2, 
mPAT4 and GAPDH. +RT and –RT indicate the presence and absence of reverse 
transcriptase in the cDNA synthesis process respectively. 
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6.3  hPAT3 studies in TM4 and HEK293 cell lines 
HEK293 was used as a control to check for transfection efficiencies and compare the 
results obtained.  
6.3.1  Confocal microscopy 
TM4 cells and HEK293 cells were analysed using confocal microscopy to study the 
transfection efficiencies in these cells. EGFP-C and EGFP-N were obtained from Dr. 
Ryan Pink (Oxford Brookes University) and both were observed to give similar 
efficiencies. Figure 6.4a and 6.4b show the confocal images obtained when co-
transfection experiments were performed in HEK293 cells and TM4 cells 
respectively. These experiments were performed to check whether there was any 
difference in the transfections observed for GFP controls. The results from imaging 
analysis show that the efficiencies did not vary depending on the kind of GFP used. 
Therefore, it was decided to use EGFP-C in the cotransfection experiments. 
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Figure 6.4a: Images obtained for HEK293 cells using confocal microscopy. The cells were grown in confocal compatible dishes 
and imaged after 48 hours. In both panels A and B, 1 is the cells transfected with pcDNA3.1(-) alone, 2 is the EGFP-C transfected 
cells and 3 is the EGFP-N transfected cells. The length between the two red dots in each images is 20 microns. In each case the 
amount of DNA used was constant and for the EGFP transfections, half the amount of pcDNA vector was used and the remaining was 
the EGFP construct. 
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Figure 6.4b: Images obtained for TM4 cells using confocal microscopy. The cells were grown in confocal compatible dishes. 1 is 
the cells transfected with pcDNA3.1(-) alone, 2 is the EGFP-C transfected cells and 3 is the EGFP-N transfected cells. The length 
between the two red dots in each images is 20 microns. In each case the amount of DNA used was constant and for the EGFP 
transfections, half the amount of pcDNA vector was used and the remaining was the EGFP construct. 
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EGFP-C was purified to obtain very high quality DNA and used in co transfection 
experiments. This means that half the amount of DNA was EGFP-C control and 
remaining was the test plasmid (i.e. the empty vector or vector with hPAT). 
HEK cells were observed to show a high efficiency in the range of >80%, 48 hours 
post transfection. TM4 cells on the other hand showed a lower efficiency, in the range 
of <50 %. As expected, the GFP was observed to localize to the entire cytoplasmic 
region. Results obtained from cotransfection experiments maintaining the total 
amount of DNA constant and using the same amount of EGFP-C in each case are 
shown in figure 6.5a (for HEK cells) and 6.5b (for HEK293 cells). 
The images show that the efficiencies observed for the different co transfection was 
uniform and these cells could then be used to perform transport assays and check for 
the amount of protein. 
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Figure 6.5a: Confocal microscopy of HEK293 cells showing results from cotransfection experiments. hPATs 2, 3.1 and 3.2 were 
cotransfected with EGFP-C and the results obtained are shown in panels 1, 2 and 3 respectively. 
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Figure 6.5b: Confocal microscopy of TM4 cells showing results from cotransfection experiments. hPATs 2, 3.1 and 3.2 were 
cotransfected with EGFP-C and the results obtained are shown in panels 1, 2 and 3 respectively. 
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6.3.2  hPAT3 transport studies in cell lines 
Fresh Krebs Ringer solution was prepared and used (materials and methods) for the 
different stages of uptake assays in the TM4 cell line. The media was prepared at 
three different pH conditions 5.5, 7.4 and 8.4. Experiments were performed using 
[3H] L-Proline as tracer. Uptake experiments were performed for 15 mins. After 
washing with Krebs Ringers solution at the same pH three times, the cells were 
washed, lysed and triplicates of the lysis products were analysed. A portion of the 
lysis product was also used to measure the protein content when compared to BSA 
standards. The average of the data obtained was then corrected for the amount of 
protein and represented as fmol/mg of protein. The values for the hPATs were then 
compared to the control (empty pcDNA vector). 
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Figure 6.6: Uptake studies of [
3
H] L-Proline in TM4 cells expressig either hPAT3.1 or hPAT3.2. The cells were co-transfected 
with EGFP-C and the hPAT. The data has been normalised to the uptake observed for pcDNA3.1(-) at the corresponding pH. The 
values for pcDNA3.1(-) at pH 5.5, 7.4 and 8.4 were 9.46 +/- 1.20 fmol/mg protein, 36.20 +/- 8.31 fmol/mg protein and 57.53+/- 11.6 
fmol/mg protein respectively (* p<0.05). n=2 to 7 experiments. 
Concentration of L-Proline in the tracer 0.25 µM. 
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6.4  Chapter summary 
• An attempt to characterize hPAT3 (the two splice variants, here referred to as 
hPAT3.1 and hPAT3.2) was made in Xenopus laevis oocytes and in cell 
culture. 
• Attempts to chatracterize the transporter included testing whether it could 
bring about transport of [3H] L-Proline across the membrane depending on the 
pH and whether the transporter showed a Na+ dependence. 
• To test the expression of this transporter in cell lines, the mouse Sertoli cell 
line TM4 was selected alongside HEK293 (which is a very well characterized 
cell line). 
• No endogenous expression of mPAT3 was detected in these cells and so it 
was decided to transfect this cell line with hPAT3.1 and hPAT3.2 in 
pcDNA3.1(-), while performing an EGFP co-transfection to check for 
transfection. 
• Experiments were performed using co transfection of hPAT 2, 3.1 or 3.2 and 
EGFP in the Sertoli cell line. Preliminary experiments have showed that 
hPAT3.2 appears to transport at pH7.4. No transport function was observed 
for hPAT3.1. 
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7.1  Introduction 
In recent years transporters have received a lot of attention due to the important role 
they play in trafficking specific drugs across the membrane of target cells and 
organelles. There are a few transporter families that still rely on H+ as its driving 
force, these include PepT1 and PATs. 
The increasing attention they have drawn is driven by the broad range of substrates 
they can transport. For instance for PepT1, apart from peptides which are transported, 
there are a variety of other substrates including therapeutic drugs like β lactam 
antibiotics, ACE inhibitors, rennin inhibitors and bestatin which also bind to PepT1 
and are successfully transported across the membrane (Han and Amidon 2000). 
Similarly the PAT family of transporters (PAT1 and 2) which are primarily 
transporters for the small neutral amino acids glycine, alanine and proline have also 
been shown to transport therapeutic drugs such as δ-aminolevulinic acid (Frølund et 
al. 2010).  
 
 
7.2  Functional studies on hPAT4 
7.2.1  Summary of findings and its relevance  
PAT4 had been placed into the PAT family based on sequence homology and until 
the studies reported here had been categorised as an orphan transporter. Based on the 
experiments performed using expression of cRNA in Xenopus laevis oocytes, we 
could show that hPAT4 is a pH dependent transporter which functions best at a pH of 
7.4. Like hPATs 1 and 2, this transporter was Na+ independent. But unlike PATs 1 
and 2, hPAT4 was shown to be electroneutral and the transport did not appear to be 
proton coupled. 
PATs 1 and 2 had the highest affinities for proline, alanine and glycine (with proline 
having the highest affinity and glycine the lowest). hPAT4 on the other hand could 
transport both proline and alanine but could neither bind nor transport glycine. 
A variety of other substrates were tested including the 20 naturally occurring amino 
acids. Of these amino acids [3H] L-Proline uptake was inhibited by proline, alanine, 
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tryptophan, cysteine, threonine, glutamine and methionine. A very high affinity was 
observed for proline and tryptophan (3.1+/-1.1 µM for proline and 1.7+/-1.1 µM for 
tryptophan) when compared to the others.  
 
7.2.2  PATs and mTOR signaling 
To understand the role of amino acid sensing and its significance in maintaining 
cellular homeostasis and nutrition levels, it is important to understand the mTOR 
signaling pathway. The mammalian Target of Rapamycin (mTOR) plays a critical 
role in nutrient sensing and growth.  
Rapamycin was isolated from soil samples and was observed to exhibit immune 
suppressive properties (Heitman,  Movva and Hall, 1991). In view of this Rapamycin 
analogs are being used in various clinical trials as a potential treatment for cancer. 
TOR is a highly conserved Serine Threonine kinase which is highly conserved across 
species. It has been shown to play an important role in a variety of processes 
including cellular metabolism and cell survival. In more recent years however, TOR 
has been receiving a lot of attention on account of data which implicates it in a 
variety of diseases including cancer and neurodegenerative disorders. The role of 
mTOR is via two separate factors mammalian Target of Rapamycin Component 1 
(mTORC1) and mTORC2. TOR binds Rapamycin and inhibits the Target of 
Rapamycin component 1(TORC1), though evidence also suggests that TORC2 might 
also be inhibited (Sarbassov et al. 2006). mTORC1 has been observed to play an 
important role in responding to changes in the growth factor and amino acid levels. 
The mechanism by which mTOR detects these changes remains largely unknown. In 
response to the stimulation by amino acids, mTOR is shuttled to the late endosomes 
and lysosomes where it can bind the Ragulator-Reg complex thereby being 
assembled into the active mTORC1 (Goberdhan, 2010). 
In recent years, a variety of transporters have been observed in mTOR activation 
(mTOR stands for the mammalian target of rapamycin). mTOR regulation is 
governed by the local nutrient availability and is particularly sensitive to amino acids. 
These transporters have been observed to be very different from each other in terms 
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of the amino acids they transport and the affinities. However all of them have been 
observed to transport the essential amino acids into the cell, especially leucine. 
PAT1 has been found to localize to the lysosomal membrane. The localization of 
hPAT4 on the other hand remains unknown. Taking into account the characteristics 
of hPAT4 (properties such as enzyme kinetics), it is likely that both the PAT 
transporters (hPAT4 and hPAT1) are expressed in the same region and interact to aid 
in the mTOR signaling pathway. This becomes more likely when taking into account 
the upregulation of mTOR, hPAT1 and hPAT4 in cancer cell lines. 
 
7.2.3  The role of Leucine in signalling 
Leucine has been shown to play a very important role in amino acid sensing by a 
number of groups (Hyde, Taylor and Hundal, 2003).  In the model proposed we take 
into account the findings of this thesis and the recent work by Sabine et al. (ref). To 
summarise the results obtainined by performing the various transport assays, leucine 
was directy transported by hPAT4 as the data in this thesis shows. Surprisingly 
however  leucine transport could not be inhibited by an excess of leucine and leucine 
transport could not be inhibited by proline.  It is therefore suggested that leucine is 
transported by hPAT4 either by conjugating with another transport molecule i.e. a 
heterodimeric protein or by causing a change in conformation of a different 
transporter and bringing about an increase in transport of leucine.  
The role of PATs in signaling 
In the recent years a lot of attention has been drawn to the role of PATs in signaling. 
PAT1 and PAT4 have been found to be most important from this point of view. 
According to the studies performed in various cancer cell lines, PAT1 and PAT4 have 
been proposed to act in conjunction and aid in signaling.  
PAT1 has been found to localize in the lysosomal membrane and in the brush border 
membrane of the intestinal epithelium (and the plasma membrane in some cell types). 
The sub cellular localization of PAT4 continues to remain unknown. Sabatini et al 
(year) have shown that PAT4 does not localize to the mitochondrial membrane. 
Taking into account the fact that PAT4 has been found to transport amino acids only 
at a pH of 7.4, this decreases the regions where PAT4 may be localized. It is however 
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possible that at a lower pH such as in the range of 6 which is observed in the late 
endosomes, PAT4 is found to bind substrates but not transport them and it is the 
binding which acts as a signal to sense the amino acid levels. Since between PAT1 
and PAT4 they cover a wide range of amino acid substrates it is possible that they act 
in coordination to participate in mTOR signaling.  
The amino acids are brought into the cytoplasm by transporters including PAT1 from 
the extracellular medium or via export from the lysosomes (the role of PAT4 at this 
stage depends on its localization). After  
Due to the extremely high affinity of hPAT4 for amino acids like proline and 
tryptophan, it is likely that under normal physiological conditions the primary role of 
this protein is not to function as a transporter (since it will be saturated). However, 
along with PAT1, this transporter could be binding the substrates without necessarily 
transporting the substrates across the membrane, rather aiding in sensing the amino 
acid concentrations. 
It is also likely that PAT4, when not saturated with amino acids could be causing an 
alteration in a different transporter that causes leucine transporter. 
A change in the change in the amino acid concentration causes the activation of the 
mTOR pathway. Heublein et al. (2010) showed that hPAT1 and hPAT4 were 
necessary in cell lines such as HEK293 and the breast cancer cell line MCF7. In 
addition to this mTOR activation following amino acid stimulation also required 
PAT1 and PAT4. According to the model they predict, PATs regulate the activity of 
mTORC1 by controlling the intracellular response to amino acids and thus participate 
in mTOR regulation. 
 
7.2.4  The PAT signalling story 
The surprisingly high affinity of hPAT4 appears to indicate that hPAT4 may be 
important as a transceptor. Transceptors are molecules that along side bringing about 
transport of substrates across the membrane are also observed to act as receptors 
which participate in different processes including signalling pathways (Kriel et al. 
2011). It is believed these transporter/receptors can sense the level of amino acid and 
act as a trigger for nutrient sensing (Hyde, Taylor and Hundal, 2003) Hundal and 
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Taylor, 2009). Further evidence for this was obtained by experiments performed in 
cell culture (Heublein et al., 2010) which highlighted the impact of hPAT4 and its 
role in the signalling cascade (mTOR signalling). Following evidence from cell 
culture experiments, it is believed that the amino acid concentration is sensed by the 
hPATs (most likely hPAT4 or an interaction between hPAT1 and hPAT4).  
One of the amino acids important in the mTOR signalling pathway is leucine. Our 
preliminary experiments involving inhibition of [3H] L-Proline uptake had indicated 
that leucine could not inhibit the uptake. However when [3H] L-Leucine was used a 
tracer, hPAT4 could bring about its transport across the membrane. Inhibition 
experiments indicated that L-proline could not inhibit the uptake of [3H] L-Leucine 
Yet another indication of the role of hPAT4 in nutrient sensing is based on 
experiments performed in Drosophila. As discussed in the introduction there are 12 
homologs of the PATs in Drosophila. One of these homologs, path was observed to 
have properties similar to PAT4. These included factors such as its substrate affinity 
(which was in the range of 2 µM) (Goberdhan et al., 2005) compared to 3 µM found 
when hPAT4 was expressed in Xenopus laevis oocytes. This lead to the conclusion 
that path was in all likelihood the Drosophila homolog of PAT4. 
The name path was given on the basis that flies that lacked this gene were observed 
to be a lot smaller than the wild type, hence the name pathetic or path. Apart from 
being smaller in size, the flies with path knock down were also observed to show 
much less development in the omatidia. Overexpression of this gene on the other 
hand, was found to result in flies which were nearly twice as large as the wild type 
with much more pronounced omatidia (numbers, size) in the eye (Goberdhan et al., 
2005). 
Sequence alignment of PAT1 and PAT4 across species (Appendix 2) also shows a > 
60% similarity. The suggested role of hPAT4 is in conjugation with hPAT1 where it 
forms a complex prior to facilitating in amino acid sensing and signalling in the 
mTOR pathway. Studies are also being undertaken to study the influence that the 
PATs have on regulating protein synthesis and influencing muscle growth in neonates 
(Suryawan and Davis, 2011). 
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7.3  Membrane topology studies on hPAT1 
7.3.1  Studies using site directed mutagenesis (epitope tagging) and 
luminometry 
Membrane transport structures are difficult to study on account of their dynamic 
nature. Obtaining a crystal structure for transport molecules is complicated by the fact 
that isolating sufficient amount of proteins that are in the same conformation is 
difficult. Currently there is no crystal structure available for any of the PAT family 
transporters despite the attention that they have received in recent years. Hydropathy 
plots of the AAAP family members (to which the PAT family belongs) indicated that 
these transporters are more likely to show the 11 transmembrane domain structures 
(Young, Jack et al., 1998).   
 Following predictions obtained from TMD prediction software and epitope tagging 
studies, we could show that hPAT1 has 11 TMDs, an internal N-terminal and an 
external C-terminal. The results from the FLAG epitope tagging studies are 
summarised in table 7.1a and b and figure 7.1. 
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External FLAG  Transport Luminometry 
F1   
F2   
F3   
F4   
F5   
F6   
Table 7.1a: Summary of the results obtained from transport assays and 
luminometry experiments using the external epitope tags. 
 
 
Internal FLAG  Transport Luminometry 
iF1   
iF2   
iF3   
iF5   
iF6   
Table 7.1b: Summary of the results obtained from transport assays and 
luminometry experiments using the internal epitope tags. 
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Figure 7.1: Diagrammatic representation of the epitope tagging and orientation of the hPAT1 molecule with 11 TMDs.  
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The predictions from modelling studies using LOMETS also agreed with our results 
and also largely agreed with the MEMSAT3 predictions.  
The significance of the hPAT1 His-55 residue was shown by Metzner et al. (2008). 
According to the model we propose, this site lies in the first trans membrane domain 
and together with residue 63 it could play an important role in the substrate binding 
site. 
Based on the positive results which were obtained from the MEMSAT predictions it 
was decided to try and used TMD prediction software to check for the number of 
TMDs for the remaining PATs as well. The data obtained from these are summarised 
in tables 7.3 a to d 
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hPAT2 
Program Amino acid 
 TMD1 TMD2 TMD3 TMD4 TMD5 TMD6 TMD7 TMD8 TMD9 TMD10 TMD11 
MEMSAT3 56-80 83-107 147-171 199-218 225-246 264-285 297-321 336-356 380-403 406-429 441-465 
TMHMM 84-106 148-170 201-218 225-247 262-284 297-319 344-366 379-401 406-428 441-463  
TopPred 59-79 82-102 149-169 223-243 265-285 297-317 342-362 405-425 444-464   
SVMtm 84-102 150-168 205-220 223-243 266-280 298-316 343-368 387-401 410-425 445-459  
TMpred 82-106 152-170 203-219 223-243 266-285 294-313 344-362 383-401 405-432 441-460  
Table 7.2a: Summary of TMD predictions for hPAT2 
 
hPAT3.1 
Program Amino acid 
 TMD1 TMD2 TMD3 TMD4 TMD5 TMD6 TMD7 TMD8 TMD9 TMD10 TMD11 
MEMSAT3 46-64 68-97 176-203 225-247 253-275 294-311 327-350 368-393 410-430 434-458 471-492 
TMHMM 72-94 177-199 230-247 254-276 291-313 326-348 377-399 412-429 439-461 474-493  
TopPred 47-67 75-95 179-199 230-250 293-313 325-345 371-391 434-454 473-493   
SVMtm 74-94 178-197 228-250 252-274 291-308 327-346 373-388 419-436 438-459 474-488  
TMpred 72-94 177-198 232-250 252-276 288-308 323-342 373-391 414-430 434-461 474-492  
Table 7.2b: Summary of TMD predictions for hPAT3.1 
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hPAT3.2 
Program Amino acid 
 TMD1 TMD2 TMD3 TMD4 TMD5 TMD6 TMD7 TMD8 TMD9 TMD10 TMD11 
MEMSAT3 46-62 66-95 131-161 184-206 212-234 253-270 286-309 327-352 369-389 393-417 430-451 
TMHMM 72-94 136-158 189-206 213-235 250-272 285-307 336-358 371-388 398-420 433-452  
TopPred 47-67 75-95 138-158 189-209 252-272 284-304 330-350 393-413 432-452   
SVMtm 74-94 136-156 187-209 211-233 250-267 286-305 332-347 378-395 397-418 433-447  
TMpred 72-94 136-157 191-207 211-235 247-267 282-301 332-350 373-389 393-420 433-451  
Table 7.2c: Summary of TMD predictions for hPAT3.2 
 
hPAT4 
Program Amino acid 
 TMD1 TMD2 TMD3 TMD4 TMD5 TMD6 TMD7 TMD8 TMD9 TMD10 TMD11 
MEMSAT3 61-85 88-112 154-178 206-229 233-253 272-290 305-329 346-369 389-412 415-438 449-473 
TMHMM 89-111 153-175 209-226 233-255 275-293 306-328 357-379 392-409 419-441 454-476  
TopPred 64-84 87-107 155-175 231-251 273-293 309-329 351-371 414-434 453-473   
SVMtm 89-106 155-173 212-226 232-251 275-289 310-324 353-368 397-428 451-470   
TMpred 87-104 157-175 211-227 232-251 274-293 306-324 350-371 393-410 414-432 454-472  
Table 7.2d: Summary of TMD predictions for hPAT4 
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According to the predictions of MEMSAT3, all for hPAT members are predicted to 
have 11 TMDs. This includes both variants of hPAT3.  
 
7.3.2  Studies on the champagne mutation 
The C to G point mutation in exon 2 of PAT1 has been found to be responsible for 
the champagne coat colour in horses. Based on membrane topology predictions this 
region in hPAT1 appears to lie within the first TMD and is thought to be one of the 
sites that is responsible for substrate binding.  
No previous transport studies have been performed using this site mutation. 
Preliminary studies were performed to check whether there was a change in the 
transport mechanisms of PAT1. Since the champagne mutation causes a difference in 
the coat colour one of the substrates it could be affecting is one of the components in 
the melanin synthesis pathway. Figure 7.2 shows the various compounds that lead to 
the synthesis of melanin. Tyrosine and DOPA are the stable compounds of this 
pathway which are the likely candidates whose transport PAT1 could be altering.  
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Figure 7.2: Melanin synthesis pathway. The different products in the melanin 
synthesis pathway are shown (Ando, Kondoh, Ichibashi, and and Hearing 2007). The 
stable products in the synthesis pathway are tyrosine and DOPA. 
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Preliminary studies were performed in Xenopus laevis oocytes injected with hPAT1 
wildtype (referred to as hPAT), hPAT1 champagne (referred to as champ) and non 
injected oocytes. 
Inhibition assays were performed using an excess of L-Proline, L-Tyrosine and L-
DOPA. Both hPAT1 and champ are inhibited by an excess of L-Proline. Neither L-
Tyrosine nor L-DOPA are observed to be inhibited by hPAT1. However preliminary 
experiments show that L-Tyrosine and L-DOPA both inhibit the uptake of [3H] L-
Proline. The results obtained are summarised in Figure 7.3. 
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Figure 7.3: Mediated uptake of 
[3H] 
L-Proline by hPAT1 and champ. The 
significance levels are those obtained when compared to non injected oocytes. Both 
hPAT1 and champ bring about transport of tracer across the membrane. L-Proline 
inhibits tracer uptake by both hPAT1 and champ. Uptake of L-Proline is not inhibited 
in the presence of an excess of L-Tyr or L-DOPA; on the other hand both L-Tyr and 
L-DOPA inhibit uptake of L-Proline in oocytes injected with champ RNA. (*** p < 
0.001). Concentration of L-Proline in the tracer 0.25 µM. 
 
 
***  ***                             ***              ***   
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7.4  Future work  
In this section, the future work that can be done on the hPATs in the context of the 
aims of this thesis will be discussed 
 
• To elucidate the function of hPAT4 (using the oocyte expression system) 
• To characterize substrate affinities, specificity and other features of the 
transporter 
hPAT4 has been characterized functionally. Besides its affinities for the proteogenic 
amino acids and a few compounds like sarcosine, DOPA and β-Alanine, its substrate 
recognition still need to be studied in more detail.  
In addition to these, the interesting results obtained from the studies using L-Leucine 
can be further investigated, especially in the context of the work done in mTOR 
regulation in cell lines (Heublein et al., 2010). 
 
• To predict the Trans Membrane Domain structure using different 
membrane prediction software 
• To confirm the predicted structure using the techniques of site directed 
mutagenesis, epitope tagging and luminometry 
Epitope tagging studies have confirmed the 11 TMD model as proposed based on the 
data from membrane prediction software (secondary structureof the protein). Using 
LOMETS, it was attempted to extend this to a tertiary structure prediction, which 
agreed with the 11 TMD model as well. The epitope tagging experiments could be 
further extended to the remaining PATs as well. 
 
• To study the champagne mutation using expression in Xenopus laevis 
oocytes and to study how the mutation might produce effects. 
According to this model, the champagne mutation appears to be in a region which 
could be playing a role in the substrate binding site. This information along with the 
significance of His-55 (Metzner et al., 2008) as the catalytic site can be further used 
to study the possible interactions between these two sites.  
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Preliminary studies using the champagne mutation in Xenopus laevis have shown that 
there appears to be an alteration in the subrate specificity. There is no change in the 
transport of L-Proline, however L-DOPA which is not a substrate for hPAT1 causes a 
change in current in the mutants (two electrode voltage clamp experiments). 
Similarly, initial inhibition experiments performed in Xenopus laevis oocytes also 
indicate that for the oocytes injected with champagne hPAT1, L-DOPA inhibits [3H] 
L-Proline uptake as compared to the wild type hPAT1. L-DOPA is one of the 
products in the melanin synthesis pathway and this difference in the transport of 
DOPA might explain the champagne coat colour observed in horses. 
While further investigation needs to be made with regards to investigating the role of 
the Threonine 63 residue in substrate binding, based on the preliminary experiments 
it seems to participate/alter the binding of amino acids. In addition to this residue, 
there is also a histidine at position 55. It is possible that this mutation is important for 
the binding of H+ prior to the translocation of substrate across the membrane. 
 
• To use Xenopus laevis oocytes and cell culture techniques to study the 
functions of hPAT3 
Transport assays under different conditions were performed in both Xenopus laevis 
oocytes and TM4 cell culture. There appeared to be some transport, but no significant 
uptake was observed for hPAT3 in repeated experiments. The function of this 
transporter needs to be investigated further. It is the only PAT family member whose 
distribution is restricted to just one organ (the testis). The initial idea was that perhaps 
the transporter is coupled to a different ion. However, the absence of any significant 
transport even at different pHs makes this less likely. The alternative suggestion is to 
check for its role in signalling by studying at what stage during development it is 
expressed or if it is constantly expressed throughout the life of the organism. 
 
There is a lot more information now available about the different transporter proteins 
due to the various advancements in the field of molecular biology; despite this many 
of them remain orphans. The relationship between transporters and signalling has 
gained a lot of attention in recent years and better understanding of the different 
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pathways involved will push forward the tranceptor studies. With more crystal 
structures being made available, the structural studies will become quicker and the 
data from membrane prediction studies a lot more accurate and this can be used for 
membrane prediction studies and for modelling a transporter whose structure is 
unknown against a range of different known transporters to study the best fit 
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APPENDIX 1: hPAT sequences and 
primers for subcloning and sequencing 
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AMINO ACID SEQUENCES OF THE hPATs 
 
hPAT1 
>gi|41352721|ref|NP_510968.2| proton-coupled amino acid transporter 1 [Homo 
sapiens] 
MSTQRLRNEDYHDYSSTDVSPEESPSEGLNNLSSPGSYQRFGQSNSTTWFQTLIHLLKGNIGTGLLGLPL 
AVKNAGIVMGPISLLIIGIVAVHCMGILVKCAHHFCRRLNKSFVDYGDTVMYGLESSPCSWLRNHAHWGR 
RVVDFFLIVTQLGFCCVYFVFLADNFKQVIEAANGTTNNCHNNETVILTPTMDSRLYMLSFLPFLVLLVF 
IRNLRALSIFSLLANITMLVSLVMIYQFIVQRIPDPSHLPLVAPWKTYPLFFGTAIFSFEGIGMVLPLEN 
KMKDPRKFPLILYLGMVIVTILYISLGCLGYLQFGANIQGSITLNLPNCWLYQSVKLLYSIGIFFTYALQ 
FYVPAEIIIPFFVSRAPEHCELVVDLFVRTVLVCLTCILAILIPRLDLVISLVGSVSSSALALIIPPLLE 
VTTFYSEGMSPLTIFKDALISILGFVGFVVGTYEALYELIQPSNAPIFINSTCAFI 
 
hPAT2 
>gi|119582082|gb|EAW61678.1| solute carrier family 36 (proton/amino acid 
symporter), member 2 [Homo sapiens] 
MSVTKSTEGPQGAVAIKLDLMSPPESAKKLENKDSTFLDESPSESAGLKKTKGITVFQALIHLVKGNMGT 
GILGLPLAVKNAGILMGPLSLLVMGFIACHCMHILVKCAQRFCKRLNKPFMDYGDTVMHGLEANPNAWLQ 
NHAHWGRHIVSFFLIITQLGFCCVYIVFLADNLKQVVEAVNSTTNNCYSNETVILTPTMDSRLYMLSFLP 
FLVLLVLIRNLRILTIFSMLANISMLVSLVIIIQYITQEIPDPSRLPLVASWKTYPLFFGTAIFSFESIG 
VVLPLENKMKNARHFPAILSLGMSIVTSLYIGMAALGYLRFGDDIKASISLNLPNCWLYQSVKLLYIAGI 
LCTYALQFYVPAEIIIPFAISRVSTRWALPLDLSIRLVMVCLTCLLAILIPRLDLVISLVGSVSGTALAL 
IIPPLLEVTTFYSEGMSPLTIFKDALISILGFVGFVVGTYQALDELLKSEDSHPFSNSTTFVR 
 
hPAT3 variant 1 i.e. 3.1 
>gi|71681851|gb|AAI01094.1| SLC36A3 protein [Homo sapiens] 
MSLLGRDYNSELNSLDNGPQSPSESSSSITSENVHPAGEAGLSMMQTLIHLLKCNIGTGLLGLPLAIKNA 
GLLVGPVSLLAIGVLTVHCMVILLNCAQHLSQRLQKTFVNYGEATMYGLETCPNTWLRAHAVWGRWNLAL 
SPRLECSGKISAHCNPHLQGSSNSPAQASRVAGIYRYTVSFLLVITQLGFCSVYFMFMADNLQQMVEKAH 
VTSNICQPREILTLTPILDIRFYMLIILPFLILLVFIQNLKVLSVFSTLANITTLGSMALIFEYIMEGIP 
YPSNLPLMANWKTFLLFFGTAIFTFEGVGMVLPLKNQMKHPQQFSFVLYLGMSIVIILYILLGTLGYMKF 
GSDTQASITLNLPNCWLYQSVKLMYSIGIFFTYALQFHVPAEIIIPFAISQVSESWALFVDLSVRSALVC 
LTCVSAILIPRLDLVISLVGSVSSSALALIIPALLEIVIFYSEDMSCVTIAKDIMISIVGLLGCIFGTYQ 
ALYELPQPISHSMANSTGVHA 
 
hPAT3 variant 2 i.e. 3.2  
>gi|72533330|gb|AAI01096.1| Solute carrier family 36 (proton/amino acid 
symporter), member 3 [Homo sapiens] 
MSLLGRDYNSELNSLDNGPQSPSESSSSITSENVHPAGEAGLSMMQTLIHLLKCNIGTGLLGLPLAIKNA 
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GLLVGPVSLLAIGVLTVHCMVILLNCAQHLSQRLQKTFVNYGEATMYGLETCPNTWLRAHAVWGRYTVSF 
LLVITQLGFCSVYFMFMADNLQQMVEKAHVTSNICQPREILTLTPILDIRFYMLIILPFLILLVFIQNLK 
VLSVFSTLANITTLGSMALIFEYIMEGIPYPSNLPLMANWKTFLLFFGTAIFTFEGVGMVLPLKNQMKHP 
QQFSFVLYLGMSIVIILYILLGTLGYMKFGSDTQASITLNLPNCWLYQSVKLMYSIGIFFTYALQFHVPA 
EIIIPFAISQVSESWALFVDLSVRSALVCLTCVSAILIPRLDLVISLVGSVSSSALALIIPALLEIVIFY 
SEDMSCVTIAKDIMISIVGLLGCIFGTYQALYELPQPISHSMANSTGVHA 
 
hPAT4 
>gi|28703727|gb|AAH47374.1| Solute carrier family 36 (proton/amino acid 
symporter), member 4 [Homo sapiens] 
MEAAATPAAAGAARREELDMDVMRPLINEQNFDGTSDEEHEQELLPVQKHYQLDDQEGISFVQTLMHLLK 
GNIGTGLLGLPLAIKNAGIVLGPISLVFIGIISVHCMHILVRCSHFLCLRFKKSTLGYSDTVSFAMEVSP 
WSCLQKQAAWGRSVVDFFLVITQLGFCSVYIVFLAENVKQVHEGFLESKVFISNSTNSSNPCERRSVDIR 
IYMLCFLPFIILLVFIRELKNLFVLSFLANVSMAVSLVIIYQYVVRNMPDPHNLPIVAGWKKYPLFFGTA 
VFAFEGIGVVLPLENQMKESKRFPQALNIGMGIVTTLYVTLATLGYMCFHDEIKGSITLNLPQDVWLYQS 
VKILYSFGIFVTYSIQFYVPAEIIIHGITSKFHTKWKQICEFGIRSFLVSITCAGAILIPRLDIVISFVG 
AVSSSTLAIILPPLVEILTFSKEHYNIWMVLKNISIAFTGVVGFLLGTYITVEEIIYPTPKVVAGTPQSP 
FLNLNSTCLTSGLK 
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PRIMERS FOR SUB CLONING THE hPATs INTO pXT7 AND THEIR 
RELATIVE POSITIONS 
Primer 
name 
Sequence Tm %GC Secondary 
structure 
Primer/
Dimer 
PAT1 
Forward 
 
GCTGGTACCCCATGTCCAC
GCAGAGACTTCG 
71.21 61.29 Weak No 
PAT1 
Reverse 
AGCCGGCCGTCCCTATATG
AAGGCACAGGTGGAATTG 
 
72.18 56.76 Moderate No 
PAT2 
Forward 
GCTGGTACCGCTCCTTGTTT
CTTAAGCAGTCATGTCTGT
G 
72.17 50 Weak No 
PAT2 
Reverse 
 
AGCCGGCCGTCGGGTGCTG
GTAGGCAAGGA 
72.93 70 Weak  No  
PAT3 
Forward 
GCTGGTACCGTTGAAGATG
TCATTGCTTGGAAGGGACT
AC 
72.58 50 Weak  No  
PAT3 
Reverse 
AGCCGGCCGGAATAAAAAC
AGATAATTATGCATGGACA
CCTGTGG 
72.77 46.67 Moderate No 
PAT4 
Forward 
 
GCTGGTACCGGCGGCGTCC
TGGAGACC 
72.9 74.07 Weak No 
PAT4 
Reverse 
AGCCGGCCGGAAGACTCAT
GATTCTGCTTTTACTATTTC
AAACCAG 
71.37 45.65 Weak no 
KEY: Ala  Res site Forward: KpnI and reverse: EagI Untranslated region  
The regions shaded in grey are the untranslated regions. The primer sequence present 
in the gene are indicated in bold 
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hPAT1 
GGGCTGTGCTGAAGCCAGAGCCGGAGCCGGAGCTGGGGCCAGAACCCGAGCAGTGAGTTCCTCCACTGGC 
TGCCGGCTGGCGGCGCTCGCCGCCTTGGGCAGGACCCACCTCGCCTTCCTCCCGGCGTGGCAGATGCTCC 
AGCTGCCATGTCCACGCAGAGACTTCGGAATGAAGACTACCACGACTACAGCTCCACGGACGTGAGCCCT 
GAGGAGAGCCCGTCGGAAGGCCTCAACAACCTCTCCTCCCCGGGCTCCTACCAGCGCTTTGGTCAAAGCA 
ATAGCACAACATGGTTCCAGACCTTGATCCACCTGTTAAAAGGCAACATTGGCACAGGACTCCTGGGACT 
CCCTCTGGCGGTGAAAAATGCAGGCATCGTGATGGGTCCCATCAGCCTGCTGATCATAGGCATCGTGGCC 
GTGCACTGCATGGGTATCCTGGTGAAATGTGCTCACCACTTCTGCCGCAGGCTGAATAAATCCTTTGTGG 
ATTATGGTGATACTGTGATGTATGGACTAGAATCCAGCCCCTGCTCCTGGCTCCGGAACCACGCACACTG 
GGGAAGACGTGTTGTGGACTTCTTCCTGATTGTCACCCAGCTGGGATTCTGCTGTGTCTATTTTGTGTTT 
CTGGCTGACAACTTTAAACAGGTGATAGAAGCGGCCAATGGGACCACCAATAACTGCCACAACAATGAGA 
CGGTGATTCTGACGCCTACCATGGACTCGCGACTCTACATGCTCTCCTTCCTGCCCTTCCTGGTGCTGCT 
GGTTTTCATCAGGAACCTCCGAGCCCTGTCCATCTTCTCCCTGTTGGCCAACATCACCATGCTGGTCAGC 
TTGGTCATGATCTACCAGTTCATTGTTCAGAGGATCCCAGACCCCAGCCACCTCCCCTTGGTGGCCCCTT 
GGAAGACCTACCCTCTCTTCTTTGGCACAGCGATTTTTTCATTTGAAGGCATTGGAATGGTTCTGCCCCT 
GGAAAACAAAATGAAGGATCCTCGGAAGTTCCCACTCATCCTGTACCTGGGCATGGTCATCGTCACCATC 
CTCTACATCAGCCTGGGGTGTCTGGGGTACCTGCAATTTGGAGCTAATATCCAAGGCAGCATAACCCTCA 
ACCTGCCCAACTGCTGGTTGTACCAGTCAGTTAAGCTGCTGTACTCCATCGGGATCTTTTTCACCTACGC 
ACTCCAGTTCTACGTCCCGGCTGAGATCATCATCCCCTTCTTTGTGTCCCGAGCGCCCGAGCACTGTGAG 
TTAGTGGTGGACCTGTTTGTGCGCACAGTGCTGGTCTGCCTGACATGCATCTTGGCCATCCTCATCCCCC 
GCCTGGACCTGGTCATCTCCCTGGTGGGCTCCGTGAGCAGCAGCGCCCTGGCCCTCATCATCCCACCGCT 
CCTGGAGGTCACCACCTTCTACTCAGAGGGCATGAGCCCCCTCACCATCTTTAAGGACGCCCTGATCAGC 
ATCCTGGGCTTCGTGGGCTTTGTGGTGGGGACCTATGAGGCTCTCTATGAGCTGATCCAGCCAAGCAATG 
CTCCCATCTTCATCAATTCCACCTGTGCCTTCATATAGGGATCTGGGTTCGTCTCTGCAGCTGCCTACCC 
CTGCCCCATGTGTCCCCCGTTACCTGTCCTCAGAGCCTCAGGTATGGTCCAGGCTCTGAGGAAAGTCAGG 
GTTGCTGTGTGGGAACCCCTCTGCCTGGCACCTGGATACCCTGGGCCAGGTAACCTGAGGGC 
 
hPAT2 
CTGTGCTGGGGTGTACATCTACACTAGACACCTTCCTGCTTCCCTCCTTCCAGAGCAGACCTCTTTGTCA 
CCCCGAGCTCCTTGTTTCTTAAGCAGTCATGTCTGTGACAAAAAGTACTGAGGGTCCCCAGGGAGCCGTT 
GCCATCAAATTGGACCTTATGTCGCCTCCTGAAAGTGCCAAGAAGTTGGAGAACAAGGACTCTACATTCT 
TGGATGAAAGTCCTTCAGAGTCGGCAGGCTTGAAGAAGACCAAGGGCATAACAGTGTTCCAGGCCTTGAT 
TCACCTGGTGAAAGGCAACATGGGCACAGGGATCCTGGGACTACCCCTCGCTGTGAAGAACGCGGGCATC 
CTGATGGGCCCACTCAGTCTGCTGGTGATGGGCTTCATTGCCTGCCACTGTATGCACATCCTGGTCAAGT 
GTGCCCAGCGCTTCTGTAAGAGGCTTAACAAGCCCTTTATGGACTATGGGGACACGGTGATGCATGGACT 
AGAAGCCAACCCCAACGCCTGGCTCCAGAATCACGCTCACTGGGGAAGGCATATCGTGAGCTTCTTCCTT 
ATTAACACCCAACTTGGCTTCTGCTGTGTGTACATTGTGTTTTTGGCTGATAATTTAAAACAGGTAGTGG 
AAGCTGTTAATAGCACAACCAACAACTGCTATTCCAATGAGACGGTGATTCTGACCCCCACCATGGACTC 
GCGACTCTACATGCTCTCCTTCCTGCCCTTCCTGGTGCTGCTGGTCCTCATCCGGAACCTCAGGATCTTG 
ACCATCTTCTCCATGCTGGCCAACATCAGCATGCTGGTCAGCTTGGTCATCATCATACAGTACATTACCC 
AGGAAATCCCAGACCCCAGCCGGTTGCCACTGGTAGCAAGCTGGAAGACCTACCCTCTCTTCTTCGGAAC 
Appendix 1 
 178
AGCCATTTTTTCTTTTGAAAGCATTGGTGTGGTTCTGCCTCTGGAAAACAAGATGAAGAATGCCCGCCAC 
TTCCCAGCCATCCTGTCTTTGGGAATGTCCATCGTCACTTCCCTATACATTGGCATGGCGGCTCTGGGCT 
ACCTGCGGTTTGGAGATGACATCAAGGCCAGCATAAGCCTTAACCTGCCTAACTGCTGGCTGTACCAGTC 
TGTCAAGCTTCTCTACATTGCCGGCATCCTGTGCACCTATGCCCTGCAGTTCTACGTCCCTGCAGAAATC 
ATCATCCCCTTTGCCATCTCCCGGGTGTCAACACGCTGGGCACTGCCTCTGGATCTGTCCATTCGCCTCG 
TCATGGTCTGCCTGACATGCCTCCTGGCCATCCTCATCCCTCGCCTGGACCTGGTCATCCCCCTGGTGGG 
CTCCGTGAGTGGCACCGCCCTGGCCCTCATCATCCCACCGCTCCTGGAGGTCACCACGTTCTACTCAGAG 
GGCATGAGCCCCCTCACCATCTTCAAGGACGCCCTGATCAGCATCCTGGGCTTCGTGGGCTTTGTGGTGG 
GGACCTACCAGGCCCTGGACGAGCTGCTCAAGTCAGAAGACTCTCACCCCTTTTCCAACTCCACCACTTT 
TGTTCGGTGAGCCTGGCACTGCTCCTTGCCTACCAGCACCCGACTTTTAATTATATGGATCTCTTTTTTT 
TCTTTTTTTTTTTTTTGAGACGGAGTTTCTGTCTTGTTGCCCAGACTGGAGCACAATGATGCGATCTCAG 
 
hPAT3.1  
TTCAGCCAGCAGCACGCATCCTTGGGGTTAGGAGCCAGCATCTCAGGTCAGCAGCCATGGTTTCTCTGGA 
GAAAGACCCATCAGAGGCTCATTCAGAGCCTTAACCCTGAGCCTCTGCCACCTACCCACCGTGTTGAAGA 
TGTCATTGCTTGGAAGGGACTACAACAGTGAGCTGAACTCCTTGGACAACGGACCTCAGTCACCCTCAGA 
GAGCAGCAGTAGCATTACTTCAGAGAATGTCCATCCTGCTGGAGAAGCTGGACTATCGATGATGCAAACT 
TTGATCCACTTGTTGAAATGCAACATTGGCACAGGGCTCCTGGGGCTTCCCCTGGCCATAAAGAATGCCG 
GCTTGTTGGTCGGTCCTGTCAGCCTTCTGGCCATCGGGGTCCTCACCGTGCACTGCATGGTCATCCTGTT 
GAACTGTGCTCAACACCTCAGCCAGAGACTGCAGAAGACTTTTGTGAACTATGGAGAGGCCACGATGTAC 
GGCCTTGAAACCTGCCCGAACACCTGGCTGAGGGCCCATGCAGTGTGGGGAAGATGGAATTTGGCTCTGT 
CACCCAGGCTGGAGTGCAGTGGCAAGATCTCAGCTCACTGCAACCCCCACCTTCAGGGTTCAAGCAATTC 
TCCTGCCCAAGCCTCCCGAGTAGCTGGGATTTACAGGTACACTGTCAGCTTCTTATTAGTCATCACCCAG 
CTGGGCTTCTGCAGTGTTTATTTTATGTTTATGGCAGACAATTTACAACAGATGGTGGAAAAAGCCCACG 
TGACCTCCAACATCTGCCAGCCCAGGGAGATTCTGACGCTGACCCCCATCCTGGACATTCGTTTCTACAT 
GCTGATAATCCTGCCCTTCCTGATCCTGTTGGTGTTTATCCAGAACCTCAAGGTGCTGTCCGTCTTCTCG 
ACATTGGCCAACATCACCACCCTTGGGAGCATGGCTCTGATCTTTGAGTATATCATGGAGGGGATTCCAT 
ATCCCAGCAACCTACCCTTGATGGCAAACTGGAAGACCTTCTTGCTGTTCTTTGGTACAGCCATCTTCAC 
ATTTGAAGGCGTCGGTATGGTTCTGCCTCTCAAAAACCAGATGAAGCATCCACAGCAGTTTTCTTTTGTT 
CTGTACTTGGGGATGTCCATTGTCATCATCCTCTATATCTTACTGGGGACACTGGGCTACATGAAGTTTG 
GGTCAGACACCCAGGCCAGCATCACCCTCAACTTGCCCAATTGCTGGTTGTACCAGTCAGTCAAGCTGAT 
GTACTCTATCGGCATCTTCTTCACCTATGCCCTCCAGTTCCACGTCCCAGCTGAGATCATCATCCCGTTT 
GCCATCTCCCAAGTGTCAGAGAGCTGGGCACTGTTTGTAGACCTGTCTGTCCGCTCAGCCTTGGTCTGTC 
TAACCTGTGTCTCAGCCATCCTCATCCCCCGCCTGGACTTGGTCATCTCCCTGGTAGGCTCCGTGAGCAG 
CAGCGCCCTGGCTCTCATCATCCCAGCCCTCCTGGAGATCGTCATCTTTTACTCTGAGGACATGAGCTGT 
GTCACCATTGCCAAGGACATCATGATTAGCATCGTGGGCCTTTTAGGGTGTATATTTGGGACATACCAAG 
CCCTCTATGAGTTGCCCCAACCCATCAGCCATTCCATGGCCAACTCCACAGGTGTCCATGCATAATTATC 
TGTTTTTATTCTAATAGCTCTCCCTTCCTCCCATCCCCAGTTTGACTTCCATGTGGATGTTATATACCTT 
CATCAAATCCCAACATCTCTATATTAATTAGTGGCGTCTTTATCTTTCCAAGAGAAATGCAGATGAGAAA 
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hPAT3.2 
AGCAGCACGCATCCTTGGGGTTAGGAGCCAGCATCTCAGGTCGGCAGCCATGGTTTCTCTGGAGAAAGAC 
CCGTCAGAGGCTCATTCAGAGCCTTAACCCTGAGCCTCTGCCACCTACCCACCGTGTTGAAGATGTCATT 
GCTTGGAAGGGACTACAACAGTGAGCTGAACTCCTTGGACAACGGACCTCAGTCACCCTCAGAGAGCAGC 
AGTAGCATTACTTCAGAGAATGTCCATCCTGCTGGAGAAGCTGGACTATCGATGATGCAAACTTTGATCC 
ACTTGTTGAAATGCAACATTGGCACAGGGCTCCTGGGGCTTCCCCTGGCCATAAAGAATGCCGGCTTGTT 
GGTCGGTCCTGTCAGCCTTCTGGCCATCGGGGTCCTCACCGTGCACTGCATGGTCATCCTGTTGAACTGT 
GCTCAACACCTCAGCCAGAGACTGCAGAAGACTTTTGTGAACTATGGAGAGGCCACGATGTACGGCCTTG 
AAACCTGCCCGAACACCTGGCTGAGGGCCCATGCAGTGTGGGGAAGGTACACTGTCAGCTTCTTATTAGT 
CATCACCCAGCTGGGCTTCTGCAGTGTTTATTTTATGTTTATGGCAGACAATTTACAACAGATGGTGGAA 
GAAGCCCACGTGACCTCCAACATCTGCCAGCCCAGGGAGATTCTGACGCTGACCCCCATCCTGGACATTC 
GTTTCTACATGCTGATAATCCTGCCCTTCCTGATCCTGTTGGTGTTTATCCAGAACCTCAAGGTGCTGTC 
CGTCTTCTCGACATTGGCCAACATCACCACCCTTGGGAGCATGGCTCTGATCTTTGAGTATATCATGGAG 
GGGATTCCATATCCCAGCAACCTACCCTTGATGGCAAACTGGAAGACCTTCTTGCTGTTCTTTGGTACAG 
CCATCTTCACATTTGAAGGCGTCGGTATGGTTCTGCCTCTCAAAAACCAGATGAAGCATCCACAGCAGTT 
TTCTTTTGTTCTGTACTTGGGGATGTCCATTGTCATCATCCTCTATATCTTACTGGGGACACTGGGCTAC 
ATGAAGTTTGGGTCAGACACCCAGGCCAGCATCACCCTCAACTTGCCCAATTGCTGGTTGTACCAGTCAG 
TCAAGCTGATGTACTCTATCGGCATCTTCTTCACCTATGCCCTCCAGTTCCACGTCCCAGCTGAGATCAT 
CATCCCGTTTGCCATCTCCCAAGTGTCAGAGAGCTGGGCACTGTTTGTAGACCTGTCTGTCCGCTCAGCC 
TTGGTCTGTCTAACCTGTGTCTCAGCCATCCTCATCCCCCGCCTGGACTTGGTCATCTCCCTGGTAGGCT 
CCGTGAGCAGCAGCGCCCTGGCTCTCATCATCCCAGCCCTCCTGGAGATCGTCATCTTTTACTCTGAGGA 
CATGAGCTGTGTCACCATTGCCAAGGACATCATGATTAGCATCGTGGGCCTTTTAGGGTGTATATTTGGG 
ACATACCAAGCCCTCTATGAGTTGCCCCAACCCATCAGCCATTCCATGGCCAACTCCACAGGTGTCCATG 
CATAATTATCTGTTTTTATTCTAATAGCTCTCCCTTCCTCCCATCCCCAGTTTGACTTCCATGTGGATGT 
TATATACCTTCATCAAATCCCAACATCTCTATATTAATTAGTGGCGTCTTTATCTTTCCAAGAGAAATGC 
AGATGAGAAAAGTTAGCACTGATGTCTCTCAGGCTACACCTCTTTTGGTTTTATATTTTTTGG 
 
hPAT4 
CCCTCCGGGCAGGGGAGGTAGGCCTGGGCCTGACGCCGGCCACGCAGCGGCGGGAGAGTGAGCACTCGGG 
CGGCGGCGTCCTGGAGACCCGCGAGAGATGGAAGCGGCGGCGACGCCGGCGGCTGCCGGGGCGGCGAGGC 
GCGAGGAGCTAGATATGGATGTAATGAGGCCCTTGATAAATGAGCAGAATTTTGATGGGACATCAGATGA 
AGAACATGAGCAAGAGCTTCTGCCTGTTCAGAAGCATTACCAACTTGATGATCAAGAGGGCATTTCATTT 
GTACAAACTCTTATGCACCTTCTTAAAGGAAATATTGGAACTGGCCTTTTAGGACTTCCATTGGCAATAA 
AAAATGCAGGCATAGTGCTTGGACCAATCAGCCTTGTGTTTATAGGAATTATTTCTGTTCACTGTATGCA 
CATATTGGTACGTTGCAGTCACTTTCTATGTCTGAGGTTTAAAAAGTCAACATTAGGTTATAGTGACACT 
GTGAGCTTTGCTATGGAAGTGAGTCCTTGGAGTTGTCTTCAGAAGCAAGCAGCATGGGGGCGGAGTGTGG 
TTGACTTTTTTCTGGTGATAACACAGCTGGGATTCTGTAGTGTTTATATTGTCTTCTTAGCTGAAAATGT 
GAAACAAGTTCATGAAGGATTCCTGGAGAGTAAAGTGTTTATTTCAAATAGTACCAATTCATCAAACCCT 
TGTGAGAGAAGAAGTGTTGACCTAAGGATATATATGCTTTGCTTTCTTCCATTTATAATTCTTTTGGTCT 
TCATTCGTGAACTAAAGAATCTATTTGTACTTTCATTCCTTGCCAACGTTTCCATGGCTGTCAGTCTTGT 
GATAATTTACCAGTATGTTGTCAGGAACATGCCAGATCCCCACAACCTTCCAATAGTGGCTGGTTGGAAG 
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AAATACCCACTCTTTTTTGGTACTGCTGTATTTGCTTTTGAAGGCATAGGAGTGGTCCTTCCACTGGAAA 
ACCAAATGAAAGAATCAAAGCGTTTCCCTCAAGCGTTGAATATTGGCATGGGGATTGTTACAACTTTGTA 
TGTAACATTAGCTACTTTAGGATATATGTGTTTCCATGATGAAATCAAAGGCAGCATAACTTTAAATCTT 
CCCCAAGATGTATGGTTATATCAATCAGTGAAAATTCTATATTCCTTTGGCATTTTTGTGACATATTCAA 
TTCAGTTCTATGTTCCAGCAGAGATCATTATCCCTGGGATCACATCCAAATTTCATACTAAATGGAAGCA 
AATCTGTGAATTTGGGATAAGATCCTTCTTGGTTAGTATTACTTGTGCCGGAGCAATTCTTATTCCTCGT 
TTAGACATTGTGATTTCCTTCGTTGGAGCTGTGAGCAGCAGCACATTGGCCCTAATCCTGCCACCTTTGG 
TTGAAATTCTTACATTTTCGAAGGAACATTATAATATATGGATGGTCCTGAAAAATATTTCTATAGCATT 
CACTGGAGTTGTTGGCTTCTTATTAGGTACATATATAACTGTTGAAGAAATTATTTATCCTACTCCCAAA 
GTTGTAGCTGGCACTCCACAGAGTCCTTTTCTAAATTTGAATTCAACATGCTTAACATCTGGTTTGAAAT 
AGTAAAAGCAGAATCATGAGTCTTCTATTTTTGTCCCATTTCTGAAAATTATCAAGATAACTAGTAAAAT 
ACATTGCTATATACATAAAAATGGTAACAAACTCTGTTTTCTTTGGCACGATATTAATATTTTGGAAGTA 
ATCATAACTCTTTACCAGTAGTGGTAAACCTATGGAAAATCCTTGCTTTTAAGTGTTAGCAATAGTTCAA 
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PRIMERS FOR SUB CLONING THE hPATs INTO pcDNA3.1(-) AND THEIR 
RELATIVE POSITIONS 
 
Primer 
name 
Sequence Tm  %G
C 
Secondary 
structure 
Primer/
Dimer 
PAT2 
Forward 
GCTGGTACCGCTCCTT
GTTTCTTAAGCAGTCA
TGTCTGTG 
72.17 50 Weak No 
PAT2 
Reverse 
 
AGCGGTACCTCGGGTG
CTGGTAGGCAAGGA 
72.93 70 Weak  No  
PAT3 
Forward 
GCTGGTACCGTTGAAG
ATGTCATTGCTTGGAA
GGGACTAC 
72.58 50 Weak  No  
PAT3 
Reverse 
AGCGGTACCGAATAA
AAACAGATAATTATGC
ATGGACACCTGTGG 
72.77 46.6
7 
Moderate No 
KEY 
Ala  Res site KpnI site Untranslated region  
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hPAT2 
CTGTGCTGGGGTGTACATCTACACTAGACACCTTCCTGCTTCCCTCCTTCCAGAGCAGACCTCTTTGTCA 
CCCCGAGCTCCTTGTTTCTTAAGCAGTCATGTCTGTGACAAAAAGTACTGAGGGTCCCCAGGGAGCCGTT 
GCCATCAAATTGGACCTTATGTCGCCTCCTGAAAGTGCCAAGAAGTTGGAGAACAAGGACTCTACATTCT 
TGGATGAAAGTCCTTCAGAGTCGGCAGGCTTGAAGAAGACCAAGGGCATAACAGTGTTCCAGGCCTTGAT 
TCACCTGGTGAAAGGCAACATGGGCACAGGGATCCTGGGACTACCCCTCGCTGTGAAGAACGCGGGCATC 
CTGATGGGCCCACTCAGTCTGCTGGTGATGGGCTTCATTGCCTGCCACTGTATGCACATCCTGGTCAAGT 
GTGCCCAGCGCTTCTGTAAGAGGCTTAACAAGCCCTTTATGGACTATGGGGACACGGTGATGCATGGACT 
AGAAGCCAACCCCAACGCCTGGCTCCAGAATCACGCTCACTGGGGAAGGCATATCGTGAGCTTCTTCCTT 
ATTAACACCCAACTTGGCTTCTGCTGTGTGTACATTGTGTTTTTGGCTGATAATTTAAAACAGGTAGTGG 
AAGCTGTTAATAGCACAACCAACAACTGCTATTCCAATGAGACGGTGATTCTGACCCCCACCATGGACTC 
GCGACTCTACATGCTCTCCTTCCTGCCCTTCCTGGTGCTGCTGGTCCTCATCCGGAACCTCAGGATCTTG 
ACCATCTTCTCCATGCTGGCCAACATCAGCATGCTGGTCAGCTTGGTCATCATCATACAGTACATTACCC 
AGGAAATCCCAGACCCCAGCCGGTTGCCACTGGTAGCAAGCTGGAAGACCTACCCTCTCTTCTTCGGAAC 
AGCCATTTTTTCTTTTGAAAGCATTGGTGTGGTTCTGCCTCTGGAAAACAAGATGAAGAATGCCCGCCAC 
TTCCCAGCCATCCTGTCTTTGGGAATGTCCATCGTCACTTCCCTATACATTGGCATGGCGGCTCTGGGCT 
ACCTGCGGTTTGGAGATGACATCAAGGCCAGCATAAGCCTTAACCTGCCTAACTGCTGGCTGTACCAGTC 
TGTCAAGCTTCTCTACATTGCCGGCATCCTGTGCACCTATGCCCTGCAGTTCTACGTCCCTGCAGAAATC 
ATCATCCCCTTTGCCATCTCCCGGGTGTCAACACGCTGGGCACTGCCTCTGGATCTGTCCATTCGCCTCG 
TCATGGTCTGCCTGACATGCCTCCTGGCCATCCTCATCCCTCGCCTGGACCTGGTCATCCCCCTGGTGGG 
CTCCGTGAGTGGCACCGCCCTGGCCCTCATCATCCCACCGCTCCTGGAGGTCACCACGTTCTACTCAGAG 
GGCATGAGCCCCCTCACCATCTTCAAGGACGCCCTGATCAGCATCCTGGGCTTCGTGGGCTTTGTGGTGG 
GGACCTACCAGGCCCTGGACGAGCTGCTCAAGTCAGAAGACTCTCACCCCTTTTCCAACTCCACCACTTT 
TGTTCGGTGAGCCTGGCACTGCTCCTTGCCTACCAGCACCCGACTTTTAATTATATGGATCTCTTTTTTT 
TCTTTTTTTTTTTTTTGAGACGGAGTTTCTGTCTTGTTGCCCAGACTGGAGCACAATGATGCGATCTCAG 
 
hPAT3.1  
TTCAGCCAGCAGCACGCATCCTTGGGGTTAGGAGCCAGCATCTCAGGTCAGCAGCCATGGTTTCTCTGGA 
GAAAGACCCATCAGAGGCTCATTCAGAGCCTTAACCCTGAGCCTCTGCCACCTACCCACCGTGTTGAAGA 
TGTCATTGCTTGGAAGGGACTACAACAGTGAGCTGAACTCCTTGGACAACGGACCTCAGTCACCCTCAGA 
GAGCAGCAGTAGCATTACTTCAGAGAATGTCCATCCTGCTGGAGAAGCTGGACTATCGATGATGCAAACT 
TTGATCCACTTGTTGAAATGCAACATTGGCACAGGGCTCCTGGGGCTTCCCCTGGCCATAAAGAATGCCG 
GCTTGTTGGTCGGTCCTGTCAGCCTTCTGGCCATCGGGGTCCTCACCGTGCACTGCATGGTCATCCTGTT 
GAACTGTGCTCAACACCTCAGCCAGAGACTGCAGAAGACTTTTGTGAACTATGGAGAGGCCACGATGTAC 
GGCCTTGAAACCTGCCCGAACACCTGGCTGAGGGCCCATGCAGTGTGGGGAAGATGGAATTTGGCTCTGT 
CACCCAGGCTGGAGTGCAGTGGCAAGATCTCAGCTCACTGCAACCCCCACCTTCAGGGTTCAAGCAATTC 
TCCTGCCCAAGCCTCCCGAGTAGCTGGGATTTACAGGTACACTGTCAGCTTCTTATTAGTCATCACCCAG 
CTGGGCTTCTGCAGTGTTTATTTTATGTTTATGGCAGACAATTTACAACAGATGGTGGAAAAAGCCCACG 
TGACCTCCAACATCTGCCAGCCCAGGGAGATTCTGACGCTGACCCCCATCCTGGACATTCGTTTCTACAT 
GCTGATAATCCTGCCCTTCCTGATCCTGTTGGTGTTTATCCAGAACCTCAAGGTGCTGTCCGTCTTCTCG 
ACATTGGCCAACATCACCACCCTTGGGAGCATGGCTCTGATCTTTGAGTATATCATGGAGGGGATTCCAT 
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ATCCCAGCAACCTACCCTTGATGGCAAACTGGAAGACCTTCTTGCTGTTCTTTGGTACAGCCATCTTCAC 
ATTTGAAGGCGTCGGTATGGTTCTGCCTCTCAAAAACCAGATGAAGCATCCACAGCAGTTTTCTTTTGTT 
CTGTACTTGGGGATGTCCATTGTCATCATCCTCTATATCTTACTGGGGACACTGGGCTACATGAAGTTTG 
GGTCAGACACCCAGGCCAGCATCACCCTCAACTTGCCCAATTGCTGGTTGTACCAGTCAGTCAAGCTGAT 
GTACTCTATCGGCATCTTCTTCACCTATGCCCTCCAGTTCCACGTCCCAGCTGAGATCATCATCCCGTTT 
GCCATCTCCCAAGTGTCAGAGAGCTGGGCACTGTTTGTAGACCTGTCTGTCCGCTCAGCCTTGGTCTGTC 
TAACCTGTGTCTCAGCCATCCTCATCCCCCGCCTGGACTTGGTCATCTCCCTGGTAGGCTCCGTGAGCAG 
CAGCGCCCTGGCTCTCATCATCCCAGCCCTCCTGGAGATCGTCATCTTTTACTCTGAGGACATGAGCTGT 
GTCACCATTGCCAAGGACATCATGATTAGCATCGTGGGCCTTTTAGGGTGTATATTTGGGACATACCAAG 
CCCTCTATGAGTTGCCCCAACCCATCAGCCATTCCATGGCCAACTCCACAGGTGTCCATGCATAATTATC 
TGTTTTTATTCTAATAGCTCTCCCTTCCTCCCATCCCCAGTTTGACTTCCATGTGGATGTTATATACCTT 
CATCAAATCCCAACATCTCTATATTAATTAGTGGCGTCTTTATCTTTCCAAGAGAAATGCAGATGAGAAA 
 
hPAT3.2 
AGCAGCACGCATCCTTGGGGTTAGGAGCCAGCATCTCAGGTCGGCAGCCATGGTTTCTCTGGAGAAAGAC 
CCGTCAGAGGCTCATTCAGAGCCTTAACCCTGAGCCTCTGCCACCTACCCACCGTGTTGAAGATGTCATT 
GCTTGGAAGGGACTACAACAGTGAGCTGAACTCCTTGGACAACGGACCTCAGTCACCCTCAGAGAGCAGC 
AGTAGCATTACTTCAGAGAATGTCCATCCTGCTGGAGAAGCTGGACTATCGATGATGCAAACTTTGATCC 
ACTTGTTGAAATGCAACATTGGCACAGGGCTCCTGGGGCTTCCCCTGGCCATAAAGAATGCCGGCTTGTT 
GGTCGGTCCTGTCAGCCTTCTGGCCATCGGGGTCCTCACCGTGCACTGCATGGTCATCCTGTTGAACTGT 
GCTCAACACCTCAGCCAGAGACTGCAGAAGACTTTTGTGAACTATGGAGAGGCCACGATGTACGGCCTTG 
AAACCTGCCCGAACACCTGGCTGAGGGCCCATGCAGTGTGGGGAAGGTACACTGTCAGCTTCTTATTAGT 
CATCACCCAGCTGGGCTTCTGCAGTGTTTATTTTATGTTTATGGCAGACAATTTACAACAGATGGTGGAA 
GAAGCCCACGTGACCTCCAACATCTGCCAGCCCAGGGAGATTCTGACGCTGACCCCCATCCTGGACATTC 
GTTTCTACATGCTGATAATCCTGCCCTTCCTGATCCTGTTGGTGTTTATCCAGAACCTCAAGGTGCTGTC 
CGTCTTCTCGACATTGGCCAACATCACCACCCTTGGGAGCATGGCTCTGATCTTTGAGTATATCATGGAG 
GGGATTCCATATCCCAGCAACCTACCCTTGATGGCAAACTGGAAGACCTTCTTGCTGTTCTTTGGTACAG 
CCATCTTCACATTTGAAGGCGTCGGTATGGTTCTGCCTCTCAAAAACCAGATGAAGCATCCACAGCAGTT 
TTCTTTTGTTCTGTACTTGGGGATGTCCATTGTCATCATCCTCTATATCTTACTGGGGACACTGGGCTAC 
ATGAAGTTTGGGTCAGACACCCAGGCCAGCATCACCCTCAACTTGCCCAATTGCTGGTTGTACCAGTCAG 
TCAAGCTGATGTACTCTATCGGCATCTTCTTCACCTATGCCCTCCAGTTCCACGTCCCAGCTGAGATCAT 
CATCCCGTTTGCCATCTCCCAAGTGTCAGAGAGCTGGGCACTGTTTGTAGACCTGTCTGTCCGCTCAGCC 
TTGGTCTGTCTAACCTGTGTCTCAGCCATCCTCATCCCCCGCCTGGACTTGGTCATCTCCCTGGTAGGCT 
CCGTGAGCAGCAGCGCCCTGGCTCTCATCATCCCAGCCCTCCTGGAGATCGTCATCTTTTACTCTGAGGA 
CATGAGCTGTGTCACCATTGCCAAGGACATCATGATTAGCATCGTGGGCCTTTTAGGGTGTATATTTGGG 
ACATACCAAGCCCTCTATGAGTTGCCCCAACCCATCAGCCATTCCATGGCCAACTCCACAGGTGTCCATG 
CATAATTATCTGTTTTTATTCTAATAGCTCTCCCTTCCTCCCATCCCCAGTTTGACTTCCATGTGGATGT 
TATATACCTTCATCAAATCCCAACATCTCTATATTAATTAGTGGCGTCTTTATCTTTCCAAGAGAAATGC 
AGATGAGAAAAGTTAGCACTGATGTCTCTCAGGCTACACCTCTTTTGGTTTTATATTTTTTGG 
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PRIMERS (apart from T7F) WHICH WERE USED FOR CONFIRMATION OF 
FLAG EPITOPE INSERTION 
 
Primer name Sequence 
PAT1.1 for 
sequencing 
AGCTGCCATGTCCACGCA 
PAT1.2 for 
sequencing 
GTGAAAAATGCAGGCATCGT 
PAT1.3 for 
sequencing 
GACGCCTACCATGGACTC 
PAT1.4 for 
sequencing 
TCTGGGGTACCTGCAATTTG 
PAT1.5 for 
sequencing 
CTTGGCCATCCTCATCCC 
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APPENDIX 2: Primers used to check 
for the endogenous expression of 
mPATs in TM4 cells 
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PRIMERS USED TO CHECK FOR THE ENDOGENOUS EXPRESSION OF 
mPATs AND THEIR RELATIVE POSITIONS 
 
mPAT1 
>gb|BC138556.1|:119-1546 Mus musculus solute carrier family 36 (proton/amino 
acid symporter), member 1, mRNA (cDNA clone MGC:170181 IMAGE:8861576), 
complete cds 
ATGTCCACACAGAGGCTTCGGAACGAAGACTATCATGACTACAGTTCCACAGACGTGAGCCCCGAGGAGA 
GCCCATCTGAAGGCCTTGGCAGCTTCTCCCCCGGCTCCTACCAACGCTTAGGAGAGAACAGTAGCATGAC 
ATGGTTCCAGACCCTGATCCACCTGCTGAAAGGCAACATTGGCACCGGACTGCTGGGGCTGCCTCTGGCA 
GTGAAGAACGCAGGCCTCCTGTTGGGTCCTCTCAGCCTGCTGGTGATTGGTATCGTGGCCGTGCACTGCA 
TGGGTATCCTGGTGAAGTGTGCTCATCACTTATGTCGTAGACTGAACAAACCCTTTTTGGACTATGGGGA 
CACGGTGATGTATGGACTAGAATGCAGCCCCAGCACCTGGGTCCGGAACCACTCCCACTGGGGAAGGCGC 
ATCGTGGACTTCTTCCTCATCGTCACTCAGCTGGGATTCTGCTGTGTCTACTTCGTGTTTCTGGCGGACA 
ACTTTAAGCAGGTGATAGAGGCAGCCAATGGGACCACCACCAACTGCAACAACAATGTGACCGTGATCCC 
GACGCCCACCATGGACTCTCGACTCTACATGCTCTCCTTCCTGCCCTTCCTGGTGTTGCTGTCTTTCATC 
AGGAACCTGCGTGTGTTGTCCATCTTCTCCCTGCTGGCCAACATCAGCATGTTCGTCAGCCTGATCATGA 
TATACCAGTTCATTGTCCAGAGGATCCCAGACCCCAGCCACCTCCCCTTGGTGGCTCCATGGAAGACCTA 
CCCTCTGTTCTTTGGCACAGCGATTTTTGCTTTTGAAGGCATTGGAGTGGTTCTACCCCTTGAGAACAAA 
ATGAAGGACTCACAGAAATTTCCATTGATTCTGTATTTGGGGATGGCTATCATCACTGTACTCTACATCA 
GCCTGGGGAGCCTGGGGTACCTGCAATTTGGAGCTAATATCAAGGGCAGCATCACCCTCAACCTGCCCAA 
CTGCTGGTTGTACCAGTCGGTGAAGCTGCTGTACTCCATAGGCATCTTCTTCACCTATGCCCTCCAGTTC 
TATGTCGCAGCTGAGATCATCATCCCGGCCATTGTGTCCCGAGTGCCTGAGCATTTCGAGCTGATGGTGG 
ACCTTTGTGTGCGCACCGCCATGGTCTGTGTGACATGTGTGCTGGCCATCCTCATCCCACGCCTGGACCT 
GGTCATCTCCCTGGTGGGCTCTGTGAGCAGCAGCGCCCTGGCCCTCATCATCCCGCCCCTGCTGGAGGTG 
GTCACCTACTATGGAGAGGGCATTAGCCCCCTGACCGTCACCAAGGATGCCCTCATCAGCATCCTGGGCT 
TCGTGGGCTTCGTGGTGGGGACCTACGAGTCTCTGTGTGAGCTGATCCAGCCAAGCCATAGCGACTCCTC 
TACCAATTCCACCAGTGCCTTCATATAA 
 
mPAT2 
>gi|238624177:119-1555 Mus musculus solute carrier family 36 (proton/amino 
acid symporter), member 2 (Slc36a2), mRNA 
ATGTCTGTGACCAAGAGTGCCAGGAGTCCGCAGGTAGCCACCCCTCTCAATCTGGACCTTCCTGAGAGTG 
CCAAGAAGCTGCAGAGCCAGGATCCCAGTCCAGCGAATGGGAGCTCTTCAGAGTCATCAAAGAAGACCAA 
GGGCATAACCGGGTTCCAGACATTGGTTCATCTGGTCAAAGGCAACATGGGCACAGGGATCCTCGGACTT 
CCCCTGGCTGTGAAGAATGCGGGCATCTTGATGGGCCCACTCAGCTTGCTGGTAATGGGCCTCATCGCCT 
GCCACTGTATGCACATCCTAGTCAGATGTGCCCAGCGCTTCTGTCACAGACTGAACAAGCCTTTCATGGA 
CTATGGGGACACAGTGATGCACGGACTGGCTTTCAGTCCCAATGCCTGGCTGCAAAACCACGCCCACTGG 
GGGAGGCGTGTCGTGAGCTTCTTCCTCATCGTCACCCAGCTGGGTTTCTGCTGTGTGTACATTGTGTTTC 
TGGCGGACAATTTAAAACAGGTAGTAGAAGCTGTTAACAGCACAACCATCAGCTGCCACAAGAACGAGAC 
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GGTAGTTCTGACGCCCACCATGGACTCTCGACTCTACATGCTCTCCTTCCTGCCCGTTCTGGGGCTTCTG 
GTGTTCGTCAGGAACCTGCGTGTCCTCACCATCTTCTCCCTGCTGGCCAACATCAGCATGCTGGTCAGCC 
TGGTCATCATTGCCCAGTACATCATCCAGGAAATTCCAGATGCCAGCCAGTTGCCACTGGTAGCAAGCTG 
GAAGACCTACCCGCTCTTCTTTGGAACAGCCATTTTTTCATTTGAAAGCATCGGTGTGGTCCTGCCTCTG 
GAAAACAAGATGAAGGATGCCCGCGGCTTCCCAACCATTCTGTCTTTGGGGATGTCCATCATCACCACCC 
TGTACATTGCTATCGGGGCTCTGGGCTACCTGCGGTTTGGAGATGACATCAAAGCCAGCATCACTCTTAA 
CCTGCCCAACTGCTGGCTGTACCAATCAGTCAAGCTCCTGTATGTCGTCGGTATCCTGTGTACCTATGCC 
CTGCAGTTCTACGTCCCTGCGGAAATCATCATCCCCCTTGCTGTCTCTCAGGTGTCAAAACGCTGGGCAC 
TGCCCGTGGACCTGTCTATCCGGCTTGCCCTGGTCTGCCTCACATGCATGCTGGCCATCCTCATCCCACG 
CCTGGACCTGGTCCTCTCCCTGGTGGGCTCTGTGAGCAGCAGCGCCCTGGCCCTCATCATCCCGCCCCTG 
CTGGAGGTGGTCACCTACTATGGAGAGGGCATTAGCCCCCTGACCGTCACCAAGGATGCCCTCATCAGCA 
TCCTGGGCTTCATGGGCTTTGTGGTGGGGACCTACCAGGCCCTGGATGAGCTGATCAAGTCCGGGAACTC 
TCCCGCCCTGTCCAACTCCACCATGTTTATTCAGTGA 
 
mPAT3 
>gi|262231847:255-1688 Mus musculus solute carrier family 36 (proton/amino 
acid symporter), member 3 (Slc36a3), mRNA 
ATGGGGAATGTGCCGCTGCTTAGAGAAGTTGGCAAGTGTCAGCGGAATATGTTCGGTCGGTCTACAGCCT 
CCTCAAAAGGCAGCAGCAACAGCAGAAGCAGCAGCAGTACCTCCCCAAAGAAGGGCCCTCGCAGGGAAGC 
TGATGCGCTAATGTTTATACAGATCTTTATCCACCTGTTGAAAAGCAACATTGGCACAGGCTTCCTGGGA 
CTGCCCCTGGCTGTGAAAAATGCTGGATTGTTGGTGGGGCCTGTCAGCCTCTTGGCCATCGGGGCGCTCA 
CAGTGCACTGTATGGATATCCTGCTGAACTGTGCCTGCCATCTCACTCAGAGACTGCAGAGGAGTTTTGT 
GAACTATGAAGAGACCACAATGTACAGCCTGGAAACGTGTCCAAGTCCTTGGCTGAGGACGCACTCAGTG 
TGGGGCAGGTACGTTGTGAGCTTCCTGCTGATCGTCACTCAGCTGGGCTTCTGCAGCGTGTACTTCATGT 
TTCTGGCGGACAACTTACAACAGATCATGGAAGAAGCCCACTTCACCTCCAACGTCTGCCAGCCGAGGCA 
GAGCCTGGTGATGACCTCCATCCTGGACACTCGCTTCTATATGCTCACCATCCTGCCCTTCCTCATCCTG 
CTGGTGCTCATCCAGAACCCACAGGTGTTGTCCATCTTCTCTACCTTGGCCACCATCACCACCCTGAGCA 
GCCTGGCTCTGATCTTCGAGTATCTCATCCAGACCCCACACCACAGCAACCTGCCCCTGGTTGCAAACTG 
GAAGACTTTCTTGCTGTTCTTTGGCACGGCTATCTTCACCTTTGAAGGCGTGGGGATGGTTCTGCCTCTC 
AAAAGCCAGATGAAGAGCCCGCAGCAGTTCCCCGCTGTGCTGTATCTGGGGATGTCCTTTGTCATCTTCC 
TCTACATCTGCCTGGGGACTCTGGGCTACATGAAGTTTGGGACAGACACTCAGGCCAGCATCACCCTCAA 
CTTGCCCATTTGCTGGCTGTACCAGTCAGTCAAGCTGATGTACTCTGTGGGCATCTTCTTCACCTATGCC 
CTCCAGTTCCACGTCCCAGCTGAGATCATCGTCCCCTATGTCGTCTCAAGAGTGTCTGAGAACTGGGCTC 
TGTTCGTAGACCTGACTGTCCGCACAGCCTTGGTCTGCCTGACCTGTTTCTCAGCCGTCCTCATCCCCCG 
CCTGGACCTGGTCATCTCCCTGGTGGGCTCTGTGAGCAGTAGCGCCCTGGCCATCATCATCCCGCCGCTG 
CTGGAGATTGCCACATTTTACTCTGAGAACATAAGCTGTGCCACCATTGTCAAGGACATCATGATCAGCA 
TCCTGGGCCTCTTAGGGTGTGTACTTGGGACATACCAAGCCCTGTACGAGATGACCCAGCAGACCCACTT 
TTACATGGCCAACTCTACAAGGGTCCACATATAA 
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mPAT4 
>gb|BC115964.1|:25-1527 Mus musculus solute carrier family 36 (proton/amino 
acid symporter), member 4, mRNA (cDNA clone MGC:141261 IMAGE:40057255), 
complete cds 
ATGGAAGCGCCGGCGCCGGCGGAGACGGCGGGATGCGAGGAGCTCGATATGGACGTGATGAGGCCCTTAA 
TAAACGAGCAGAATTTCGATGGGTCGTCCGACGAGGAGCAGGAACAGACGCTTGTGCCCATACAGAAGCA 
CTACCAGCTCGATGGGCAGCACGGGATTTCGTTCCTGCAGACCTTGGTGCATCTTCTCAAGGGGAACATC 
GGGACTGGCCTTTTAGGGCTCCCCTTGGCTATAAAGAACGCGGGCATCGTGCTTGGACCAATCAGCCTTG 
TGTTTATAGGAATTATTTCCGTCCACTGTATGCACATATTGGTACGTTGCAGTCACTTTCTATGTCAGAG 
GTTTAAGAAGTCAACATTGGGGTACAGTGACACCGTGAGTTTTGCCATGGAGGCTAGTCCGTGGAGTTGC 
CTTCAGCGACAGGCAGCATGGGGGCGGAGCGTGGTCGACTTCTTTCTGGTGATAACACAGCTGGGATTCT 
GCAGCGTCTACATTGTCTTCTTAGCTGAGAATGTGAAACAGGTTCATGAAGGATTCCTGGGGAGCACGCC 
GATTGTTTCAAATGGCTCGGACCTGTCTCATGCCTGTGAGAGAAGAAGTGTGGACCTCAGGGTCTATATG 
CTCTGCTTTCTCCCACTTATAATTCTCTTGGTCTTCATTCGCGAGCTGAAGAATCTCTTTGTACTTTCAT 
TCCTTGCCAACATTTCCATGGCTGCCAGTCTTGTGATAATTTACCAGTATGTTGTTAGGAACATGCCAGA 
TCCCCACAACCTTCCAATAGTGGCCGGCTGGAAGAAATACCCACTGTTTTTTGGCACTGCTGTGTTTGCT 
TTTGAAGGCATAGGAGTGGTGCTACCACTGGAAAACCAAATGAGAGAGTCCAAACGCTTCCCTCAGGCAT 
TGAACATCGGCATGGCCATCGTCACCGTGCTGTACATCAGCCTAGCCACTTTAGGCTACATGTGTTTCCG 
TGACGAGATCAAAGGCAGCATTACACTGAATCTTCCCCAGGACATGTGGTTGTATCAGTCAGTGAAAATT 
CTGTATTCCTTTGGCATTTTTGTGACCTATTCAATTCAGTTCTATGTCCCAGCAGAGATCATTATCCCTG 
GAGTCACTGCTAGACTTCATGCCAAATGGAAGCGCATTTGTGAATTTGGGATACGGTCCCTCTTGGTTAG 
TATCACCTGTGCTGGGGCGATTCTCATTCCTCGCCTAGACATTGTGATCTCCTTCGTGGGGGCTGTGAGC 
AGCAGTACACTAGCCCTGATCCTGCCCCCACTTGTGGAAATCCTTACATTTTCTAAGGACCACTACAACA 
TATGGATGATCCTGAAAAACATTTCCATAGCGTTCACTGGAGTCGTGGGCTTCTTGTTGGGCACCTATGT 
CACTGTTGAAGAAATTATTTATCCGACTACGGCAGTTGTTGCTGGCACCTCCCAGAGTCCCTTTCTGAAT 
GTGAACTCTACATGCATAACAAGTGGTTTGTAA 
 
mGAPDH  
>gb|GU214026.1|:72-1073 Mus musculus glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) mRNA, complete cds 
ATGGTGAAGGTCGGTGTGAACGGATTTGGCCGTATTGGGCGCCTGGTCACCAGGGCTGCCATTTGCAGTG 
GCAAAGTGGAGATTGTTGCCATCAACGACCCCTTCATTGACCTCAACTACATGGTCTACATGTTCCAGTA 
TGACTCCACTCACGGCAAATTCAACGGCACAGTCAAGGCCGAGAATGGGAAGCTTGTCATCAACGGGAAG 
CCCATCACCATCTTCCAGGAGCGAGACCCCACTAACATCAAATGGGGTGAGGCCGGTGCTGAGTATGTCG 
TGGAGTCTACTGGTGTCTTCACCACCATGGAGAAGGCCGGGGCCCACTTGAAGGGTGGAGCCAAAAGGGT 
CATCATCTCCGCCCCTTCTGCCGATGCCCCCATGTTTGTGATGGGTGTGAACCACGAGAAATATGACAAC 
TCACTCAAGATTGTCAGCAATGCATCCTGCACCACCAACTGCTTAGCCCCCCTGGCCAAGGTCATCCATG 
ACAACTTTGGCATTGTGGAAGGGCTCATGACCACAGTCCATGCCATCACTGCCACCCAGAAGACTGTGGA 
TGGCCCCTCTGGAAAGCTGTGGCGTGATGGCCGTGGGGCTGCCCAGAACATCATCCCTGCATCCACTGGT 
GCTGCCAAGGCTGTGGGCAAGGTCATCCCAGAGCTGAACGGGAAGCTCACTGGCATGGCCTTCCGTGTTC 
CTACCCCCAATGTGTCCGTCGTGGATCTGACGTGCCGCCTGGAGAAACCTGCCAAGTATGATGACATCAA 
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GAAGGTGGTGAAGCAGGCATCTGAGGGCCCACTGAAGGGCATCTTGGGCTACACTGAGGACCAGGTTGTC 
TCCTGCGACTTCAACAGCAACTCCCACTCTTCCACCTTCGATGCCGGGGCTGGCATTGCTCTCAATGACA 
ACTTTGTCAAGCTCATTTCCTGGTATGACAATGAATACGGCTACAGCAACAGGGTGGTGGACCTCATGGC 
CTACATGGCCTCCAAGGAGTAA 
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Alignments of hPATs 
hPAT1              --MSTQRLRN--EDYHDYSSTDVSPEESPSEGLNNLS--------SPGSYQRFGQSNSTT 48 
hPAT2              --MSVTKSTEGPQGAVAIKLDLMSPPESAKKLENKDST---FLDESPSESAGLKKTKGIT 55 
hPAT3_longer_      --MSLLGRDYN-SELNSLDNGPQSPSESSSS--------------ITSENVHPAGEAGLS 43 
hPAT3              --MSLLGRDYN-SELNSLDNGPQSPSESSSS--------------ITSENVHPAGEAGLS 43 
hPAT4              MEAAATPAAAGAARREELDMDVMRPLINEQNFDGTSDEEHEQELLPVQKHYQLDDQEGIS 60 
                      :              .     *  . ..                 .        . : 
 
hPAT1              WFQTLIHLLKGNIGTGLLGLPLAVKNAGIVMGPISLLIIGIVAVHCMGILVKCAHHFCRR 108 
hPAT2              VFQALIHLVKGNMGTGILGLPLAVKNAGILMGPLSLLVMGFIACHCMHILVKCAQRFCKR 115 
hPAT3_longer_      MMQTLIHLLKCNIGTGLLGLPLAIKNAGLLVGPVSLLAIGVLTVHCMVILLNCAQHLSQR 103 
hPAT3              MMQTLIHLLKCNIGTGLLGLPLAIKNAGLLVGPVSLLAIGVLTVHCMVILLNCAQHLSQR 103 
hPAT4              FVQTLMHLLKGNIGTGLLGLPLAIKNAGIVLGPISLVFIGIISVHCMHILVRCSHFLCLR 120 
                    .*:*:**:* *:***:******:****:::**:**: :*.:: *** **:.*:: :. * 
 
hPAT1              LNKSFVDYGDTVMYGLESSPCSWLRNHAHWG----------------------------- 139 
hPAT2              LNKPFMDYGDTVMHGLEANPNAWLQNHAHWG----------------------------- 146 
hPAT3_longer_      LQKTFVNYGEATMYGLETCPNTWLRAHAVWGRWNLALSPRLECSGKISAHCNPHLQGSSN 163 
hPAT3              LQKTFVNYGEATMYGLETCPNTWLRAHAVWG----------------------------- 134 
hPAT4              FKKSTLGYSDTVSFAMEVSPWSCLQKQAAWG----------------------------- 151 
                   ::*. :.*.::. ..:*  * : *: :* **                              
 
hPAT1              ------------RRVVDFFLIVTQLGFCCVYFVFLADNFKQVIE---AANGTTNNCHNNE 184 
hPAT2              ------------RHIVSFFLIITQLGFCCVYIVFLADNLKQVVE---AVNSTTNNCYSNE 191 
hPAT3_longer_      SPAQASRVAGIYRYTVSFLLVITQLGFCSVYFMFMADNLQQMVE---KAHVTSNICQPRE 220 
hPAT3              ------------RYTVSFLLVITQLGFCSVYFMFMADNLQQMVE---KAHVTSNICQPRE 179 
hPAT4              ------------RSVVDFFLVITQLGFCSVYIVFLAENVKQVHEGFLESKVFISNSTNSS 199 
                               *  *.*:*::******.**::*:*:*.:*: *     :   . .   . 
 
hPAT1              TVILTPTMDSRLYMLSFLPFLVLLVFIRNLRALSIFSLLANITMLVSLVMIYQFIVQRIP 244 
hPAT2              TVILTPTMDSRLYMLSFLPFLVLLVLIRNLRILTIFSMLANISMLVSLVIIIQYITQEIP 251 
hPAT3_longer_      ILTLTPILDIRFYMLIILPFLILLVFIQNLKVLSVFSTLANITTLGSMALIFEYIMEGIP 280 
hPAT3              ILTLTPILDIRFYMLIILPFLILLVFIQNLKVLSVFSTLANITTLGSMALIFEYIMEGIP 239 
hPAT4              NPCERRSVDIRIYMLCFLPFIILLVFIRELKNLFVLSFLANVSMAVSLVIIYQYVVRNMP 259 
                          :* *:*** :***::***:*::*: * ::* ***::   *:.:* ::: . :* 
 
hPAT1              DPSHLPLVAPWKTYPLFFGTAIFSFEGIGMVLPLENKMKDPRKFPLILYLGMVIVTILYI 304 
hPAT2              DPSRLPLVASWKTYPLFFGTAIFSFESIGVVLPLENKMKNARHFPAILSLGMSIVTSLYI 311 
hPAT3_longer_      YPSNLPLMANWKTFLLFFGTAIFTFEGVGMVLPLKNQMKHPQQFSFVLYLGMSIVIILYI 340 
hPAT3              YPSNLPLMANWKTFLLFFGTAIFTFEGVGMVLPLKNQMKHPQQFSFVLYLGMSIVIILYI 299 
hPAT4              DPHNLPIVAGWKKYPLFFGTAVFAFEGIGVVLPLENQMKESKRFPQALNIGMGIVTTLYV 319 
                    * .**::* **.: ******:*:**.:*:****:*:**..::*.  * :** **  **: 
 
hPAT1              SLGCLGYLQFGANIQGSITLNLPN-CWLYQSVKLLYSIGIFFTYALQFYVPAEIIIPFFV 363 
hPAT2              GMAALGYLRFGDDIKASISLNLPN-CWLYQSVKLLYIAGILCTYALQFYVPAEIIIPFAI 370 
hPAT3_longer_      LLGTLGYMKFGSDTQASITLNLPN-CWLYQSVKLMYSIGIFFTYALQFHVPAEIIIPFAI 399 
hPAT3              LLGTLGYMKFGSDTQASITLNLPN-CWLYQSVKLMYSIGIFFTYALQFHVPAEIIIPFAI 358 
hPAT4              TLATLGYMCFHDEIKGSITLNLPQDVWLYQSVKILYSFGIFVTYSIQFYVPAEIIIHGIT 379 
                    :. ***: *  : :.**:****:  *******::*  **: **::**:*******     
 
hPAT1              SRAPEHCELVVDLFVRTVLVCLTCILAILIPRLDLVISLVGSVSSSALALIIPPLLEVTT 423 
hPAT2              SRVSTRWALPLDLSIRLVMVCLTCLLAILIPRLDLVISLVGSVSGTALALIIPPLLEVTT 430 
hPAT3_longer_      SQVSESWALFVDLSVRSALVCLTCVSAILIPRLDLVISLVGSVSSSALALIIPALLEIVI 459 
hPAT3              SQVSESWALFVDLSVRSALVCLTCVSAILIPRLDLVISLVGSVSSSALALIIPALLEIVI 418 
hPAT4              SKFHTKWKQICEFGIRSFLVSITCAGAILIPRLDIVISFVGAVSSSTLAIILPPLVEILT 439 
                   *:         :: :*  :*.:**  ********:***:**:**.::**:*:*.*:*:   
 
hPAT1              FYSEGMSPLTIFKDALISILGFVGFVVGTYEALYELIQPS---------NAPIFINSTCA 474 
hPAT2              FYSEGMSPLTIFKDALISILGFVGFVVGTYQALDELLKSE---------DSHPFSNSTTF 481 
hPAT3_longer_      FYSEDMSCVTIAKDIMISIVGLLGCIFGTYQALYELPQP----------ISHSMANSTGV 509 
hPAT3              FYSEDMSCVTIAKDIMISIVGLLGCIFGTYQA---------------------------- 450 
hPAT4              FSKEHYNIWMVLKNISIAFTGVVGFLLGTYITVEEIIYPTPKVVAGTPQSPFLNLNSTCL 499 
                   * .*  .   : *:  *:: *.:* :.*** :                             
 
hPAT1              FI--- 476 
hPAT2              VR--- 483 
hPAT3_longer_      HA--- 511 
hPAT3              ----- 
hPAT4              TSGLK 504                         
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Alignments of PAT1 across species 
 
Homo_sapiens           MSTQRLRNEDYHDYSSTDVSP--EESPSEGLNNLSSPGSYQRFGQSNSTTWFQTLIHLLK 58 
Bos_taurus             MSTQRLRDEDYRDYSSTDASP--EESPSEGLNNFSSSGSYMRFGESNSTTWFQTLIHLLK 58 
Mus_musculus           MSTQRLRNEDYHDYSSTDVSP--EESPSEGLGSFS-PGSYQRLGENSSMTWFQTLIHLLK 57 
Rattus_norvegicus      MSTQRLRNEDYHDYSSTDVSP--EESPSEGLGSFS-PGSYQRLGENSSMTWFQTLIHLLK 57 
Xenopus_laevis         MDTSRLTSDRYNDYSSTEVSPSEENSPGTIGNNVSRPRQYERLGEDSSTTWYQTLIHLLK 60 
                       *.*.** .: *.*****:.**  *:**.   ...* . .* *:*:..* **:******** 
 
Homo_sapiens           GNIGTGLLGLPLAVKNAGIVMGPISLLIIGIVAVHCMGILVKCAHHFCRRLNKSFVDYGD 118 
Bos_taurus             SNIGTGLLGLPLAVKNAGILMGPLSLLVIGLVAVHCMRILVKCAHHFCYRLNKPFVDYGD 118 
Mus_musculus           GNIGTGLLGLPLAVKNAGLLLGPLSLLVIGIVAVHCMGILVKCAHHLCRRLNKPFLDYGD 117 
Rattus_norvegicus      GNIGTGLLGLPLAVKNAGLLLGPLSLLVIGIVAVHCMGILVKCAHHLCRRLNKPFLDYGD 117 
Xenopus_laevis         GNIGTGLLSLPLAVKNAGIVLGPLSLVFMGIIAVHCMDLLVKCAHHLCQREQRPFVDYGD 120 
                       .*******.*********:::**:**:.:*::***** :*******:* * ::.*:**** 
 
Homo_sapiens           TVMYGLESSPCSWLRNHAHWGRRVVDFFLIVTQLGFCCVYFVFLADNFKQVIEAANGTTN 178 
Bos_taurus             TVMYSLEASPISWLRNHAHWGRRMVDFFLIVTQLGFCCIYFVFLADNFKQVIEMANGTTN 178 
Mus_musculus           TVMYGLECSPSTWVRNHSHWGRRIVDFFLIVTQLGFCCVYFVFLADNFKQVIEAANGTTT 177 
Rattus_norvegicus      TVMYGLECSPSTWIRNHSHWGRRIVDFFLVVTQLGFCCVYFVFLADNFKQVIEAANGTTT 177 
Xenopus_laevis         ALMYGMQGCPSQWLQRNSVWGRWIVGFFLILTQLGFCCVYFVFLADNIKQVVEAANGTTN 180 
                       ::**.:: .*  *::.:: *** :*.***::*******:********:***:* *****. 
 
Homo_sapiens           NCHNNETVILTPTMDSRLYMLSFLPFLVLLVFIRNLRALSIFSLLANITMLVSLVMIYQF 238 
Bos_taurus             NCHNNETVILTPTMDSRLYMLTFLPFMVLLVFIRNLRALSIFSLLANITMAVSLVMIYQF 238 
Mus_musculus           NCNNNVTVIPTPTMDSRLYMLSFLPFLVLLSFIRNLRVLSIFSLLANISMFVSLIMIYQF 237 
Rattus_norvegicus      NCNNNETVILTPTMDSRLYMLTFLPFLVLLSFIRNLRILSIFSLLANISMFVSLIMIYQF 237 
Xenopus_laevis         DCSANETVVLVESMDSRLYILSFLPFLILLVFITNLRYLSIFSLLANLSMLGSVIMIYQY 240 
                       :*  * **: . :******:*:****::** ** *** *********::*  *::****: 
 
Homo_sapiens           IVQRIPDPSHLPLVAPWKTYPLFFGTAIFSFEGIGMVLPLENKMKDPRKFPLILYLGMVI 298 
Bos_taurus             TVQNIPDPSHLPLVASWKTYPLFFGTAIFAFEGIGMVLPLENKMKDPKKFSLILYVGMAI 298 
Mus_musculus           IVQRIPDPSHLPLVAPWKTYPLFFGTAIFAFEGIGVVLPLENKMKDSQKFPLILYLGMAI 297 
Rattus_norvegicus      IVQRIPDPSHLPLVAPWKTYPLFFGTAIFAFEGIGVVLPLENKMKDSQKFPLILYLGMAI 297 
Xenopus_laevis         IGRDIPDPTHLSYVSSWRSFALFFGTAIFAFEGIGVVLPLENKMKIPHQFPVVLYVGMGI 300 
                         : ****:**. *:.*:::.********:*****:********* .::*.::**:** * 
 
Homo_sapiens           VTILYISLGCLGYLQFGANIQGSITLNLPNCWLYQSVKLLYSIGIFFTYALQFYVPAEII 358 
Bos_taurus             VTALYVSLGILGYLHFGANIQGSITLNLPNCWLYQSVKLLYSVGIFFTYALQFYVPAEII 358 
Mus_musculus           ITVLYISLGSLGYLQFGANIKGSITLNLPNCWLYQSVKLLYSIGIFFTYALQFYVAAEII 357 
Rattus_norvegicus      ITVLYISLGSLGYLQFGADIKGSITLNLPNCWLYQSVKLLYSIGIFFTYALQFYVAAEII 357 
Xenopus_laevis         VTILYISMGTLGFLRFGSSIQASITLNLPNCWFYQSVKLLYSFGIFITFALQFYVAAEII 360 
                       :* **:*:* **:*:**:.*:.**********:*********.***:*:******.**** 
 
Homo_sapiens           IPFFVSRAPEHCELVVDLFVRTVLVCLTCILAILIPRLDLVISLVGSVSSSALALIIPPL 418 
Bos_taurus             IPFFVARGPEHCELVIDLSVRTVLVCLTCILAILIPRLDLVISLVGSVSSSALALIIPPL 418 
Mus_musculus           IPAIVSRVPEHFELMVDLCVRTAMVCVTCVLAILIPRLDLVISLVGSVSSSALALIIPPL 417 
Rattus_norvegicus      IPAIVSRVPERFELVVDLSARTAMVCVTCVLAVLIPRLDLVISLVGSVSSSALALIIPPL 417 
Xenopus_laevis         VPTVTLHVHDRWVRCMDLTVRAALVCLTCVLAILIPHLGLVISLVGSVSSSALALIIPPL 420 
                       :* .. :  ::    :** .*:.:**:**:**:***:*.********************* 
 
Homo_sapiens           LEVTTFYSEGMSPLTIFKDALISILGFVGFVVGTYEALYELIQPSNAPIFINSTCAFI-- 476 
Bos_taurus             LEITTYYSEGMSPITIVKDALISILGFVGFVVGTCLTLYELIQPSSAPIFINSTSAFV-- 476 
Mus_musculus           LEVVTYYGEGISPLTVTKDALISILGFVGFVVGTYESLCELIQPSHSDSSTNSTSAFI-- 475 
Rattus_norvegicus      LEVTTYYGEGISPLTITKDALISILGFVGFVVGTYESLWELIQPSHSDSSTNSTSAFI-- 475 
Xenopus_laevis         LEILTYYTEGLSRWVIAKDIFISLVGFLGFVLGTYVALWELIVPEVSP-ALNETALFVVQ 479 
                       **: *:* **:*  .: ** :**::**:***:**  :* *** *. :    *.*. *:   
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Alignments of PAT4 across species 
 
Homo_sapiens           MEAAATPAAAGAARREELDMDVMRPLIN-EQNFDGT------------SDEEHEQELLP- 46 
Bos_taurus             MEAAA-PAAAEAAGREELDMDVMRPLIN-EQNFDGT------------SDEEQEQELLP- 45 
Mus_musculus           MEAPA---PAETAGCEELDMDVMRPLIN-EQNFDGS------------SDEEQEQTLVP- 43 
Rattus_norvegicus      MEAPA---PAEAAGCEELDMDVMRPLIN-EQNFDGS------------SDEEQEQTLLP- 43 
Xenopus_laevis         MDATE---LGVSGEGEEIDMEVMRPLIESEDRFEGTYGEKKHLQRYLNSDNKKDEEVMKP 57 
                       *:*.     . :.  **:**:******: *:.*:*:            **::::: ::   
 
Homo_sapiens           -----------------VQKHYQLDDQEGISFVQTLMHLLKGNIGTGLLGLPLAIKNAGI 89 
Bos_taurus             -----------------VQKHHQLDDQEGISFVQTLIHLLKGNIGTGLLGLPLAIKNAGI 88 
Mus_musculus           -----------------IQKHYQLDGQHGISFLQTLVHLLKGNIGTGLLGLPLAIKNAGI 86 
Rattus_norvegicus      -----------------MQKHYQLDGQHGISFVQTLMHLLKGNIGTGLLGLPLAIKNAGI 86 
Xenopus_laevis         LIENEDDSDGTCDEHQYLQRHPDLDNKDGLTFFQTLIHLLKGNIGTGLLGLPLAMKNAGV 117 
                                        :*:* :**.:.*::*.***:*****************:****: 
 
Homo_sapiens           VLGPISLVFIGIISVHCMHILVRCSHFLCLRFKKSTLGYSDTVSFAMEVSPWSCLQKQAA 149 
Bos_taurus             VLGPISLVFIGIISVHCMHILVRCSHFLCQRFKKSTLGYSDTVSFAMEVSPWSCLQKQTA 148 
Mus_musculus           VLGPISLVFIGIISVHCMHILVRCSHFLCQRFKKSTLGYSDTVSFAMEASPWSCLQRQAA 146 
Rattus_norvegicus      VLGPISLVFIGIISVHCMHILVRCSHFLCQRFKKSTLGYSDTVSFAMEASPWSCLQRQAA 146 
Xenopus_laevis         LLGPISLLFFGIISIHCMNILVRCSHFLCQRYKKANLGYSDTVGLALEVGPG-VLQRHAS 176 
                       :******:*:****:***:********** *:**:.*******.:*:*..*   **:::: 
 
Homo_sapiens           WGRSVVDFFLVITQLGFCSVYIVFLAENVKQVHEGFLESKVFISNSTNSSNPCERRSVDI 209 
Bos_taurus             WGRNVVDFFLVITQLGFCSVYIVFLAENVKQVHEGFLESKVFVLNSTNSSSPCERRSIDL 208 
Mus_musculus           WGRSVVDFFLVITQLGFCSVYIVFLAENVKQVHEGFLGSTPIVSNGSDLSHACERRSVDL 206 
Rattus_norvegicus      WGRSVVDFFLVITQLGFCSVYIVFLAENVKQVHEGLLETTVVVSNSSDLSQVCERRSVDL 206 
Xenopus_laevis         FGRNLVDWFLVVTQLGFCSVYFVFLAENIKQVFEVFLETKLQQSEIG-------IWSLDL 229 
                       :**.:**:***:*********:******:***.* :* :.    :           *:*: 
 
Homo_sapiens           RIYMLCFLPFIILLVFIRELKNLFVLSFLANVSMAVSLVIIYQYVVRNMPDPHNLPIVAG 269 
Bos_taurus             RIYMLCFLPFLILLVFIRELKNLFVLSFLANISMAVSLVIIYQYVVRNMPDLHNLPIVAG 268 
Mus_musculus           RVYMLCFLPLIILLVFIRELKNLFVLSFLANISMAASLVIIYQYVVRNMPDPHNLPIVAG 266 
Rattus_norvegicus      RVYMLCFLPLLILLVFIRELKSLFVLSFLANISMAASLVIIYQYVVRSMPDPHNLPIVAG 266 
Xenopus_laevis         RIYMFSFLPLIIPLVFIRDLKNLSLLSFFANVSMAISLLIVYQYVIRNLSDPRTLPLGTS 289 
                       *:**:.***::* *****:**.* :***:**:*** **:*:****:*.:.* :.**: :. 
 
Homo_sapiens           WKKYPLFFGTAVFAFEGIGVVLPLENQMKESKRFPQALNIGMGIVTTLYVTLATLGYMCF 329 
Bos_taurus             WKKYPLFFGTAVFAFEGIGVVLPLENQMKESKRFPQALNIGMGIVTALYVSLATLGYMCF 328 
Mus_musculus           WKKYPLFFGTAVFAFEGIGVVLPLENQMRESKRFPQALNIGMAIVTVLYISLATLGYMCF 326 
Rattus_norvegicus      WKKYPLFFGTAVFAFEGIGVVLPLENQMRESKRFPQALNIGMAIVTVLYISLATLGYMCF 326 
Xenopus_laevis         WKTYPLFFGTAIFAFEGIGVVLPLENRMRDKKDFSKALNIGMAIVTTLYISLATLGYFCF 349 
                       **.********:**************:*::.* *.:******.***.**::******:** 
 
Homo_sapiens           HDEIKGSITLNLPQDVWLYQSVKILYSFGIFVTYSIQFYVPAEIIIHGITSKFHTKWKQI 389 
Bos_taurus             HDDIKGSITLNLPQDVWLYQSVKILYSFGIFVTYSIQFYVPAEIIIPVITSRFHAKWKQI 388 
Mus_musculus           RDEIKGSITLNLPQDMWLYQSVKILYSFGIFVTYSIQFYVPAEIIIPGVTARLHAKWKRI 386 
Rattus_norvegicus      RDEIKGSITLNLPQDMWLYQSVKILYSFGIFVTYSIQFYVPAEIIIPAVTARLHAKWKCI 386 
Xenopus_laevis         GDQIKGSITLNLPQDSWLYQLVKILYSFGIYVTYAIQYYVPAEIILPAVTSRVQKTRKLL 409 
                        *:************ **** *********:***:**:*******:  :*::.: . * : 
 
Homo_sapiens           CEFGIRSFLVSITCAGAILIPRLDIVISFVGAVSSSTLAIILPPLVEILTFSKEHYNIWM 449 
Bos_taurus             YEFAIRSFLVTITCAGAILIPRLDIVIAFVGAVSSSTLALILPPLVEILTFSKEHYSIWM 448 
Mus_musculus           CEFGIRSLLVSITCAGAILIPRLDIVISFVGAVSSSTLALILPPLVEILTFSKDHYNIWM 446 
Rattus_norvegicus      CDFGIRSLLVSITCAGAVLIPRLDIVISFVGAVSSSTLALILPPLVEILTFSKDHYNVWM 446 
Xenopus_laevis         CEFTMRFFLVCLTCAVAVLIPRLDLVISFVGAVSSSTLALILPPLVEIITYHKENLSPWV 469 
                        :* :* :** :*** *:******:**:***********:********:*: *:: . *: 
 
Homo_sapiens           VLKNISIAFTGVVGFLLGTYITVEEIIYPTPKVVAGTPQSPFLNLNSTCLTSGLK 504 
Bos_taurus             VLKNVSIVFTGVVGFLLGTYVTVEEIIYPTPRAITSTPHGPSLNLNSTCFTSGLK 503 
Mus_musculus           ILKNISIAFTGVVGFLLGTYVTVEEIIYPTTAVVAGTSQSPFLNVNSTCITSGL- 500 
Rattus_norvegicus      VLKNISIAFTGFVGFLLGTYVTVEEIIYPTTAVADGASQSLSLNVNSTCVSSGL- 500 
Xenopus_laevis         IMKDVGIAVIGFVGFIAGTYVTIEEMIYPISYVPPNVSHSDFGVLNNTVLEGH-- 522 
                       ::*::.*.. *.***: ***:*:**:*** . .  ...:.    :*.* . .    
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